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1. Men dient zich ervan bewust te zijn dat bij patienten met een GIST, met name in het geval van 
progressieve ziekte, paraneoplastische hypoglykemieen kunnen optreden ( dit proefschrift). 
2. 'Big'-IGF-II en de insuline receptor spelen een rol bij de overleving van GIST cellen (dit proefschrift). 
3. De waargenomen overexpressie van IGF-lR in GISTen zonder KIT en PDGFRA mutaties zou 
kunnen betekenen dat deze subklasse van tumoren geschikt is voor behandeling met monoklonale 
antilichamen tegen IGF-lR, hetgeen nader onderzocht dient te worden ( dit proefschrift; Tam et al, 
Proc Natl Acad Sci US A 2008; Janeway et al, Int J Cancer 2010). 
4. De death receptor Fas is een potentiele target voor therapie bij GIST (dit proefschrift). 
5. Er zijn geen overtuigende aanwijzingen dat imatinib gepaard gaat met cardiotoxiciteit (dit 
proefschrift). 
6. Het KIT en PDGFRA genotype van een GIST zal naar verwachting in de toekomst een belangrijke rol 
spelen bij de keuze voor de behandeling met een specifieke tyrosinekinaseremmer. 
7. Ondanks het frequente gebruik van FOG-PET ter evaluatie van tumorrespons na het starten van 
systemische behandeling dient de exacte waarde hiervan bij GIST nog prospectief te worden 
vastgesteld. 
8. Imatinib zorgt voor sterke botten (Vandyke et al, Blood 2010). 
9. Hoewel GIST als kanker en gist als micro-organisme niks met elkaar van doen hebben, moet men 
rekening houden met een zeer sterke aantrekkingskracht tussen beide in een kweekflaconnetje. 
10. Het voomemen van de minister van volksgezondheid om arts-assistenten zelf bij te laten dragen 
aan de kosten van hun opleiding tot medisch specialist doet afbreuk aan hun productiviteit en gaat 
voorbij aan de ondoorzichtige besteding van het geld uit de 'rugzakjes'. 
11. Lachen is lief! (Loek Rikhof) 
BartRikhof 
Groningen, 19 mei 2010 
c�·i:r !c , 
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Introduction 
Gastrointestinal stromal tumours (GISTs) are mesenchymal tumours with a spindle cell 
or epithelioid morphology. They arise primarily in the muscle wall of the gastrointestinal 
tract, most commonly the stomach or small bowel, but they also occur in the colon, 
rectum, mesentery and omentum. GISTs tend to metastasize to the liver, very rarely to 
the lungs, and intra-abdominal by spreading over serosal surfaces [l]. Although they are 
the most common malignant mesenchymal tumours of the gastrointestinal tract, their 
incidence is very low. The incidence in the Netherlands is estimated at 13 per million 
people annually, which is in agreement with the reported incidence in other countries 
[1,2]. GISTs are typically detected in adults over the age of 40 with a peak age around 60 
years but they may also occur in children and adolescents. 
GIST has only recently been identified as a separate tumour entity. Until the late 
1990s, these tumours were often classified as smooth muscle tumours. The recognition 
that a subset of mesenchymal tumours originating from the stomach or bowel showed 
marked morphological similarities, including over-expression of the receptor tyrosine 
kinase KIT, with a population of cells located in the gut wall called interstitial cells of 
Cajal, defined GIST as an unique tumour group [3,4]. KIT appeared to be mutated in 
the far majority of GISTs and, a few years later, also mutations in the closely related 
platelet-derived growth factor receptor a (PDGFRA) was reported to occur in a small 
proportion (-5 percent) of GISTs [5,6]. These mutations are considered as initiating steps 
in the tumorigenesis of GIST and successive genetic changes are needed for a stromal 
tumour to develop towards malignancy [7]. In about 10 to 15 percent of GISTs no 
mutations of KIT or PDGFRA are found. In these so called 'wild-type' tumours other, 
yet unidentified oncogenic events may occur that probably activate similar intracellular 
signal transduction pathways as mutated KIT or PDGFRA [l]. 
Surgical resection is the only curative treatment option for GIST so far. Until 
recently, no further treatment options were available for patients with non-resectable 
and/or metastastic disease as GISTs are highly resistant to conventional single-agent 
or combination chemotherapy and radiotherapy. Since imatinib, a drug originally 
developed for treatment of chronic myelogenous leukaemia, was introduced as a therapy 
for GIST in 2001, the perspectives for patients with GIST have improved dramatically. 
Imatinib is a small-molecule tyrosine kinase inhibitor that is active against a number 
of kinases including KIT, PDGFRA and Bcr-Abl. Clinical trials showed that imatinib is 
highly effective in patients with advanced GIST achieving disease control in 70 to 80 
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percent of the patients with a median progression-free survival up to 20-24 months [8,9]. 
Nowadays, imatinib is the standard therapy for advanced GIST. Despite these successes, 
complete responses are almost never seen in patients with imatinib. Furthermore, some 
GISTs are intrinsic resistant to this compound, while almost all patients finally develop 
disease progression after an initial tumour response. Therefore, alternative or additional 
treatment strategies are needed. 
In this thesis, studies exploring new molecular targets for the treatment of GIST are 
described. Furthermore, studies evaluating potential side-effects of imatinib and markers 
for response to imatinib are presented. 
Outline of this thesis 
The identification of critical cellular signalling pathways, in addition to those activated 
by mutated KIT or PDGFRA is an important issue for the development of new targeted 
therapies in GIST. The insulin-like growth factor (IGF) signalling system could play a role 
in the tumorigenesis of GIST. Chapter 2 describes the current knowledge about the IGF 
system and highlights the experimental and clinical evidence supporting the role of IGF 
signalling in the cellular transformation and progression of several types of malignant 
mesenchymal tumours arising from bone and soft tissues, including GIST. 
Patients with sarcomas occasionally suffer from a paraneoplastic syndrome called 
non-islet cell tumour-induced hypoglycaemia (NICTH). NICTH is characterized by 
recurrent fasting hypoglycaemia and is associated with the secretion of incompletely 
processed precursors of insulin-like growth factor-II ('big' -IGF-II) by the tumour. Chapter 
3a focuses on the tumour types and symptoms associated with NICTH as well as the 
pathogenesis, diagnosis and treatment of this rare paraneoplastic phenomenon. Two 
illustrative cases of patients suffering from NICTH caused by a solitary fibrous tumour 
and a haemangiopericytoma, respectively, are reported in this chapter. In chapter 3b, a 
case of a GIST patient suffering from NICTH is described. 
As patients with a GIST tend to be at risk for the development of NICTH, we studied 
the clinical relevance of determining the plasma levels of 'big'-IGF-II and other IGF­
related proteins in GIST patients in chapter 4. In this study, we determined the plasma 
levels of IGF-I, total IGF-II, pro-IGF-IIE [68-88] ('big' -IGF-II), IGF binding protein 
(IGFBP)-2, IGFBP-3 and IGFBP-6 for a cohort of 24 patients with a GIST, before and 




to the occurrence of hypoglycaemia, disease progression and response on treatment 
were subsequently evaluated. In addition, we assessed whether the observed changes 
in plasma levels of pro-IGF-IIE[68-88] and IGFBP-2 were associated with expression of 
these proteins in the corresponding tumour samples from these patients. 
Following the observations in the previous chapter, the biological role of 'big'-IGF-II 
secretion in GIST was investigated in chapter 5. IGF-II (both in its mature and its partially 
processed form) has been shown to act as an autocrine growth and survival factor in 
several tumour types by binding to the IGF receptor type 1 (IGF-lR) and/or the insulin 
receptor isoform A. We hypothesized that 'big' -IGF-II secretion by GIST could provide 
a pro-survival signal in addition to constitutively activated KIT or PDGFRA. Therefore, 
the expression of 'big'-IGF-II and its cognate receptors was evaluated in a comprehensive 
cohort of GIST tissues. The effects of down-regulation of autocrine produced 'big'-IGF-II 
and silencing of the insulin receptor with short interference RNA on cellular survival and 
apoptosis was subsequently investigated in GIST cell lines. 
Apoptosis can be induced through several mechanisms. One of these mechanisms 
involves the inhibition of receptor tyrosine kinases such as constitutively activated KIT or 
'big' -IGF-II-activated insulin receptor isoform A in GIST. Another option is the activation 
of the cellular extrinsic apoptosis pathway through activation of death receptors. In 
chapter 6, we studied whether the death receptor Fas could be used as therapeutic target 
in GIST. We therefore evaluated the effectiveness of MegaFasL, a recently developed 
hexameric form of soluble Fas ligand (FasL), as an apoptosis-inducing agent in a panel 
of imatinib-sensitive and imatinib-resistant cell lines, alone and in combination with 
imatinib. In addition, the expression of Fas and FasL was evaluated in 45 primary GISTs 
with immunohistochemical stainings. 
Although imatinib inhibits KIT and PDGFRA in GIST, it can also inhibit these or 
other targets in normal tissues which may result in side-effects. Case reports of patients 
treated with imatinib and data from animal studies suggested that this tyrosine kinase 
inhibitor may induce cardiomyopathy. Consequently, careful cardiac monitoring was 
advocated for clinical studies. The purpose of the study described in chapter 7 was to 
evaluate whether imatinib induces early, subclinical, cardiac toxicity. In 55 patients with 
locally advanced and/or metastatic GIST, serial plasma N-terminal pro B-type natriuretic 
peptide and serum cardiac troponin T measurement was performed before, and one and 
three months after the start of imatinib treatment. These measurements were related to 
patient medical history and physical examinations. 
-12-
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Recently, several case reports and cross-sectional studies suggested that imatinib 
might influence normal tissue homeostasis inducing alterations in bone and mineral 
metabolism and causing hypogonadism in male patients. In the study described in 
Chapter 8, hormonal and electrolyte changes during the first 6 months of treatment 
with imatinib were analysed. In addition, the observed changes were related to tumour 
response to imatinib as evaluated with CT scanning in an attempt to explore additional 
early predictive biomarkers. 
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Chapter 2 
Abstract 
Sarcomas are a diverse group of malignant mesenchymal tumours arising from bone and 
soft tissues. The identification of critical cellular signalling pathways in sarcomas is an 
important issue for the development of new targeted therapies. This review highlights 
the experimental and clinical evidence supporting the role of the insulin-like growth 
factor (IGF) signalling system in the cellular transformation and progression of several 
types of sarcoma, including rhabdomyosarcoma, synovial sarcoma, leiomyosarcoma, 
Ewing's sarcoma and osteosarcoma. Preclinical data suggest that the IGF system could 
be a promising target for therapy in these sarcomas. Currently, therapies interrupting 
IGF signalling have been or are being developed. In recent phase 1 clinical studies 
with humanized monoclonal antibodies directed against IGF receptor type 1 (IGF-lR), 
objective tumour responses were observed in several patients with Ewing's sarcoma 
encouraging further clinical testing in Ewing's sarcoma and other sarcoma (sub)types. 
Moreover, the occasional occurrence of paraneoplastic hypoglycaemia as a result of the 
secretion of incompletely processed forms of pro-IGF-II by sarcomas is discussed. 
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Introduction 
Sarcomas are rare tumours of mesenchymal origin comprising about 1 % of all adult 
malignancies and 12% of paediatric cancers (1,2]. They form a heterogeneous group 
of solid tumours arising from soft tissue or bone. There are more than 50 histological 
(sub)types of soft tissue and bone sarcomas. These subtypes display different biological 
characteristics, clinical behaviour and therapeutic options [l]. On the basis of cytogenetics, 
sarcomas have been divided into two major classes. The first class consists of sarcomas 
with simple karyotypes and specific genetic alterations, including chromosomal 
translocations or specific gene mutations. The second category is characterized by a 
complex unbalanced karyotype with non-specific genetic alterations [3]. Overall, there 
is a poor response of sarcomas from both categories to chemotherapy. Recent advances 
in the treatment of gastrointestinal stromal tumours (GIST) with the tyrosine kinase 
inhibitor imatinib [4] and Ewing's sarcoma with the insulin-like growth factor receptor 
type 1 (IGF-lR) antagonist R1507 [5] have shown that understanding of the biology of 
sarcomas and identification of critical signalling pathways involved in the aetiology 
and progression of these tumours, can lead to the recognition of molecular targets for 
therapy. Research performed in the last two decades has demonstrated that the insulin­
like growth factor (IGF) system plays an important role in tumorigenesis of several 
sarcoma (sub)types. Therefore, this system could be a target for antisarcoma therapy. 
Furthermore, mesenchymal neoplasms are occasionally associated with paraneoplastic 
hypoglycaemias as a result of pro-IGF-11 secretion by the tumour. The purpose of this 
review is to highlight the biological, therapeutical and clinical role of the IGF system in 
sarcoma. 
Components of the IGF signalling system 
The IGF system consists of three ligands (IGF-I, IGF-11 and insulin), four cell-membrane 
receptors (IGF-lR, insulin receptor isoform A (IR-A), hybrid receptors and IGF receptor 
type 2 (IGF-2R)), and six IGF binding proteins (IGFBP-1 through -6; figure 1). 
IGFs 
The majority of circulating IGF-I is produced by the liver and its expression is stimulated 
by growth hormone (GH). Other organs can also produce IGF-1. In this way, IGF-I 
-17-
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functions as an endocrine growth factor but also as an autocrine or paracrine factor [6]. 
Mature IGF-1 consists of 70 amino acid residues (7.65 kDa) and shares 62% homology in 
amino acid sequence with IGF-11 [7]. 
IGFBPs ,._ IProteaseij 
/". 





Figure 1. The components of the IGF system. IGF-1, IGF-11 and insulin interact with their 
cognate receptors as indicated. IGF-11 has a high affinity for the insulin receptor isoform A (IR­
A) but not for IR-B. IGF-lR and insulin receptor isoforms can form heterodimers, called hybrid 
receptors. The function of IGF-1 and IGF-11 is modulated by IGF binding proteins (IGFBP-1 to 
-6) which in their turn are subjected to cleavage by proteases. 
Similar to IGF-1, IGF-11 is expressed in the liver and extrahepatic sites but its 
expression, in contrast, is not regulated by GH. In humans, IGF-11 is the predominant 
circulating IGF with plasma levels 3- to 7-fold higher than IGF-1 [8]. Mature IGF-11 is a 
single-chain polypeptide consisting of 67 amino acids (7.47 kDa). It is synthesised as a 
180 amino acid preprohormone with a 24 amino acid signal peptide at the N-terminal 
end and a C-terminal extension of 89 amino acids called the E-domain. During 
intracellular processing the signal peptide and the E-domain are cleaved in several steps 
from the precursor protein resulting in mature IGF-11 [9]. Due to incomplete processing 
of pro-IGF-11, larger forms of IGF-11 can be formed that still contain 21 amino acids of 
the E-domain. These forms of incompletely processed IGF-11 are called 'big'-IGF-11 and 
-18-
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constitute less than 10% of total human serum IGF-11. However, some malignancies, 
especially sarcomas, secrete large amounts of 'big'-IGF-11 resulting in high circulating 
levels of this protein with associated hypoglycaemia (see below) [10]. 
The human IGF2 gene is located at the short arm of chromosome 11 (locus llp15.5). 
The transcription of IGF2 is regulated by four separated promoters (Pl-P4). These four 
promoters are active in a developmental and tissue specific manner [11]. In most non­
malignant tissue, IGF2 is transcribed from the paternal allele with the maternal allele 
being imprinted and thus silent. The imprinting of the JGF2 gene is influenced by the 
neighbouring downstream H19 gene, which encodes a non-translated RNA. IGF2 and 
H19 are oppositely imprinted. On the paternal chromosome, the promoter region of 
H19 is imprinted by methylation causing silencing of the gene and providing access 
of several enhancers, located 3' of H19, to the JGF2 promoters . The opposite occurs 
on the maternal gene [12]. Loss of imprinting (LOI) is one of several mechanisms that 
cause enhanced expression of IGF-11 in human malignancies including some types of 
sarcomas. In this way, transcription occurs from two copies (both paternal and maternal) 
of the IGF2 gene, leading to elevated mRNA levels. Some sarcoma subtypes (e.g. 
embryonal rhabdomyosarcoma) show loss of the maternal llp15.5 locus causing loss of 
heterozygosity (LOH). LOH is associated with duplication of the paternal allele of IGF2 
(paternal isodisomy), resulting in the expression of two paternal genes. Furthermore, 
enhanced expression of transcription initiators, for example AP-2, or loss of inhibitors 
of IGF-11 expression, such as p53, could play a role in increased expression observed in 
several sarcoma subtypes [13]. 
IGF receptors 
IGF-lR is a transmembrane receptor formed by two extracellular ligand binding a 
subunits and two � subunits comprising the transmembrane and tyrosine kinase catalytic 
domains. IGF-lR is highly expressed in many human cancers including sarcomas. The 
expression of IGF-lR is predominantly determined at the transcriptional level and 
increased expression in cancers results from loss of transcriptional repressors, such as 
p53, or increased expression of transcriptional activators such as chimeric transcription 
factors found in, for example, alveolar rhabdomyosarcoma [14]. Amplification of the IGFlR 
locus is an uncommon event, although very recently amplification of IGFlR was found 
in a subset of GISTs [14,15]. Both IGF-1 and IGF-11 can bind and activate IGF-lR. Binding 
of these ligands causes a conformational change followed by autophosphorylation of the 




(IRS-1 to -4) and Src homology 2 domain-containing protein (She) are recruited to the 
phosphorylation sites in the cytoplasmic domain that activate at least two major signal 
transduction pathways. One of these routes is the phosphatidylinositol-3-kinase (PI3K) 
pathway, the other involves the mitogen-activated protein kinase (MAPK) pathway 
(figure 2) [16]. Depending on the cellular context, activation of these pathways results in 
cell proliferation and inhibition of apoptosis. Furthermore, IGF-lR signalling has been 
implicated in the induction of malignant transformation, the regulation of cell adhesion 
and motility, and stimulation of differentiation [17]. 
There are two isoforms of the insulin receptor (A and B) that arise due to alternative 
splicing of exon 11. IR-A, lacking the 12 amino acids encoded by exon 11, can bind to IGF-
11 with almost the same affinity as to insulin [18]. Under normal physiological conditions, 
IR-A is predominantly expressed in fetal cells, while IR-B is primarily expressed in adult 
tissue to mediate the metabolic effects of insulin [19]. Increased expression of IR-A has 
been reported in carcinomas of breast, colon, lung, thyroid and ovary [18] . As for IGF-lR, 
the expression of the insulin receptor is principally regulated at the transcriptional level. 
The factors contributing to the switch from isoform B into isoform A in cancer are poorly 
understood [18,20]. By using similar signalling pathways as IGF-lR, IR-A induces cell 
proliferation, survival and migration upon IGF-11 and insulin binding [21,22] . 
As IGF-lR and insulin receptor are closely homologous, they are able to interact with 
each other to form heterodimers. Both insulin receptor isoforms are able to form these 
hybrid receptors by binding to IGF-lR. Hybrid receptors containing IR-B bind IGF-I with 
high affinity. In contrast, hybrid receptors with IR-A not only bind IGF-I but also IGF-11 
and insulin with a high affinity resulting in receptor autophosphorylation and activation 
of downstream signalling pathways [20]. However, the exact role of hybrid receptors in 
tumour formation and progression needs further investigation. 
IGF-2R is a multifunctional receptor that lacks an intracellular signalling domain. It 
is also known as the cation-independent mannose 6-phosphate receptor which binds 
a diverse group of mannose 6-phosphate-tagged proteins for endosomal trafficking 
and degradation by the lysosome [23] . IGF-2R binds to extracellular IGF-11 and causes 
internalization and subsequent clearance by the lysosome. In this way IGF-2R is involved 
in the regulation of the extracellular concentration of IGF-11 [23]. Many tumours have 
been found with loss of IGF-2R expression or function by either LOH or inactivating 
mutations [24,25]. In addition, over-expression of IGF-2R leads to reduced tumour 
growth and delayed tumorigenesis in in vivo models suggesting that IGF-2R functions as 
a tumour suppressor [26,27] . 
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Figure 2. Schematic overview of the major IGF-lR and insulin receptor signalling pathways. 
Following ligand binding, IGF-lR and insulin receptor become activated resulting in receptor 
autophosphorylation and recruitment of several adaptor proteins such as the insulin receptor 
substrates (IRS-1 to -4) and the Src homology collagen-like (She) adaptor protein that bind to 
specific phosphorylated residues on the cytoplasmic domains of the receptors. IRS couples the 
receptors to the phosphatidylinositol-3-kinase (PI3K) pathway, while She couples the receptors 
to the mitogen-activated protein kinase (MAPK) pathway. In the PI3K pathway, binding of the 
p85 and pllO subunits of PI3K to IRS induces the conversion of phosphatidylinositol-4,5-
biphoshate (PIP 2) to phosphatidylinositol-3,4,5-biphoshate (PIP 3) that subsequently activates 
phosphoinositide-dependent kinase-I (PDKl). PDKl phosphorylates the serine/threonine 
kinase AKT resulting in its activation. AKT has many substrates that are inhibited or activated 
by its phosphorylation such as glycogen synthase kinase-3 (GSK3), the Bcl-2 family member 
Bad, and p27Kipl_ These substrates are involved in the diverse cellular functions of AKT which 
include regulation of cell survival, proliferation, and metabolism. In addition, AKT activates 
the mammalian target of rapamycin (mTOR) by releasing the inhibitory activity of tuberous 
sclerosis complex-2 (TSC2) through phosphorylation. Activated mTOR stimulates protein 
synthesis and cell growth via at least two downstream targets, 4E-binding protein-I (4EBP1) 
and S6 kinase (S6K). Several mechanisms exist that inhibit PI3K signalling. The phosphatase 
- 21 -
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and tensin homologue (PTEN) negatively regulates the formation of PIP 3. Another mechanism 
includes the phosphorylation of serine residues on IRS-1 by S6K which targets IRS-1 for 
degradation. In the MAPK pathway, She, growth factor receptor-bound protein-2 (Grb2) and 
son of sevenless (Sos) cooperate to activate Ras by catalysing the replacement of GDP with GTP. 
Activated Ras subsequently activates the kinase activity of Raf. This protein phosphorylates 
the MAPK/ERK kinases (MEKl and MEK2), which phosphorylates and activates extracellular 
signal-regulated kinase-1 and -2 (ERKl and ERK2). ERK has numerous target proteins in both 
the cytosol and the nucleus. These target proteins regulate processes such as proliferation, 
survival, differentiation and migration. 
IGFBPs 
The effects of IGF-I and -II are modulated by IGFBPs, a family of six homologous 
multifunctional proteins. In the circulation, IGF-I and IGF-II are mainly bound to IGFBP-3 
which is the most abundant IGFBP in serum. About 75-80 percent of the IGFs circulate as 
150 kDa ternary complexes that also consist of IGFBP-3, or to a much lesser extent IGFBP-5, 
and a third protein called acid-labile subunit (ALS). The remainder of IGFs exists as 40-
50 kDa binary complexes bound solely to one of the six IGFBPs. Ternary complexes are 
not able to cross the capillary endothelial barrier due to the high molecular mass of these 
complexes. In this way, these large complexes are restricted to the vascular compartment 
prolonging the half-life of IGF-I and -II in the circulation (15-20 h). In contrast, binary 
complexes (and unbound IGFs) can easily leave the circulation (estimated half life -30 
min) facilitating the biological effects of IGFs to the tissue compartments [28,29]. 
On the cellular level, the interaction of IGFs with their receptors is influenced by 
the presence of IGFBPs. Depending on the cellular context and the IGFBP present, the 
actions of IGFs can be either enhanced or inhibited. In addition, IGF-binding capacity of 
IGFBPs is regulated by the presence of a wide range of proteolytic enzymes. Thus, there 
is a complex situation of local regulation of IGF activity. Interestingly, more and more 
evidence suggests that binding proteins also have IGF-independent functions (for review 
see Firth et al. [30]). For example, it has been shown that IGFBP-3 itself has a proapoptotic 
function although the exact signalling mechanism still needs to be elucidated. 
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The role of the IGF system in sarcoma 
The current literature about the involvement of IGF signalling in the development 
and progression of various sarcomas will be discussed in the following sections and is 
summarised in table 1. 
Rhabdomyosarcoma 
Rhabdomyosarcoma is a malignant soft tissue tumour showing varying degrees of 
skeletal muscle differentiation. It is the most common soft tissue sarcoma of childhood. 
Two major histologic subtypes exist, alveolar and embryonal rhabdomyosarcoma. 
Embryonal rhabdomyosarcoma mainly affects children less than 10 years of age. 
Alveolar rhabdomyosarcoma is predominantly found in adolescents and young adults 
and is associated with a poorer prognosis than embryonal rhabdomyosarcoma [31]. Both 
rhabdomyosarcoma subtypes have distinct genetic alterations that have been shown to 
play a role in the pathogenesis of these tumours. Alveolar rhabdomyosarcomas carry a 
characteristic non-random translocation involving the DNA binding domain of PAX3 
on the long arm of chromosome 2 or PAX7 on the short arm of chromosome 1, and 
the transactivation domain of FKHR on the long arm of chromosome 13 (encoding for 
the PAX3-FKHR and PAX7-FKHR fusion proteins) [32]. No consistent chromosomal 
rearrangements have been identified in embryonal rhabdomyosarcoma. However, 
embryonal rhabdomyosarcoma is characterized by the frequent LOH at the llpl5.5 locus 
[33,34]. 
Consistent over-expression of IGF-11 has been identified in both embryonal and 
alveolar rhabdomyosarcoma tissue samples, and in cell lines derived from these tumours 
[35-38]. Both tumours and cell lines expressed IGF-lR [39]. Increased expression of 
this receptor was recently found to be associated with a poor survival of patients [40]. 
Rhabdomyosarcoma cell lines secreting IGF-11 were able to grow in serum free media. 
Treatment of these cells with an antagonistic antibody against IGF-lR inhibited cell 
growth under serum-free conditions suggesting that IGF-11 functions as an autocrine/ 
paracrine growth factor in rhabdomyosarcoma [39]. Furthermore, IGF-11 stimulated 
the motility of rhabdomyosarcoma cells [36,39]. In vivo, tumour formation and growth 
of rhabdomyosarcoma cells were inhibited by treating the mice with an antagonistic 
antibody against IGF-lR [41]. Also other approaches targeting IGF-lR by antisense RNA 
or expression of a kinase deficient form of this receptor have resulted in the suppression 
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IGF and sarcomas 
Activation of the PI3K pathway downstream of IGF-lR and insulin receptor is 
subjected to negative feedback regulation by mammalian target of rapamycin (mTOR) 
and S6 kinase (S6K) through inhibition of IRS function (figure 2) [44]. In accordance 
with these observations, an IGF-lR activation dependent increase in AKT activation was 
found in rhabdomyosarcoma cells upon inhibition of mTOR by rapamycin. Therefore, an 
even more efficient inhibition of rhabdomyosarcoma growth both in vitro and in vivo was 
observed when an IGF-lR antagonistic antibody was combined with rapamycin [45,46]. 
Interestingly, a recent study found that patients with a poor survival may have tumours 
with a disruption in the feedback mechanisms between mTOR and IRS resulting in an 
increased phosphorylation of AKT in contrast to a group of patients with a favourable 
outcome [40]. 
Rhabdomyosarcoma probably arises as a consequence of regulatory disruption 
of the growth and differentiation of myogenic precursor cells. PAX3 and PAX7 are 
transcription factors that are both required for normal muscle development [47]. Also 
IGF-11 is implicated in normal skeletal muscle growth and differentiation [48]. The 
PAX3-FKHR fusion protein is a much stronger transactivator than PAX3 and is able 
to transform chicken fibroblast and inhibits myogenic differentiation of C2C12 mouse 
myoblasts [49,50]. Mixed results were reported about the forced over-expression of IGF-
11 in mouse myoblast cells. One study found that IGF-11 induced enhanced differentiation 
of these cells [51]. However, another study showed that mouse myoblasts transfected 
with IGF-11 alone or cotransfected with PAX3 or PAX3-FKHR, transform in vitro and can 
form tumours in vivo. Benign tumours were formed in all groups except for those cells 
transfected with both IGF-11 and PAX3-FKHR. These cells developed invasive, poorly 
differentiated tumours with higher microvessel density and lower apoptotic rate [52]. 
These results suggest that IGF-11 and PAX3-FKHR can cooperate in the formation of 
alveolar rhabdomyosarcoma. Of interest, PAX3-FKHR fusion protein can induce both 
IGF-11 and IGF-lR expression resulting in enhanced IGF signalling [53,54]. 
Mouse models have been established in which spontaneous embryonal rhabdo­
myosarcomas develop. A mouse model for nevoid basal cell carcinoma syndrome, 
an overgrowth syndrome associated with tumour development including rhabdo­
myosarcoma, was created by introduction of a heterozygous deletion of the gene Patched 
(Ptch), a tumour suppressor gene involved in sonic hedgehog signalling. Nine percent of 
these mice developed embryonal rhabdomyosarcoma and the tumours expressed elevated 
levels of IGF-11 [55]. Interestingly, when female heterozygous Ptch-knockout mice were 
crossed with male heterozygous IGF2-knockout mice, those mice with an IGF2-deficient 
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background did not develop rhabdomyosarcoma [56]. These data suggest that IGF-II is 
required for rhabdomyosarcoma formation in mice with loss of Ptch function. 
More evidence about the role of IGF-II in the development of embryonal 
rhabdomyosarcomas comes from the observation that patients with Beckwith-Wiedemann 
syndrome, a rare disease characterized by fetal overgrowth, have an increased risk of 
developing embryonal tumours such as rhabdomyosarcoma. Inherited alterations of the 
llpl5.5 locus, including LOI and LOH of IGF2, are found in this syndrome leading to an 
increased expression of IGF-II [57,58]. Also in many sporadic rhabdomyosarcomas, of both 
embryonal and alveolar histology, transcription occurs from two copies of the IGF2 gene 
by both LOH and LOI [59]. As stated above, most of the embryonal rhabdomyosarcomas 
show loss of the maternal llpl5.5 locus with duplication of the paternal allele of IGF2 
[60]. LOH has also been reported in alveolar rhabdomyosarcoma but LOI of IGF2 is more 
often found [34,61,62]. 
Also other mechanisms are involved in the deregulation of IGF-II expression. P53 
mutations and loss of p53 function as a result of MDM2 over-expression have frequently 
been found in rhabdomyosarcoma [63]. As p53 inhibits the expression of IGF-II, loss of 
p53 could increase the expression of IGF-11. Restoration of wild-type p53 in an alveolar 
rhabdomyosarcoma cell line expressing mutant p53 resulted in a significant decrease 
in IGF-11 expression [64]. Furthermore, the levels of the transcription factor AP-2 are 
increased in rhabdomyosarcoma causing elevated IGF-II expression by binding to the P3 
promoter [65]. 
In summary, IGF-II appears to function as an autocrine/paracrine growth factor 
in rhabdomyosarcoma by signalling through IGF-lR. In both embryonal and alveolar 
rhabdomyosarcoma, up-regulation of IGF-II appears to provide a secondary signal in the 
malignant transformation of myogenic precursor cells. As the IGF-II/IGF-lR signalling 
pathway plays an important role in the initiation and progression of rhabdomyosarcoma, 
disruption of this pathway could potentially be used as a therapeutic target. 
Leiomyosarcoma 
Leiomyosarcoma is a malignant tumour composed of spindle cells displaying features 
of smooth muscle differentiation. They account for 5 to 10% of all soft tissue sarcomas 
[66]. Leiomyosarcomas develop principally in adults and are most common in women. 
According to their localization, they can be divided into different subgroups: deep 
soft tissue tumours (retroperitoneum, abdominal cavity, and intramuscular), uterine 
tumours, (sub)cutaneous tumours, and vascular leiomyosarcomas. These subgroups 
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also differ in their clinical characteristics, with cutaneous tumours showing a better 
prognosis [67]. It has been reported that about half of the leiomyosarcomas studied 
express IGF-II at a high level compared with normal myometrium and leiomyomas. In 
some uterine leiomyosarcomas, LOI has been implicated in increased IGF-II expression 
[68,69]. In addition, equal to lower levels of IGF-lR were expressed in leiomysarcomas 
compared with non-malignant smooth muscle tissues and IGFBP-3 levels were decreased 
[68,70,71]. The latter could result in facilitation of IGF signalling. Indeed, constitutive 
activation of IRS-1 has been reported [72]. Furthermore, the PI3K pathway was highly 
activated in leiomyosarcomas, which appeared to be a critical event in the formation 
of leiomyosarcoma in mice [73]. Recently, Siacca et al. reported the production of IGF­
II by several leiomyosarcoma cell lines. These cell lines expressed the insulin receptor, 
predominantly as IR-A, and variably expressed IGF-lR. It was shown that IR-A was able 
to mediate IGF-II autocrine signalling [22]. Still, more studies are needed to investigate 
the contribution of the IGF signalling system to the development and progression of 
leiomyosarcoma. 
Synovial sarcoma 
Synovial sarcoma is a mesenchymal spindle cell tumour which displays variable epithelial 
glandular differentiation. It accounts for 5 to 10% of all soft tissue sarcomas and can occur 
at every age but is most common in young adults. Synovial sarcomas are characterized 
by a specific reciprocal translocation between chromosome 18 and the X-chromosome 
resulting in the fusion of the genes 5518 and 55X1, 55X2 or 55X4. These SS18-SSX fusion 
proteins act as aberrant transcriptional regulators [74]. High expression levels of IGF-II 
were found in synovial sarcoma samples by microarray analysis [75,76]. Two studies 
investigating the effect of the 5518-55X1 or 5518-55X2 fusion gene in immortalised 
fibroblasts or kidney cells on gene expression found that IGF2 was the most up-regulated 
gene [77,78]. This up-regulation was associated with changes in histone acetylation en 
methylation within the IGF2 promoter and increased methylation of the IGF2 imprinting 
control region [78]. LOI was found in a limited number of primary synovial sarcomas 
indicating that the SS18-SSX protein induces IGF-II expression in an epigenetic fashion 
[77]. Increased IGF-II production in 5518-55X transfected cells protected the cells against 
apoptosis while growing under anchorage-independent conditions. Furthermore, it was 
shown that these transfected cells form synovial sarcoma-like tumours in vivo, in contrast 
to transfected cells in which IGF-II was down-regulated by siRNA [77]. IGF-lR seems 
to be involved in IGF-II signalling as down-regulation or inhibition of this receptor 
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leads to increased numbers of apoptotic cells in S518-SSX transformed cells or synovial 
sarcoma cell lines [77,79]. In addition, a study investigating the IGF-lR expression in 35 
synovial sarcomas found that there was an association between IGF-lR expression and 
an increased incidence in lung metastasis [80] . These data suggest that the IGF-II/IGF-lR 
pathway is involved in the development and aggressiveness of synovial sarcomas. 
Kaposi's sarcoma 
Kaposi's sarcoma is a locally aggressive endothelial tumour that typically presents with 
cutaneous lesions but may also involve mucosa! sites, lymph nodes and visceral organs. 
Kaposi's sarcoma is the most common neoplasm that occurs in patients with AIDS and is 
uniformly associated with Kaposi's sarcoma-associated herpes virus (KSHV, also known 
as human herpes virus 8) infection [1,81] . IGF-lR and insulin receptor expression has 
been detected in Kaposi's sarcoma tissue samples [82,83]. IR-A, strongly up-regulated 
in dermal microvascular endothelial cells after infection with KSHV, was necessary 
for KSHV-induced transformation in contrast to IGF-lR [84]. Interestingly, IGF-2R was 
also up-regulated after infection of endothelial cells with KSHV and was required for 
transformation by retaining cathepsin B intracellular [85]. The role of IGF-lR in Kaposi's 
sarcoma is rather unclear. One study found that IGF-II stimulated proliferation and 
inhibit apoptosis via IGF-lR in an autocrine manner in a Kaposi's sarcoma cell line [82] . 
Furthermore, it has been suggested that activation of IGF-lR in Kaposi's sarcoma cells 
could contribute to the vascular phenotype of this tumour [86]. 
GIST 
GISTs are the most common sarcomas of the gastrointestinal tract. These tumours are 
characterized by the over-expression of the receptor tyrosine kinase KIT. Activating 
mutations in this receptor or, less frequently, in the platelet-derived growth factor receptor 
a (PDGFRA) play a fundamental role in the pathogenesis of GIST. A subset of tumours 
lacks these mutations and in these, so called, wild-type GIST, other oncogenic events 
could play an important role in the development of these tumours [87]. Recently, it was 
demonstrated that wild-type GISTs express much higher levels of IGF-lR than mutant 
GISTs, which was associated with IGFlR gene amplification [15] . Also in paediatric GIST, 
a very rare disease with typically wild-type tumours, markedly increased expression 
levels of IGF-lR mRNA were observed that even exceeded the expression in wild-type 
adult tumours [88,89]. Immunohistochemical analysis revealed that IGF-I and/or IGF-II 
were expressed in the majority of (mutant and wild-type) GISTs and the expression of 
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each ligand was associated with a more aggressive phenotype and decreased disease-free 
survival [90]. To date, there are numerous reports about the occurrence of paraneoplastic 
hypoglycaemia with associated high plasma levels of 'big' -IGF-II in patients with a GIST 
[10,91-95]. This implies that large amounts of ('big'-)IGF-II are secreted by at least some 
tumours. Together, these data suggest that the IGF system could be involved in the 
pathogenesis of GIST, at least in wild-type tumours. 
Ewing's sarcoma 
Ewing's sarcomas may arise in either bone or soft tissues. It is the second most common 
cancer of bone in children and adolescents with a peak incidence during the second 
decade of life. Ewing's sarcomas are characterized by a recurrent chromosomal 
translocation resulting in the fusion of the EWS gene on chromosome 22 with one of 
several genes of the ETS family of transcription factors. The most common fusion, 
detected in approximately 85% of the cases, occurs with the FLil gene resulting from the 
translocation t(11;22)(q24;q12) [1]. EWS-ETS fusion proteins promote oncogenesis in a 
dominant fashion in model systems and are necessary for continued growth of Ewing's 
sarcoma cell lines by acting as aberrant transcription factors [96]. Recent studies suggest 
that primary bone marrow-derived mesenchymal progenitor cells may be involved in 
Ewing's sarcoma development as expression of EWS-FLI-1 in these cells leads to Ewing's 
sarcoma-like transformation [97-99]. In association with this transformation, it was 
found that IGF-I was up-regulated and that transformed cells were dependent on IGF­
lR signalling [99]. In addition, it has been shown that IGF-lR expression is required 
for EWS-FLI-1 mediated transformation of mouse fibroblasts [100]. In agreement with 
these findings suggesting an important role of IGF signalling in these Ewing's sarcoma 
models, consistent expression of IGF-I and IGF-lR was demonstrated in Ewing's sarcoma 
cell lines and tumour tissues [101,102]. Cases of Ewing's sarcomas that express type 1 
EWS-FLI-1 are associated with a favourable prognosis and with lower IGF-lR expression 
compared to cases with non-type 1 EWS-FLI-1 translocations. In addition, the rate of IGF­
lR expression in Ewing's sarcoma samples was shown to correlate with the proliferative 
index [103]. Many studies have investigated the effect of blocking the function of IGF­
lR in preclinical models. Targeting the IGF-lR pathway in Ewing's sarcoma cell lines in 
vitro and/or in vivo by using dominant negative receptors [104], antisense strategies [105], 
antagonistic antibodies [102,106,107], small-molecule receptor tyrosine kinase inhibitors 
[108-110], or inhibitors of downstream signalling molecules (PI3K or MEK) [ 111,112] all 
appeared to be effective. Recently, it was shown that EWS-FLI-1 can bind to the IGFBP-3 
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promoter in vitro and in vivo and can repress its activity. Up-regulation of IGFBP-3 caused 
by EWS-FLI-1 inactivation induced apoptosis in Ewing's sarcoma cells in both an IGF­
I-dependent and independent manner suggesting that repression of IGFBP-3 rescues 
Ewing's sarcoma cells from apoptosis [113]. 
These data imply that IGF-lR signalling contributes to Ewing's sarcoma development 
and progression with IGF-1 as a possible autocrine factor with increased activity due to 
loss of IGFBP-3 expression. However, it is noteworthy that the age associated with the 
peak incidence of Ewing's sarcoma coincides with augmented IGF-I secretion in bone as 
a result of a burst in GH production. IGF-I induction could therefore provide a survival 
signal that is essential during early cell transformation by EWS-FLI-1 [114]. 
Osteosarcoma 
Osteosarcoma is the most common primary malignant tumour of the bone. It most 
frequently occurs in the second decade of life, although one third of the cases are 
observed in patients over 40 years of age [l]. Osteosarcomas are characterized by a 
complex unbalanced karyotype. Although no characteristic reciprocal translocations 
are found in these sarcomas, non-random chromosomal abnormalities are observed, 
affecting for example the p53 and retinoblastoma tumour suppressor pathways [115]. 
The IGF system plays an important role in the formation and homeostasis of bone 
[116,117]. Differential expression of IGF-I and IGF-II and a more consistent expression 
of IGF-lR in osteosarcoma tissue samples and cell lines has been observed [118,119]. 
LOI of IGF2 has also been reported [120]. However, there is no clear evidence that IGF-I 
or IGF-II function as a dominant autocrine growth or motility factor in osteosarcoma 
[119]. As for Ewing's sarcoma, the peak incidence of osteosarcoma coincides with the 
burst of GH release during puberty suggesting a causal relationship [115]. Indeed, 
osteosarcoma cells appeared to be IGF-I dependent for growth in vitro [121,122]. 
Furthermore, delayed tumour growth and inhibition of metastatic behaviour of murine 
osteosarcoma was observed in hypophysectomized mice [121]. In addition, inhibition 
of GH release by somatostatin analogs or antagonists of GB-releasing hormone in mice 
decreased serum IGF-1 levels and inhibited tumour growth probably as a result of a 
combination of reduced IGF-1 stimulation and direct effects on cellular growth by these 
compounds [123,124]. However, a phase 1 clinical trial with a long-acting somatostatin 
analog showed that serum IGF-I levels could be lowered but no clinical responses were 
observed [125]. An alternative therapeutic strategy would be targeting of IGF-lR. Both 
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antagonistic antibodies and tyrosine kinase inhibitors appeared to be effective in several 
preclinical models [107,108]. 
Recently, a study investigated whether single nucleotide polymorphisms in genes 
of several components of the IGF system could influence the risk of osteosarcoma 
development. A single nucleotide polymorphism in IGF2R was identified that was 
associated with an increased risk of osteosarcoma. This might suggest that a variant of 
IGF-2R is involved in the pathogenesis of osteosarcoma [126]. 
Other sarcomas 
Solitary fibrous tumours are fibroblastic tumours that are anatomically ubiquitous. 
Although most tumours are benign, about 10 to 15% of these tumours behaves in a 
locally aggressive or malignant, sarcoma-like, manner [1]. Solitary fibrous tumours are 
frequently associated with hypoglycaemia due the expression and secretion of 'big' -IGF­
II [127,128]. It has been reported that solitary fibrous tumours express the insulin receptor, 
predominantly as isoform A, in contrast to IGF-lR that was not detected. Furthermore, 
the insulin receptor and its downstream signalling pathways were constitutively active, 
suggesting that IR-A is the receptor involved in potential IGF-II autocrine signalling 
[129]. 
Desmoplastic small round cell tumours (DSRCT) are characterized by the recurrent 
chromosomal translocation t(11;22)(p13;q12) that results in the fusion of the EWS gene 
to the WT1 gene. The WTl protein plays a role in transcriptional regulation. EWS­
WTl chimeras are heterogeneous because of fusions of different regions of the EWS 
gene to the WT1 gene. The various isoforms of the EWS-WT1 fusion protein are able to 
transactivate the IGF-1R promoter and to stimulate its expression, although to a various 
extent [130-132]. However, the exact role of EWS-WTl induced up-regulation of IGF-1R 
in the aetiology of DSRCT needs to be determined. 
Congenital fibrosarcoma and cellular mesoblastic nephroma are closely related 
malignancies that are characterized by the t(12;15)(p13;q25) reciprocal translocation 
resulting in the ETV6-NTRK3 fusion gene. The chimeric ETV6-NTRK3 protein functions 
as a constitutively active tyrosine kinase. IGF-lR and IRS-1 are required for ETV6-NTRK3 
induced transformation of murine fibroblasts in vitro [133,134]. In addition, these tumours 
showed increased expression of IGF-II, probably as a result of trisomy of chromosome 
11 that is another characteristic cytogenetic abnormality of congenital fibrosarcoma and 
cellular mesoblastic nephroma [133]. Taken together these results imply that intact IGF 
signalling plays an important role in ETV6-NTRK3 induced transformation. 
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The IGF system as a therapeutic target in sarcomas 
Current systemic therapies with chemotherapy for sarcomas of bone and soft tissues result 
in limited response rates. Childhood sarcomas, mostly embryonal rhabdomyosarcomas, 
form an exception as chemotherapy greatly improved overall survival of these patients. 
However, also in this group of patients, metastatic disease reflects a poor prognosis [135]. 
Furthermore, chemotherapy is characterized by a narrow therapeutic index showing 
toxicity on the short but also on the long term, which is of importance for the often 
young sarcoma survivors. New systemic therapies are therefore warranted to increase 
the survival of patients with sarcomas together with a decrease in the overall toxicity. As 
the IGF system plays an important role in the biology of several sarcomas, as discussed 
in this review, targeting IGFs or its receptors could be a promising therapeutic option. 
Several (preclinical) strategies have been developed to decrease the bioavailability 
of IGF-1 or -II to tumours. These include approaches to reduce ligand availability by 
somatostatin analogues or antagonists of CH-releasing hormone, neutralising antibodies 
and recombinant human IGFBPs [136]. Somatostatin analogues or antagonists of CH­
releasing hormone could be safe for clinical use [137]. As stated above, these compounds 
were effective in preclinical osteosarcoma models, but no tumour responses were 
observed in a phase 1 clinical trial [123-125]. 
Another approach is to target IGF-lR. The expression of this receptor can be reduced 
by anti-sense and RNA interference strategies, or inhibited by antagonistic antibodies 
and small-molecule receptor tyrosine kinase inhibitors. At this moment, antibodies and 
tyrosine kinase inhibitors appear to be the most promising strategies to block IGF-lR 
function in patients. Recently, a phase 1 clinical trial was conducted with the single­
agent R1507, a human anti-IGF-lR antibody. It was reported that four of the eight heavily 
pretreated patients with Ewing's sarcoma included in this study demonstrated clinical 
benefit and two patients achieved a durable partial response [5]. Another phase 1 study 
with an antibody against IGF-lR, AMG479, reported a complete response in a patient 
with Ewing's sarcoma [138]. A partial response in a patient with this type of sarcoma was 
also observed in a phase 1 study with the human monoclonal antibody CP-751,871 [139]. 
The drug was well tolerated in these studies and the maximum tolerated dose was not 
achieved. One of the most frequently reported adverse events was hyperglycaemia that 
could be managed with standard oral diabetic therapy [140]. Currently, several phase 
2 studies with IGF-lR directed antibodies are running globally. Phase 2 studies with 
R1507, AMG479 and CP-751,871 have been initiated studying the effects of these agents 
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specifically in patients with Ewing's sarcoma but also in patients with other types of 
sarcoma (ClinicalTrials.gov identifiers NCT00642941, NCT00563680, and NCT00560235). 
All these recently developed antibodies against IGF-lR have similar mechanisms of 
action. They block the interaction of IGF-lR with IGF-I and IGF-II and, most importantly, 
they induce down-regulation of the receptor by internalization and degradation via 
the endosome [141]. It has also been reported that most of these antibodies can bind to 
and induce internalization of hybrid receptors [142]. However, the insulin receptor is 
unaffected providing a theoretical escape mechanism for mitogenic IGF-II and insulin 
signalling. 
In addition to antibodies, a number of low molecular weight compounds have been 
developed that inhibit the tyrosine kinase activity of IGF-lR by targeting its intracellular 
kinase domain. Because the kinase domains of IGF-lR and insulin receptor share a very 
high protein sequence identity, the development of specific kinase inhibitors of IGF-lR 
appeared to be a major challenge [136]. Specificity of these inhibitors is an important 
issue, because the potential co-inhibition of the insulin receptor (isoform B) is expected to 
result in hyperglycaemia. Several compounds have been claimed to be selective towards 
IGF-lR, such as NVP-AEW541 and NVP-ADW742 [143,144]. These inhibitors were active 
in preclinical models of musculoskeletal sarcomas [108-110]. Small-molecule inhibitors 
of IGF-lR have not yet entered phase 1 clinical testing. 
As IGF-lR signalling is involved in the protection of tumour cells from many types 
of insults, targeting IGF-lR could result in the sensitization of cells to chemotherapy 
or other anticancer drugs [145]. Many preclinical studies using different cancer types, 
including Ewing's sarcoma, showed an increased sensitivity toward chemotherapy using 
inhibitors of IGF-lR [109,146,147]. Also combinations with other targeted therapies, such 
as mTOR inhibitors, could be of interest in sarcomas [145]. Further clinical testing will 
have to reveal the optimal combination schemes for each sarcoma type. 
Non-islet cell tumour-induced hypoglycaemia 
As already stated above, several types of (soft tissue) sarcoma are relatively often 
associated with hypoglycaemias due to the massive secretion of incompletely processed 
forms of pro-IGF-II, called 'big' -IGF-II. This form of paraneoplastic hypoglycaemia is 
called non-islet cell tumour-induced hypoglycaemia (NICTH). In general, NICTH is 
an uncommon phenomenon and the incidence is unknown. However, about half of the 
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reported cases occurred in patients with a mesenchymal malignancy [128] . Many different 
sarcomas have been associated with NICTH. Solitary fibrous tumours are one of the most 
common mesenchymal tumours associated with hypoglycaemia. In a case series of 223 
patients with a solitary fibrous tumour of the pleura, 3% percent with benign and 1 1  % 
with malignant tumours developed hypoglycaemia [127] . Other sarcomas frequently 
associated with NICTH are mesotheliomas, leiomyosarcomas, and fibrosarcomas [128] . 
Tumours causing hypoglycaemia are usually large (i.e. a diameter more than 10 cm) 
[148]. It is unknown whether the existence of NICTH is of prognostic value with respect 
to predicting the degree of malignancy of a tumour and the (progression-free) survival 
of the patient [128] . 
With regard to the pathogenesis of NICTH, 'big'-IGF-11 appears to have properties 
that do not allow the proper formation of the ternary 150 kDa complex with IGFBP-3 
and ALS in the circulation, and competes with mature IGF-11 and IGF-I for binding to 
IGFBP-3 and other IGFBPs. As a consequence, 'big' -IGF-11, mature IGF-11 and IGF-I 
mainly circulate either as smaller binary complexes with IGFBPs or in the unbound, 
free form. In contrast to the ternary complexes, the binary complexes and free IGFs can 
easily cross the capillary membrane, hence increasing the bioavailability of IGFs to the 
tissue compartments. Finally, this may lead to hypoglycaemia as a result of excessive 
stimulation of the insulin receptor. In addition, IGFBP-3 and ALS levels are lowered 
since their CH-dependent production by the liver is suppressed, presumably due to an 
increased feedback inhibition by IGFs [149] . 
Increased 'big'-IGF-11 production by tumour cells could simply be the result of an 
inadequate capacity of intracellular enzymes to process the relatively high amounts 
of pro-IGF-11 [150]. However, increased production of 'big' -IGF-11 (and resulting 
hypoglycaemia) might reflect the existence of an autocrine loop, because, similar to 
mature IGF-11, it is able to activate IGF-lR and insulin receptor. Furthermore, 'big'-IGF-11 
could have properties that are of more benefit for tumour cells than mature IGF-11. Sparse 
data suggests that 'big' -IGF-11 is at least as mitogenic as mature IGF-11 [151-154] which 
possibly depends on the amount of glycosylation of 'big'-IGF-11 [154] . However, the exact 
role of 'big' -IGF-11 production by sarcomas needs further delineation. 
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Conclusion 
The IGF-lR/IR-A pathway is a commonly activated pathway in a variety of sarcomas. 
This pathway is either activated by endocrine, paracrine or autocrine produced IGF-1 
or ('big' -) IGF-II. Targeting this pathway or its ligands could therefore be an attractive 
therapeutical option. Recent successes reported in patients with Ewing's sarcoma treated 
wit an anti-IGF-lR antibody highlights the importance of the IGF system in this type of 
sarcoma and encourages further (pre)clinical studies investigating the benefit of targeting 
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Abstract 
This review focuses on the tumour types and symptoms associated with non-islet 
cell tumour-induced hypoglycaemia (NICTH) as well as the pathogenesis, diagnosis 
and treatment of this rare paraneoplastic phenomenon. In addition, we report two 
illustrative cases of patients suffering from NICTH caused by a solitary fibrous tumour 
and a haemangiopericytoma, respectively. In the first case NICTH resolved following 
complete resection of the tumour, but in the second case the patient needed long term 
treatment aimed at controlling hypoglycaemia because of non-resectable metastases. 
Many tumour types have been associated with NICTH. The initiating event in the 
development of NICTH seems to be over-expression of the IGF-II gene by the tumour. 
NICTH is characterized by recurrent fasting hypoglycaemia and is associated with the 
secretion of incompletely processed precursors of insulin-like growth factor-II ('big' -IGF-
11) by the tumour. This induces dramatic secondary changes in the circulating levels of 
insulin, growth hormone (GH), IGF-I and the insulin-like growth factor binding proteins 
(IGFBPs), resulting in an insulin-like hypoglycaemic activity of 'big' -IGF-II. 
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Introduction 
Hypoglycaemia is a common medical emergency, mostly as a result of a complication 
of therapy with insulin and/or oral hypoglycaemic agents in diabetes mellitus. In rare 
cases hypoglycaemia can be a manifestation of neoplastic disease. Tumours related to the 
occurrence of hypoglycaemia can, as a general rule, be divided into three groups. First, 
tumours can produce excess insulin such as pancreatic insulinomas or ectopic insulin 
producing tumours. Second, hypoglycaemia can be caused by tumour-related factors 
such as destruction of the liver and adrenal glands by massive tumour infiltration. 
Finally, hypoglycaemia rarely can be induced by the production of substances interfering 
with glucose metabolism including insulin-receptor antibodies (in Hodgkin's disease 
and other haematological malignancies) [1], various cytokines including tumour necrosis 
factor-alpha and interleukin-1 and -6 [1,2], catecholamines (in phaeochromocytomas), 
secretion of insulin-like growth factor (IGF)-1 [3], and tumours that secrete partially 
processed precursors of IGF-11 ('big'-IGF-11) [1,4]. The latter condition is also known as 
non-islet cell tumour-induced hypoglycaemia (NICTH). 
This review will focus on NICTH. So far, the literature on this rare and complex 
biochemical syndrome involving many types of tumours is mostly limited to case­
reports. For this reason, besides a brief description of two new cases of NICTH, this 
paper reviews the available literature on this paraneoplastic phenomenon with respect 
to its pathogenesis, diagnosis and treatment. 
The IGF system 
IGF physiology 
The IGF system is composed of two IGF ligands (IGF-1 and IGF-11) and two IGF receptors 
(the IGF-1 receptor (IGF-lR) and the IGF-11/mannose-6-phosphate-receptor (IGF-2R)) [5]. 
The majority of circulating IGF-1 and IGF-11 are produced by the liver, although various 
tissues and cell types are also capable to synthesize these peptides locally. The synthesis of 
IGF-1 by the liver and various other organs largely depends on its stimulation by growth 
hormone (GH) through the CH-receptor, whereas the synthesis of IGF-11 is relatively 
independent of GH action. The GH/IGF-1 axis is the primary regulator of postnatal 
growth while IGF-11 appears to have an important role during foetal development, cell 
proliferation and apoptosis [6-8]. 
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Both IGF-I and IGF-11 are structurally and functionally related to insulin. Most of the 
biological actions of IGF-I and IGF-11 are thought to be mediated via IGF-lR as reviewed 
extensively by others [8-13]. However, IGFs may also interact with the insulin receptor 
which contributes to the pleiotrophic nature of IGF activity in the body. 
The IGF-lR is a tyrosine kinase receptor consisting of two extracellular ligand binding 
a-subunits and two f3-subunits comprising the transmembrane and tyrosine kinase 
domains [14] . IGF-lR signalling can induce differentiation, malignant transformation 
and regulate cell-cell adhesion [8-13]. 
Due to alternative splicing of exon 11 of the insulin receptor gene, there are two 
isoforms of the insulin receptor (isoform A and B). The insulin receptor-A isoform, is 
preferentially expressed in foetal tissues and in certain human malignancies, whereas 
the insulin receptor-B isoform is mainly expressed in important target tissues for the 
metabolic effects of insulin including liver, muscle and fat. IGF-I has low affinity for these 
receptors, but IGF-11 binds with high affinity (comparable to its affinity for IGF-lR) and 
activates isoform A [15]. This interaction leads predominantly to mitogenic effects [15-
17]. In contrast, the low-affinity binding of IGF-11 to the B-isoform of the insulin receptor 
results in insulin-like, metabolic effects. 
Insulin and IGF-I receptors are structurally homologous - both exhibit intrinsic tyrosine 
kinase activity and in part interact with various similar intracellular signal transduction 
mediators [8,18,19]. The structural homogeneity allows formation of hybrid receptors of 
IGF-lR and insulin receptor-A or -B. When IGF-lR and insulin receptor are co-expressed 
on the same cell, receptor hybrids form by random assembling and the least abundant 
receptor is drawn predominantly into hybrid receptors [20]. IGF-11 can bind these hybrid 
receptors with high affinity but the biological role of these hybrid receptors remains 
largely unknown. 
In addition, IGF-11 also binds to the IGF-2R. Besides its role in the transport of lysosomal 
enzymes from the Golgi-apparatus to the lysosomes, this receptor is thought to function 
primarily as a scavenger receptor, promoting the endocytosis and degradation of 
extracellular IGF-11, thus regulating local IGF-11 levels [6,8]. 
The glucose-lowering effect of IGFs is approximately 10 times lower than that of insulin, 
but in healthy subjects the serum concentration of IGFs is about 1000 times higher than 
insulin [21,22]. However, in contrast to insulin and proinsulin, in the circulation most 
(>90%) of the IGFs are tightly bound to IGF-binding proteins (IGFBPs). A total of six 
different high-affinity binding proteins have been identified (IGFBP-1-6). Although the 
majority of the circulating IGFBPs are derived from the liver, many other organs also 
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produce one or more IGFBPs [5,9,23]. Under normal circumstances, IGFBP-3 is the most 
abundant IGFBP in serum and binds more than 95% of the IGFs [8,23]. In normal human 
serum, approximately 70-80% of the IGFs forms a 150 kDa ternary complex with either 
IGFBP-3 or (to a much lesser extent) IGFBP-5, and an acid-labile subunit (ALS), a leucine­
rich glycoprotein of approximately 85 kDa. Most of the residual IGFs are associated with 
IGFBP-1 to -6 (predominantly IGFBP-2 and -3) as smaller -40-50 kDa binary complexes 
[23-25]. Only less than 1 % of the IGFs circulates in the free form [23,26,27]. Due to its 
large molecular mass, the ternary complex is not able to pass the capillary membrane. 
Hence, the IGFs captured within this type of complex have a rather extended half life 
in the circulation (T112 -15 h) compared to the various binary complexes (T112 -25 min) 
or the free unbound IGFs (T 112 -10 min). Thus, the unbound IGFs and the pool of IGFs 
associated with binary complexes in the circulation are considered to exchange relatively 
rapidly with the tissue compartments [28] and are more readily available for binding to 
IGF receptors and insulin receptors [29,30]. 
The IGF-11 gene and protein 
The IGF-II gene is one of the few genes known to have parental allele-specific expression. 
As such, it is referred to as an imprinted gene. The gene for IGF-II, together with two 
putative tumour suppressor genes, H19 and p57K1P2, is located on chromosome llpl5. 
In normal cells, the IGF-II gene is maternally imprinted in that it is expressed only from 
the paternal copy of the gene while H19 and p57K1P2 are expressed from the maternal 
allele. H19 and p57K1P2 are implicated in conserving imprinting of IGF-II [10,31,32]. The 
IGF-II gene consists of nine exons, including six non-coding ones, with four promoters 
(Figure 1). Promotor usage seems to be tissue specific and developmentally regulated 
which leads to multiple transcripts that all encode the same monomeric primary IGF­
II translation product, pre-pro-IGF-II [33]. Pre-pro-IGF-II consists of 180 amino-acids 
including a N-terminal signal peptide of 24 amino acid residues, the 67 amino acids 
long mature IGF-II (7.5 kDa), and an 89 residue extension at the C-terminus . The latter 
has been designated the E-domain. Post-translational processing of pre-pro-IGF-II 
involves removal of the N-terminal signal sequence, addition of sialic acid containing 
oligosaccharides through O-linkage to one or more threonine residues of the E-domain, 
followed by sequential proteolysis of the latter extension into the mature protein. During 
this process a relatively stable intermediate is formed, pro-IGF-IIE[68-88], that may be 
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Figure 1. Structure of the insulin-like growth factor (IGF)-II gene and the precursor-IGF-II 
protein. The IGF-II gene has four promoters (P1-P4). Only exons 7, 8 and a part of 9 (depicted 
in gray) encode for the pre-pro-IGF-II protein. The N-terminal signalling peptide (SP) is 
enzymatically cleaved leading to the formation of pro-IGF-II. The E-domain is degraded 
through several steps into the mah1re 7.5 kDa IGF-II. Pro-IGF-IIE[68-88] is a relatively stable 
intermediary in this process. 
Clinical features of non-islet cell tumour-induced hypoglycaemia 
NICTH is a rare paraneoplastic phenomenon. It was first described in 1929 in a patient 
with a hepatocellular carcinoma [36]. Since then, many tumour types have been associated 
with hypoglycaemia. In 1988, Daughaday et al showed for the first time that tumour­
induced hypoglycaemia was associated with the aberrant production of pro-IGF-11 ('big' -
IGF-11) resulting in a persistent insulin-like activity [37]. The two new cases we describe 
next, illustrate the clinical course and therapeutic problems that can be encountered in 
patients presenting with NICTH. 
Case reports 
Case 1 
A 83-year-old man was admitted with confusion and lethargy without loss of 
consciousness. Over the last months he had lost 8 kg in weight. His medical history 
revealed atrial fibrillation and epilepsy for which he was treated with acenocoumarol 
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and carbamazepine. On admission, serum glucose was 1. 1 mmol/L (normal fasting 
glucose: 4.0-5.4 mmol/L). Serum levels of insulin and C-peptide were suppressed. 
Sulfonylurea derivatives or insulin antibodies were not detected and the presence of 
a phaeochromocytoma was excluded. The concentration of serum IGF-I was reduced 
considerably whereas that of total IGF-II was within the normal range (molar ratio 
between total IGF-II and IGF-I: 17.7; reference value: <10). The serum levels of pro­
IGF-IIE[68-88] ('big' -IGF-II) were markedly elevated (Table 1). Computed Tomography 
demonstrated a large tumour mass in the right kidney which histologically proved to be 
a solitary fibrous tumour. No metastases were found. Serum levels of glucose, IGF-I and 
pro-IGF-IIE[68-88] levels normalised after nefrectomy. Histochemical analysis of tumour 
tissue by in situ hybridization, using digoxigenin-labelled IGF-II cRNA probes [38,39] 
revealed an abundant and high expression level of IGF-II mRNA (Figure 2). 
s 
Figure 2. In situ hybridization of insulin-like growth factor (IGF)-II mRNA in a solitary fibrous 
tumour of the right kidney from patient 1, demonstrating high expression of the IGF-II gene 
(A). IGF-I is not expressed (B). 
Case 2 
A 48-year-old woman was admitted in coma . She was diagnosed with haeman­
giopericytoma of the meninges at the age of 35 for which she underwent surgery. She had 
two recurrences that were treated with radiosurgery. Five months prior to presentation, 
a large liver metastasis was histologically confirmed. Further medical history was 
uneventful. On admission serum glucose was 0.8 mmol/L and serum insulin was 
suppressed with normal levels of C-peptide. IGF-I, IGFBP-3 and ALS levels were below 
normal (Table 1). The amount of total IGF-II was within normal range. However, levels 
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of 'big' -IGF-11 were markedly elevated. She recovered quickly after administration of 
intravenous glucose. A carbohydrate rich diet could hardly prevent more hypoglycaemic 
events and prednisolone 100 mg per day was started. Eventually, 40 mg daily was needed 
as maintenance therapy to prevent recurrent hypoglycaemias. Furthermore, she started 
with dacarbazine 800 mg/m2 once every three weeks. After six courses she developed 
lung metastases and she switched to doxorubicin 50 mg/m2 every three weeks which 
provided stable disease after six courses and, combined with steroids, kept her free of 
hypoglycaemic episodes for almost a year. 
Table 1. Biochemical features of both patients with non-islet cell tumour-induced 
hypoglycaemia 
Patient l Patient 2 
IGF-I (nmol/L) 3.4 (-5.5) <1.6 (<-7.4) 
Total IGF-II (nmol/L) 60.1 (0.9) 44.4 (-1.4) 
Pro-IGF-IIE[68-88] (nmol/L) 37.7 (9.3) 22.9 (5.4) 
IGFBP2 (nmol/L) n.d. 21.2 (2.6) 
IGFBP3 (nmol/L) n.d. 22.3 (-3.9) 
Insulin (mE/L) 1.6 18 
C-peptide (nmol/L) 0.03 0.31 
ALS (nmol/L) n.d. 44.2 (-5.4) 
Serum levels of IGF-I, total IGF-II, pro-IGF-IIE[68-88], and IGFBP-3 were determined as described previously 
[38,57]. Data are also expressed as SD scores for age and gender (in parenthesis). Reference ranges for insulin and 
C-peptide are <20 mE/L and 0.18-0.63 nmol/L, respectively. 
Incidence and tumour types 
Data on the exact incidence and prevalence of NICTH are not available. It has been 
estimated that NICTH is four times less common than insulinoma, but the true incidence 
is probably higher since many cases go unrecognised, especially concerning patients 
with disseminated disease [1]. NICTH can arise in virtually every benign and malignant 
tumour. However, it mainly occurs in patients with solid tumours of mesenchymal 
and epithelial origin, but rarely also in patients with tumours of haematopoietic and 
neuroendocrine origin (Table 2) [1,30,40-42] . In general, the mesenchymal tumours have 
in common that they are well differentiated and slowly growing, although many usually 
weigh between 2 and 4 kg at diagnosis. 
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Table 2. Non-islet cell tumours associated with hypoglycaemia 
Tumour 
Tumours of mesenchymal origin 
Mesothelioma 
Haemangiopericytoma 
Solitary fibrous tumour 
Leiomyosarcoma/Gastrointestinal stromal tumour 
Fibrosarcoma 
Others 











Tumours of neuroendocrine origin 
Tumours of haematopoietic origin 





















Tumours of unknown origin 14 
Data extracted from Marks and Teale [l], Fukuda et al [41], Tsuro et al [42], Frystyk et al [30] and Zapf [40]. 
Symptoms 
Hypoglycaemia 
In unconscious cancer patients without signs of vascular events or brain metastases, 
NICTH should be considered. Subtle symptoms of hypoglycaemia, especially when they 
occur between meals and in the morning, can point towards the diagnosis. NICTH is 
thought to be a fasting hypoglycaemia characterized by: 1) diminished hepatic glucose 
production due to inhibition of glycogenolysis and gluconeogenesis [40,43,44]; 2) 
diminished lipolysis in adipose tissue resulting in low serum free fatty acids levels [ 40] 
and 3) increased peripheral glucose consumption [40,43-45]. These phenomena point 
to an enhanced insulin like activity in the body. Furthermore, glucose consumption 
by the tumour itself might contribute to hypoglycaemia [40]. As we also encountered 
in the present two cases, insulin levels are generally low or immeasurable in NICTH 
[1,37,40,46]. In NICTH, the onset of symptoms is frequently gradual with lethargy, 
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sweating, diminished motor activity and somnolence before a progressive drift into a 
coma. Recovery may occur spontaneously but is accelerated by the intake of carbohydrates 
or the administration of parenteral glucose or glucagon [1,46]. 
Several studies on NICTH indicate that a major part of the glucose intake is rapidly 
disposed into peripheral tissues, especially skeletal muscle, rather than consumed by 
the tumour. Suppression of hepatic glucose production or fat oxidation does occur but 
seems to play a minor role in the development of hypoglycaemia [44,45,47]. Indeed, 
in contrast to the liver, skeletal muscle contains large numbers of both the IGF-lR and 
insulin receptors [48] and the effect of 'big'-IGF-11 on peripheral tissue was greater than 
its effect on the liver [47]. 
Other symptoms 
In addition to hypoglycaemic symptoms, acromegaloid skin changes such as skin tags, 
excessive oiliness of the skin and rhinophyma have been described in patients with 
NICTH [49,50]. Elevated serum levels of total IGF-11 are frequently found in acromegalic 
patients and it is known that prolonged activation of the IGF-lR by IGF-11 may contribute 
to the development of acromegaloid features [51,52] . Therefore it is conceivable that the 
secretion of high molecular weight forms of IGF-11 by tumour tissue into the circulation 
might play a role in the development of external signs of acromegaly in some NICTH 
patients. 
Clinical course 
NICTH can be either the presenting symptom of a tumour or present in patients with 
a history of a neoplasm. In a large study from Japan, describing 78 patients, the clinical 
course of patients with NICTH was analysed [41]. In 48% of these cases, a hypoglycaemic 
episode was the initial sign that led to the diagnosis and the discovery of a tumour. In the 
remainder of the patients, hypoglycaemia was detected during the period of observation 
and treatment of the underlying malignancy. Furthermore, 13% of the NICTH patients 
investigated had a histologically identical tumour resected in the past without any 
evidence of hypoglycaemia at that time. Vice versa, and quite surprisingly, hypoglycaemia 
does not always reappear when a previously NICTH-causing tumour recurs and grows 
back to its former size. 
(Pro-) IGF-11 is expressed in a broad spectrum of malignant (and benign) tumours 
and IGF-11 may act as an autocrine growth factor through binding to the IGF-lR or the 
isoform A of the insulin receptor which conduct a strong mitogenic and antiapoptotic 
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activity [53,54]. Although both IGF-II and 'big'-IGF-II are capable of inducing the 
phosphorylation of partially purified preparations of both the insulin receptor and 
IGF-lR [55,56], it has not been unambiguously demonstrated that 'big'-IGF-II indeed 
stimulates tumour progression [35]. Furthermore, it is not known whether the existence 
of NICTH is of prognostic value with respect to predicting the degree of malignancy of a 
tumour or the (disease-free) survival of the patient. 
Pathogenesis of non-islet cell tumour-induced hypoglycaemia 
Involvement of IGFs 
The incongruity between the clear insulin deficiency in patients with NICTH on the 
one hand and metabolic features pointing to enhanced insulin action on the other hand, 
suggests that IGFs play a major role in NICTH. In contrast to insulin and IGF-I which are 
under endocrine control, IGF-II production is predominantly autocrine and paracrine. 
The level of IGF-I in serum of NICTH patients is usually decreased. On the other hand, 
circulating levels of total IGF-II, as determined by conventional immunometric or 
receptor assays, may be either increased, decreased or within the normal range [38,55,57]. 
These puzzling observations were clarified by Daughaday et al in 1988. The 
concentration of total IGF-II levels in serum from a NICTH patient with a leiomyo­
sarcoma investigated by them was within the normative range as measured by both 
radioimmunoassay and radioreceptorassay. However when the patient's serum was 
subjected to Biogel P-60 column chromatography at acidic pH, about 70% of the total 
IGF-II appeared to be recovered in a higher molecular weight (10-17 kDa) fraction. The 
remainder of the IGF-II was in the mature 7.5 kDa form. In contrast, in normal serum, 
high molecular forms of IGF-II ('big IGF-II') contributed only in about 10-20% to the total 
IGF-II pool. Furthermore, the tumour contained high concentrations of IGF-II mRNA. 
The authors also demonstrated that after removal of the tumour, 'big'-IGF-II levels in the 
patient's serum normalised [37]. These findings suggested that the IGF system indeed 
was involved in pathogenesis of NICTH. 
Aberrant IGF expression in NICTH 
As illustrated in the case of patient 1, NICTH-causing tumours abundantly express 
IGF-II mRNA. IGF-II gene over-expression is more widespread than first thought and 
appears to occur in various malignancies, albeit to a variable extent [58,59]. Nowadays it 
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is generally accepted that IGF-II is involved in oncogene-induced tumorigenesis [32,60]. 
Over-expression of IGF-II in tumours has been mainly attributed to either a loss of 
imprinting or mutations in tumour suppressor genes [32,61,62]. The mechanisms leading 
to IGF-II mRNA over-expression in NICTH have rarely been studied [50,58]. Hodzic et al 
reported loss of imprinting of the IGF-II gene in a mesothelioma causing hypoglycaemia 
[58]. In addition, Bertherat and colleagues studied allele specific expression of the IGF-II 
gene in a pleural fibrosarcoma causing NICTH. They observed a loss of imprinting of 
both parental alleles causing increased expression of the IGF-II gene and decreased 
expression of the genes encoding the tumour suppressors H19 and p57K1P2 [50]. Besides 
elevated levels of mRNA for IGF-II, in some cases tumours causing NICTH occasionally 
also express mRNAs for either IGFBP-4, -5 or -6 [57,63-65]. Patients with NICTH usually 
exhibit elevated levels of IGFBP-2 in their circulation but the source (with exception of 
one reported case with a IGFBP-2 expressing tumour) [65] and pathophysiologic role of 
this IGFBP are not established [57,63-65]. 
'Big'-IGF-11 and NICTH 
Not all tumours that overexpress the IGF-II gene cause NICTH and many NICTH cases 
involve pre-existing tumours. It is not clear whether serum pro-IGF-II levels in patients 
with these tumours are already elevated prior to the first signs of hypoglycaemia. In 
non-islet cell tumours causing hypoglycaemia, post-translational processing of pro­
IGF-II is abnormal [66-69]. As depicted in Figure 1, over-expression of the IGF-II gene 
causes overproduction of pro-IGF-II [66]. Incompletely processed pro-IGF-II accounts 
for 10-20% of the total IGF-II in the normal human serum [34] and is O-glycosylated 
[70,71]. In serum of patients with NICTH, a much higher proportion (usually >60%) of 
IGF-II is in a higher molecular weight form that seems to be mainly non-glycosylated and 
consists primarily of IGF-II with a 21 amino acid extension of the E-domain (pro-IGF­
IIE[68-88]) [37,68,70]. Glycosylation may therefore be a targeting signal for cleavage of 
the E-domain peptide and contribute to the size heterogeneity observed in 'big'-IGF-II. It 
seems likely that in many neoplastic cells the levels of the various enzymes involved in 
post-translational processing are not sufficient to handle the relatively high amounts of 
pro-IGF-II produced adequately [l,37,38,40,67,72-78]. 
As emphasized previously, 'big' -IGF-II is biologically active and is present in 
relatively high amounts in the serum of NICTH patients. In most cases the serum level 
of total IGF-II is not elevated. Therefore, it seems that 'big'-IGF-II must have specific 
biochemical properties, being different from those of mature IGF-II, that lead to an 
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enhanced bioavailability and, consequently, increased insulin-like activity in the body 
[68]. 
'Big'-IGF-II has equal affinity for the IGFBPs compared to fully processed IGF-II and 
can therefore form the binary complex with all IGFBPs [27,68]. However, although the 
exact mechanism is still unknown, 'big' -IGF-II seems to possess properties, which do not 
allow the proper formation of a 150 kDa complex together with IGFBP-3 and ALS (Figure 
3). It seems that in NICTH the binary complex of 'big'-IGF-II and IGFBP-3 has a strongly 
reduced affinity for ALS since a deficiency in or dysfunction of ALS do not occur [79-
81]. Possibly, the heavy N-linked carbohydrate moiety of IGFBP-3, which is absent from 
IGFBP-5, may interact with the E-domain of 'big'-IGF-II leading to steric interference and 
consequently reduction of the affinity for ALS [27,81]. Indeed, IGFBP-5 is still capable 
of forming ternary complexes with IGF-I and ALS [27]. As a consequence of impaired 
formation of the 150 kDa complex, tumour-derived 'big'-IGF-II primarily forms smaller 
binary complexes with IGFBPs and a greater fraction may stay in the free unbound 
form [25,68,82]. These smaller complexes have a greater capillary permeability and thus 
are thought to increase IGF bioavailability to the tissues, resulting in hypoglycaemia 
through action on the insulin receptors and IGF-lR. In light of this, it is fascinating that 
tumours causing NICTH display elevated serum levels of particular IGFBPs [57,63-65]. 
Apparently, some tumours can be more or less self sufficient in delivering IGF-II from the 
circulation to its target tissues causing hypoglycaemia. 
Serum of patients with NICTH has been shown to contain 4 and 20 times the 
concentration of free IGF-I and free total IGF-II (these measurements do not discriminate 
between free mature and free 'big'-IGF-II), respectively, as normally present in serum, 
although serum levels of total IGF-I and IGF-II were lower [30]. A possible explanation 
(besides the impaired formation of 150 kDa complexes) may be that increased production 
of 'big'-IGF-II by the tumour displaces free IGFs from the IGFBPs leading to increased 
serum concentrations of free, unbound IGFs. The significant positive correlation between 
'big'-IGF-II and free total IGF-II observed in the serum of NICTH patients supports such 
hypothesis [30]. Highly elevated levels of free IGF-I and free IGF-II most likely imply 
an enhanced hypoglycaemic insulin-like activity, and may, through negative feedback, 
contribute to the marked suppression of GH secretion by the anterior pituitary gland as 
observed in NICTH. As a consequence of reduced GH release, the concentrations of the 
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Figure 3. Analysis of complex formation in patient 2 using S200 column chromatography. 
An aliquot of patient's serum (250 µl) or normal control serum was incubated with 50 µl 
1251-labelled purified human insulin-like growth factor (IGF)-I (100 000 c.p.m.) and the 
different complexes were subsequently separated. In patient's serum, 150 kDa complex 
formation is reduced and, instead, relatively higher proportions of [1251]-IGF-I are associated 
with the smaller 40-50 kDa binary complexes and remain unbound. 
Thus, as summarised in figure 4, it can be hypothesised that excessive production of 
'big'-IGF-II by a tumour leads in fact to a vicious circle whereby the impaired formation 
of ternary complexes is gradually worsened by an increasing feedback inhibition of 
GH production that reduces the amounts of IGFBP-3 and ALS available for complex 
formation further. Quite probably, hypoglycaemia occurs when the various counter­
regulatory processes cannot compensate anymore for the increasing insulin-like activity. 
Other causes of hypoglycaemia 
Of course, other combinations of factors may occur as well. Decreased hepatic glucose 
output associated with destruction of the liver by tumour infiltration may also be a critical 
factor in the onset of hypoglycaemia. In addition, sometimes patients with NICTH do not 
have elevated 'big' -IGF-II levels and hypoglycaemia may be caused by the increased 
secretion of mature instead of 'big'-IGF-II [40], IGF-I [3], insulin or other peptides with 
insulin-like activity [1,83] or a combination of cachexia, renal and hepatic dysfunction, 
and glucose consumption by the tumour [84]. 
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'Big'-IGF-11 and other disease entities 
There are other disease entities in which abnormal processing of pro-IGF-II plays a role 
in the aetiology and/or pathophysiology. For example, Daughaday et al reported that 
individuals who have immunologic markers of hepatitis B virus infection may exhibit 
an increased proportion of partially processed pro-IGF-II in their circulation. However, 
these patients had no evidence of hypoglycaemia [85]. 
Patients with hepatitis C-associated osteosclerosis (HCAO) have a specific increase 
in circulating 'big' -IGF-II and IGFBP-2 levels. However, HCAO patients do not exhibit 
hypoglycaemia, nor have NICTH patients been reported to have osteosclerosis. The 
predominant circulating forms of 'big'-IGF-II in HCAO and NICTH are clearly different, 
including pro-IGF-IIE[l-104] and pro-IGF-IIE[l-88], respectively, perhaps accounting for 
the development of osteosclerosis in one syndrome and hypoglycaemia in the other [86]. 
Furthermore, in HCAO, the 150 kDa ternary complexes in serum are formed normally 
and there is no increase in serum free IGFs [87]. 
Diagnosis 
NICTH suppresses insulin secretion by beta-cells, lipolysis, and ketogenesis [40,43,44], 
leading to low C-peptide, and inappropriately low GH and beta-hydroxybutyrate (�-OHB) 
concentrations in the circulation [1,46]. In case of hypoinsulinaemic hypoglycaemia the 
assessment of elevated serum levels of 'big' -IGF-II or E [68-88]-peptide, in combination 
with increased levels of IGFBP-2 by specific immunometric assays is of high diagnostic 
value [38]. Size-exclusion acid chromatography, a very time-consuming procedure, 
has been considered the gold standard method for detection of 'big' -IGF-II in NICTH. 
However, measurement of the serum concentration of 'big' -IGF-II determined by 
immunoblot analysis of 'big' -IGF-II and mature IGF-II after 16.5% tricine-sodium dodecyl 
sulphate-polyacrylamide gels has proven to be a more rapid, reproducible and equally 
sensitive method and a useful laboratory evaluation of patients with a clinical diagnosis 
of NICTH [88]. 
Since GH secretion is restrained with subsequent lowering of GH dependent IGF-1 
and IGFBP-3 production by the liver (figure 4), reduced levels of the latter proteins in 
serum represent useful additional markers, as well as an increased ratio between total 
IGF-II and IGF-1. Despite hypoglycaemia, levels of glucagon are often within the normal 
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Figure 4. Proposed mechanism of the development of non-islet cell tumour-induced 
hypoglycaemia (NICTH). It is likely that tumour cells cannot process the augmented amounts 
of pro-insulin-like growth factor-II (pro-IGF-II) synthesized, resulting in a substantial release 
of 'big'-IGF-II into the circulation. 'Big'-IGF-II competes with the mature IGF-II and IGF-I for 
binding to IGF-binding proteins (IGFBPs). However, the formation of the ternary complex 
between 'big'-IGF-II, IGFBP-3 and the acid-labile subunit (ALS) in the circulation is hampered. 
As a consequence, primarily 40-50 kDa binary complexes are formed. In addition, both free 
fractions of IGF-I and total IGF-II are increased. Since the binary complexes and free IGFs 
can pass the capillary membrane relatively easily when compared to the 150 kDa ternary 
complex, the concentrations of IGFs, presumably especially 'big'-IGF-II, at the tissue level will 
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rise inducing a strong insulin-like effect via the insulin receptors, causing hypoglycaemia. 
Moreover, because of an increasing negative feedback on growth hormone (GH) production 
by the anterior pituitary gland, the synthesis of CH-dependent peptides such as IGF-I, 
IGFBP-3, IGFBP-5 and ALS is decreased. This leads to even further declined formation of 
ternary complexes. Abbreviations: FFA, free fatty acids. 
However, in the absence of diffuse liver metastases, tumour-induced hypoglycaemia 
often is associated with increased, rather than depleted, hepatic glycogen stores [18,45]. 
Furthermore, hypokalaemia is often associated with hypoglycaemia, presumably due to 
the insulin-like activity of ('big'-) IGF-II [41] .  
Since tumours causing NICTH are usually very large, they can be readily detected by 
conventional radiological imaging using computed tomography or magnetic resonance 
imaging. However, one has to bear in mind that functional tumour imaging techniques 
such as fluorodeoxyglucose-positron emission tomography may lead to false-negative 
results [90]. Presumably this is due to an accelerated uptake of fluorodeoxyglucose by 
especially the heart and skeletal muscle that competes with the slower rate of uptake of 
tracer by tumour tissue. Other nuclear tracers such as radiolabelled tyrosine can provide 
an alternative [91]. 
Treatment 
Curative and palliative measures 
The long-term therapeutic strategies in NICTH involve complete removal of the tumour 
or reduction of the tumour mass. The metabolic alterations caused by NICTH are 
fully reversible after successful surgical removal of the 'big' -IGF-II producing tumour 
[37,40,68], as also demonstrated in case 1. 
In many cases, including patient 2, the malignancy causing NICTH is a large mass 
infiltrating into surrounding tissue and often accompanied by disseminated disease. 
Alleviating hypoglycaemia is subsequently a therapeutic challenge. When curative 
resection is no longer possible, various approaches to the treatment of NICTH have 
been tried with the initial aim of relieving the hypoglycaemic symptoms. Chemotherapy 
directed against the tumour or selective embolisation of tumour mass can also reduce 
the occurrence of hypoglycaemic events. However, when the tumour has only partially 
disappeared, hypoglycaemia is likely to reoccur when the tumour grows again [92]. 
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Increasing serum glucose 
In order to treat hypoglycaemia, a short-term beneficial effect is best achieved with 
(continuous) parenteral administration of glucose and dietary guidelines. However, 
especially when taken into account the condition of the patient, these measures are 
sometimes difficult to realise. As in insulinomas, diazoxide-chlorothiazide treatment may 
improve NICTH-symptoms [1]. Correction of hypoglycaemia also has been attempted 
successfully by the administration of glucagon. It does so primarily by increasing 
hepatic glucose output [18]. Interestingly, Hoff and Vassilopoulou-Sellin reported that a 
glycaemic response to a glucagon stimulation test predicted good response to long term 
treatment with glucagon (0.06-0.3 mg/hour), via continuous intravenous infusion [93]. 
Somatostatin analogues 
The presence of somatostatin receptors has been demonstrated previously in a pleural 
fibroma causing NICTH [94] and in approximately 40-55% of hepatocellular carcinomas 
[95,96]. However, in NICTH the administration of somatostatin analogues such as 
octreotide, generally does not restore glucose levels, probably because somatostatin 
receptors, if present at all in the hypoglycaemia-causing tumour, are non-functional 
[94,97,98]. Nonetheless, in a case of an intra-abdominal haemangiopericytoma, the 
prolonged infusion of somatostatin appeared to reduce the secretion of 'big'-IGF-11 by 
the tumour [45]. 
G 1 ucocorticosteroids 
Glucocorticosteroid treatment seems to be the most effective one in terms of long-term 
relief from hypoglycaemia by stimulating glyconeogenesis and suppressing, although 
not in all cases, the production of 'big'-IGF-11 and correcting the attendant biochemical 
abnormalities involving the GH-IGF axis [63,94,99,100]. Moderate to high doses of 
glucocorticosteroids may cause shrinkage of the tumour. A recent study extended these 
findings by demonstrating that the beneficial effects of glucocorticosteroids are dose­
dependent and reversible when treatment is withdrawn or when the dose falls below a 
critical level [101]. 
Growth hormone 
In a recent review [102], the stimulation of IGFBP-3 and ALS production by the liver after 
the administration of rhGH was considered to be beneficial in the treatment of NICTH. 
However, in two cases of NICTH associated with pleural solitary fibrous tumours, 
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successful GH treatment lead to only moderate increments of circulating IGF-1 and 
IGFBP-3 levels [103]. This would suggest that alternative, possible direct, mechanisms 
of action of GH in alleviating hypoglycaemia most likely play a role. Although increases 
in serum concentrations of IGFBP-3 and ALS indisputably occur, it seems that either 
the production rise is insufficient and/or the amount of tumour-derived 'big'-IGF-11 
is still sufficient to inhibit formation of ternary complexes [65,100]. Analogous to the 
induction of glucose intolerance in acromegaly, stimulation of hepatic gluconeogenesis 
and glycogenolysis may be an important aspect of the effect of (recombinant) GH. As 
demonstrated previously [99,103], GH can alleviate hypoglycaemia. Aside from their 
influence on serum insulin and glucose the diverse metabolic effects of GH (in protein 
sparing) and glucocorticosteroids (in tumour suppression) suggest that their combined 
use may be feasible in the treatment of NICTH [63,100,101,104]. 
Conclusion 
In patients with a mesenchymal or malignant epithelial tumour suffering from 
hypoglycaemic episodes or unconsciousness, NICTH should be considered. NICTH 
follows the production of partially processed forms of pro-IGF-11, called 'big'-IGF-11, 
which, apart from direct insulin-like biological activity, fails to form inactive ternary 
complexes with IGFBPs and ALS and would increase bioavailability of IGFs. At the 
target tissues, ('big' -)IGF-11 interacts with IGF-lR and insulin receptors resulting in 
hypoglycaemia. Low serum insulin in combination with elevated levels of 'big' -IGF-11 
and an increased IGF-11:IGF-I ratio would confirm the diagnosis. Removal of the tumour 
can cure NICTH but when that is no longer possible, treatment with glucocorticosteroids, 
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Chapter 3b 
Tumour-induced hypoglycaemia is a rare paraneoplastic phenomenon. Insulinomas 
are the most common tumours associated with hypoglycaemia. The incidence of these 
insulin secreting tumours is estimated at 0.5 to 4 per million people per year [1 ,2]. 
However, hypoglycaemia may also occur in solid tumours of epithelial or mesenchymal 
origin. Hypoglycaemia caused by these types of tumours is referred to as non-islet cell 
tumour hypoglycaemia (NICTH). NICTH is generally attributable to the secretion of 
large amounts of incompletely processed insulin-like growth factor II (IGF-II), also called 
'big' -IGF-II [3]. 
In this report, we describe the case of a patient with metastatic gastrointestinal stromal 
tumour (GIST) who presented with a loss of consciousness due to hypoglycaemia caused 
by increased concentrations of 'big'-IGF-II. 
Case report 
A SO-year-old man was admitted to the hospital because of loss of consciousness. He 
was known for a large retroperitoneal GIST diagnosed three years earlier as a recurrence 
of a previously resected sarcoma, at that time interpreted as a leiomyosarcoma. In 
the summer of 2001, the patient was enrolled in a clinical trial with the tyrosine 
kinase inhibitor imatinib mesylate (gleevec®). From that moment, stable disease was 
established during a year followed by local tumour progression. At that time, debulking 
of the tumour was performed. Three months later, a CT-scan revealed multiple liver 
metastases. Subsequently, the patient was included in a phase I study. However, during 
the following months he showed further disease progression. 
On admission, physical examination revealed a comatose patient with a Glascow 
Coma Score of 1-4-1. A CT-scan was performed because a neurological cause was 
considered. However, his serum glucose level turned out to be 1.0 mmol/L (normal 
fasting glucose 4.0-5.4 mmol/L). Further laboratory investigation showed normal kidney 
function, slightly abnormal liver function tests and low insulin (<2 mU/L) levels. He 
recovered quickly after glucose infusion. A carbohydrate rich diet could hardly prevent 
more hypoglycaemic events and prednisolone 30 mg per day was started. The patient 
died a month later. 
Because NICTH was suspected, serum samples obtained during the phase of stable 
disease, disease progression and a month prior to admission were analysed. IGF-I and 
IGF-binding protein 3 (IGFBP-3) levels were reduced and the concentration of IGFBP-2 
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was elevated a month prior to admission (table 1) . In contrast, the levels of these proteins 
at the other time points fell within the normal range. The amount of total IGF-II was 
not deviated from normal control at all the time points. However, levels of pro-lGF­
IIE[68-88] ('big'-IGF-II) were markedly elevated a month before admission. 
Table 1. IGF and IGFBP levels at various time points1 
Stable disease Disease progression Prior to admission 
IGF-I (nmol/L) 10.6 (-1 .19)2 19.5 (1 .10) 3.9 (-4.56) 
IGF-II (nrnol/L) 49.4 (-0.83) 71.2 (1.16) 48.5 (-0.92) 
Pro-IGF-IIE[68-88] (nrnol/L) 6.24 (0.16) 7.13 (0.35) 21.9 (5.23) 
IGFBP-2 (nmol/L) 12.8 (1.89) 11 .6 (1 .65) 23.6 (3.27) 
IGFBP-3 (nmol/L) 44.7 (-1.49) 55.0 (-0.64) 22.3 (-4.44) 
1 Serum concentrations were determined by Jaap van Doorn, Laboratory of Endocrinology, Wilhelmina Children's 
Hospital, Utrecht, The Netherlands 
2 Standard deviation scores (Z-scores) are given between hedges. 
Discussion 
There are several mechanisms by which solid tumours can cause hypoglycaemia: (1) 
insulin secreting insulinornas, (2) non-islet cell tumours secreting aberrant IGF-11 and (3) 
liver and adrenal failure due to tumour invasion [2]. Our patient had elevated levels of 
'big'-IGF-II that is associated with NICTH and had no signs of liver failure. 
Both IGF-II and IGF-I are structurally and functionally related to insulin [4,5]. They 
can exert an insulin-like activity by binding to the insulin receptor and IGF receptor type 
1 [6]. This insulin-like activity is only 5% of insulin but the total serum concentration of 
IGFs is about 1000-fold higher than the mean insulin concentration. Hypoglycaemia does 
not occur, however, because of binding to IGFBPs. Under physiological conditions, 75-
80 percent of the IGFs are bound to IGFBPs, mostly IGFBP-3, and an acid-labile subunit 
(ALS). The remainder is bound to IGFBP-3 alone as a binary complex or, less than 1 
percent, circulates in a free form. The ternary complex has a molecular mass of about 
150 kDa and is not able to pass the capillary membrane. In this way the availability of 
IGFs to their target tissues is limited [7]. IGF-1, IGFBP-3 and ALS are produced by the 
liver and their production is stimulated by growth hormone (GH) secretion. GH, in turn, 
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is negatively regulated by IGF-I and IGF-II. In contrast, IGF-II is produced by various 
tissues which is CH-independent [6]. 
Non-islet cell tumours causing hypoglycaemia contain elevated levels of mRNA for 
IGF-II [8,9]. IGF-II is thought to act as an autocrine growth factor in various tumours 
[8,10]. It is produced as a pre-prohormone. During intracellular processing, tumour 
cells fail to cleave the large E-domain from pro-IGF-II, which leads to the secretion of 
an extraordinary large amount of uncleaved peptide, the so called 'big'-IGF-II [11]. 
In NICTH, high serum concentrations of 'big'-IGF-II are associated with a shift in the 
distribution of IGFs from high-molecular-weight ternary complexes to binary complexes 
and to the unbound form [9,12]. Therefore, it seems likely that abundant 'big'-IGF-II leads 
to an impaired formation of the ternary complex. This could be due to several factors. 
In the first place, It has been reported that the aberrant form of IGF-II and IGFBP-3 have 
the inability to form complexes with ALS [13]. Furthermore, an increase in circulating 
'big'-IGF-II levels could suppress GH secretion. As a consequence, IGFBP-3 and ALS 
production by the liver is decreased, leading to a further decrease in ternary complexes 
[9]. Binary complexes and unbound IGF can easily cross the capillary membrane. 
'Big'-IGF-II has the same affinity to the insulin and IGF receptor type 1 as normal IGF­
II [9]. Excessive receptor stimulation causes increased peripheral glucose uptake and 
suppressed hepatic glucose output, resulting in hypoglycaemia [14]. 
Laboratory investigation can confirm the diagnosis NICTH. Low insulin and 
C-peptide levels are detected, related to a low glucose concentration. GH, IGF-I 
and IGFBP-3 levels are typically decreased. An elevated level of IGFBP-2 is also a 
characteristic finding in patients with NICTH, although the mechanisms by which it is 
increased are unclear [15]. The concentration of E-domain containing forms of IGF-II is 
increased [11] .  However, total IGF-II levels are usually within the normal range, which is 
probably due to increased turnover rates. Furthermore, an IGF-II:IGF-I molar ratio >10 is 
also considered pathognomic of NICTH [2]. All these characteristic laboratory findings 
were retrospectively found in our patient, including markedly elevated big-IGF-II levels 
(standard deviation score 5.23) and a IGF-II:IGF-1 molar ratio of 12.4 (table 1). 
Data on the exact incidence of NICTH are not available. It has been estimated that 
NICTH is four times less common than insulinoma, but the true incidence is probably 
higher [2]. In most of the cases, NICTH is caused by a tumour of mesenchymal origin. 
These tumours are usually large and can be both benign and malignant. The most 
common histological types causing hypoglycaemia are fibrosarcomas, mesotheliomas, 
leiomyosarcomas, and haemangiopericytomas [3]. 
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Our patient suffered from a large GIST with multiple liver metastases. GISTs are a 
group of mesenchymal neoplasms, showing differentiation towards the interstitial cells 
of Cajal, also known as the pacemaker cells of the gastrointestinal tract. Virtually all GISTs 
over-express the receptor tyrosine kinase KIT that, in most cases, contains mutations 
leading to ligand-independent activation of the receptor. Until recently, stromal 
tumours of the gastrointestinal tract were regarded as leiomyomas, leiomyosarcomas 
or leiomyoblastomas. However, these tumours do not express KIT and nowadays GISTs 
are considered as a distinct clinicopathological entity [16]. The introduction of imatinib 
mesylate, an inhibitor of KIT, has dramatically improved the life expectancy of patients 
with metastatic GIST [17]. Recently, Beckers et al have described a patient with NICTH due 
to a GIST [18]. This report is the second one about this topic. There are several reported 
cases about hypoglycaemia caused by a leiomyosarcoma of the stomach or bowel [19,20]. 
Advances in KIT immunostaining has revealed that leiomyosarcomas of stomach and 
bowel are extremely rare. Therefore, it is very suggestive that these tumours should have 
been GIST and probably more cases associated with hypoglycaemia will be reported in 
the near future. 
In order to treat the hypoglycaemia, a short-term effect is best achieved with infusion 
of glucose and dietary guidelines. The best long-term treatment is to reduce the tumour 
by surgery, irradiation or chemotherapy [6]. In our patient, frequent carbohydrate rich 
meals could not prevent the recurrence of new hypoglycaemic events. When tumour 
reduction can not be established and dietary measurements and infusion of glucose is 
not sufficient, administration of glucocorticoids, glucagon and high dose GH can be tried 
[21-23]. 
In conclusion, in unconscious cancer patients - especially those diagnosed with 
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Chapter 4 
Abstract 
Objective: Patients with a gastrointestinal stomal tumour (GIST) suffering from non-islet 
cell tumour-induced hypoglycaemia (NICTH), being associated with increased plasma 
levels of pro-insulin-like growth factor (IGF)-IIE[68-88], have been reported occasionally. 
We studied the clinical relevance of pro-IGF-IIE[68-88] and other IGF-related proteins in 
GIST patients. 
Patients and methods: Twenty-four patients were included. Plasma samples were 
collected before, 1 week, and median 5 months after start of treatment with imatinib, and 
levels of IGF-I, total IGF-11, pro-IGF-IIE[68-88], IGFBP-2, -3 and -6 were determined. GIST 
specimens from 17 patients and tumour cyst fluid from two patients were analysed for 
IGF-11 and IGFBP-2. 
Results: Before treatment and/or during follow-up, 3/24 (13%) patients showed increased 
plasma levels of pro-IGF-IIE[68-88]. All three developed NICTH. Overall, patients with 
either metastatic disease, elevated serum LDH activity, or total tumour size >12 cm had 
the highest pro-IGF-IIE[68-88] levels. Most patients had increased plasma IGFBP-2 levels 
and these levels were significantly higher in patients with progressive disease. (pro-)IGF-
11 was expressed in 82% of GISTs, and IGFBP-2 only in one case. 
Conclusions: We identified pro-IGF-IIE[68-88] as a marker that may be used in the 
surveillance of GIST. 
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Introdudion 
Gastrointestinal stomal tumours (GISTs) are the most common mesenchymal malignant 
tumours of the gastrointestinal tract. GISTs are characterised by the over-expression 
of the receptor tyrosine kinase KIT. In about 80 percent of the GISTs, KIT gain-of­
function mutations are found, while 5-7 percent of the tumours harbour platelet-derived 
growth factor receptor a (PDGFRA) activating mutations [1]. Patients with metastatic 
or unresectable GIST are successfully treated with imatinib, an inhibitor of KIT and 
PDGFRA [2]. 
Non-islet cell tumour-induced hypoglycaemia (NICTH) is a paraneoplastic syndrome 
characterised by recurrent fasting hypoglycaemia. It is associated with the secretion of 
incompletely processed precursors of insulin-like growth factor-II (IGF-11) by the tumour 
into the circulation. These precursors consist mainly of mature IGF-11 with a 21-residue 
carboxyl extension of the E-domain of pro-IGF-11, called pro-IGF-IIE[68-88] or 'big' -IGF-
11 (for review, see [3]). Patients with NICTH usually exhibit low circulating levels of IGF­
binding protein-3 (IGFBP-3) and total IGF-I, whereas those of IGFBP-2, (occasionally) 
IGFBP-6, and free unbound IGFs are increased [3,4]. 
Recently, we and others have reported on the occurrence of NICTH in patients with 
a GIST [5-10]. Based on these relatively high number of cases reported so far, it seems 
that patients with a GIST are at risk for developing NICTH. In the present study, we 
determined the plasma levels of IGF-I, total IGF-11, pro-IGF-IIE[68-88], IGFBP-2, -3, and 
-6 for a cohort of patients with a GIST, before and during treatment with imatinib. The 
predictive values of these parameters with respect to the occurrence of hypoglycaemia, 
disease progression and response on treatment were evaluated. 
Patients and methods 
Patients 
Twenty-four consecutive newly treated patients at the department of Medical Oncology 
of the University Medical Center Groningen were included in this study. Patients were 
eligible in case of advanced unresectable or metastatic histologically proven GIST, as 
characterised by CD117 positivity, for which treatment with imatinib was indicated. 
Every patient underwent a routine computed tomography (CT) scan prior to the start of 
therapy, 8 weeks after start of therapy, and every 3 months thereafter until progression 
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of disease. In addition, routine 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG)-positron 
emission tomography (PET) scanning was performed a few days before and one week 
after the start of imatinib. EDTA-plasma samples were collected prior to the start of 
treatment, 1 week after start of therapy, and during the first year (median 5 months, 
range 2-12 months) of treatment. For those patients who developed hypoglycaemia 
during clinical follow-up, routine, non-fasting, EDTA-plasma samples were taken to 
diagnose NICTH. 
Overall tumour size was determined by the sum of the longest diameter for all target 
lesions as defined by RECIST [11]. Initial overall response to therapy was defined when 
at least two of the following events were noted in an individual patient: (1) improvement 
of clinical symptoms, (2) CT scan response (partial response according to RECIST, i.e. 
�30% decrease in the sum of the longest diameter of target lesions based on CT before 
and 8 weeks after start of treatment [11], or (3) >25% decrease in FDG uptake on PET 
scanning on day 8 compared with the pretreatment scan [12,13]. The examination of 
the PET images was performed as described previously by using standardized uptake 
value (SUV) analysis [14]. Disease progression after initial response was defined as (1) 
the occurrence of a new lesion, (2) increasing size of the pre-existing lesions (as defined 
by RECIST), or (3) development of an intratumoral nodule and/or an increase in 'solid' 
tissue, in the background of a hypodense lesion [13]. 
The study protocol was approved by the Medical Ethics Committee of the University 
Medical Center Groningen and all patients gave their informed consent. 
Measurement of plasma levels of IGFs and IGFBPs 
Concentrations of IGFBP-2, IGFBP-3, IGFBP-6, IGF-I, pro-IGF-IIE[68-88], and total 
IGF-II (i.e. both mature 7.4 kDa IGF-II and pro-IGF-IIE[68-88] are detected in this 
radioimunnoassay with nearly equal potency) in plasma and cyst fluid were determined 
as described previously [15-17]. 
Cyst fluid, GIST specimens and histological examinations 
For two patients cyst fluid was aspirated from metastatic lesions using a routine 
procedure to relieve abdominal tension. 
From 17 of 24 patients paraffin-embedded tumour samples were available. From each 
tumour sample three (distinct) representative 0.6 mm cores were taken and transferred 
to a standard-size recipient paraffin block and immunohistochemistry was performed as 
described previously [18]. Antigen retrieval was performed by boiling slides in 0.01 M 
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citrate buffer (pH 6.0). Primary antibodies were rabbit anti-IIE[68-88] antiserum (1:200; 
WKZ6279) [16] and polyclonal goat anti-IGFBP-2 (1:500; Santa Cruz Biotechnology, Santa 
Cruz, Ca, USA). As a negative control, a serial section was processed by replacement of 
primary antibody with preimmune primary antisera or normal goat IgG. The methods 
used for in situ hybridisation with digoxigenin-labeled hlGF-11 complementary RNA 
probes have been described previously [19]. Negative controls for in situ hybridisation 
were prepared using sense probes. For both immunohistochemistry and in situ 
hybridisation, normal tissue samples derived from first trimester placenta served as 
positive controls [20]. The intensity of histochemical staining was evaluated by two 
independent observers (B.R. and A.J.H.S). Tissue cores from a particular tumour were 
judged to be positive when there was a clear cytoplasmic staining in at least two of the 
three cores. 
Tumours from patients with NICTH were analysed for KIT and PDGFRA mutations 
as described in the supplementary materials and methods section and the supplementary 
table. 
Statistics 
As the plasma levels of most of the IGFs and IGFBPs are age- and sex-dependent, the 
concentrations were compared with age- and sex-dependent references and expressed 
as standard deviation scores (SDS) [15-17]. The Wilcoxon signed ranks test was used 
to compare plasma levels with the reference population or to analyse paired data. 
Differences between two groups were studied with the Mann-Whitney U test. Correlations 
were described by the Spearman's rank correlation coefficient (r). The log rank test was 
applied to analyse the impact of variables on survival. A double-sided P-value <0.05 was 
considered statistically significant using SPSS for windows version 12.0. 
Results 
General clinical characteristics of the GIST patients 
Patient characteristics are summarised in table 1. Two third of the patients had metastatic 
disease and the median total tumour size was 14 cm. The initial overall response to 
imatinib was 75% with a median progression-free survival of 25 months which is in 
agreement with previous reports [2]. Three patients encountered episodes of symptomatic 
hypoglycaemia, with fasting plasma glucose levels lower than 3.0 mmol/L, either during 
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treatment with a tyrosine kinase inhibitor or in the course of follow-up after treatment. 
These patients will be presented in more detail in the last paragraph. 
Table 1. Patient characteristics (n=24) 
n (%) Median (range) 
Sex 
Male 16 (67) 
Female 8 (33) 
Age (years) 62 (24 - 82) 
Primary tumour localisation 
Stomach 8 (33) 
Small bowel 10 (42) 
Colon 3 (13) 
Other site 3 (13) 
Disease stage 
Primary disease only 8 (33) 
Metastatic disease 16 (67) 
Total tumour size (cm) 14 (4 - 47) 
Serum LDH (U/L) 263 (117 - 902) 
Serum albumin (g/L) 37 (28 - 45) 
Initial overall response 
Response 18 (75) 
No response 6 (25) 
PET-response 
Response 19 (79) 
No response 5 (21) 
CT-response 
Partial response 7 (29) 
Stable disease 16 (67) 
Progressive disease 1 (4) 
Clinical symptoms 
Improvement 16 (67) 
No improvement 3 (13) 
No symptoms 5 (21) 
Progression-free survival (months) 25 
Follow-up (months) 37 (4 - 85) 
LDH, lactate dehydrogenase; PET, positron emission tomography; CT, computed tomography. 
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Pretreatment plasma levels of IGFs and IGFBPs 
Pretreatment plasma samples were available from 22 of 24 patients included in this 
study. The median SDS values of the IGFs and IGFBPs, as determined prior to imatinib 
treatment, are shown in table 2. Eight patients (36%) showed plasma pro-IGF-IIE[68-88] 
levels higher than 1 .0 SDS, including one patient with a plasma level higher than 2.0 
SDS. This patient developed NICTH. The median concentration of IGFBP-2 in the plasma 
of GIST patients was markedly higher than that observed in healthy individuals. For 
14 patients (64%), the plasma IGFBP-2 levels exceeded 2.0 SDS. In contrast, the median 
IGFBP-3 SDS for GIST patients was slightly but significantly reduced compared to the 
reference population. 
Table 2. Plasma levels of IGFs and IGFBPs, expressed as standard deviation scores, for patients 
(n=22) before the start of treatment with imatinib 
Median (range) P-value (vs. normal)1 
IGF-I 0.07 (-2.26 -2.66) 0.95 
Total IGF-11 -0.07 (-2.99 -2.05) 0.63 
Pro-IGF-IIE[68-88] 0.47 (-2.17 -7.08) 0.077 
IGFBP-2 2.20 (-0.62 - 3.65) <0.001 
IGFBP-3 -0.58 (-1 .84 -2.38) 0.009 
IGFBP-6 0.08 (-1.47 -2.11) 0.88 
1Wilcoxon signed ranks test, the P-value indicates whether a median SOS is different from normal (i.e. 0 SOS). 
IGF, insulin-like growth factor; IGFBP, insulin-like growth factor-binding protein; SOS, standard deviation scores. 
Patients with a relatively high tumour load (i.e. total diameter >12 cm [21]) exhibited 
significantly higher pretreatment plasma levels of pro-IGF-IIE[68-88] than subjects with 
a lower tumour load. Furthermore, plasma levels of pro-IGF-IIE[68-88] were higher in 
patients with metastatic disease than those with single primary (unresectable) tumours. 
In addition, we encountered that increased serum LDH (i.e. >235 U/L) predicted a 
relatively high plasma pro-IGF-IIE[68-88] level (table 3). Serum LDH correlated well 
with total tumour size (r=0.848, p<0.001) .  
We found a significant inverse correlation between serum albumin levels and plasma 
IGFBP-2 SDS values (r=-0.559, p=0.007) . No associations were found between IGF-I, total 
IGF-II, IGFBP-3 and IGFBP-6 plasma levels and any of the clinical parameters studied. 
Elevated plasma levels (i.e. either SDS >l.0 or >2.0) of any component of the IGF system 
investigated did not predict progression-free survival. In addition, we analysed the 
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Table 3. Association between patient and tumour characteristics and baseline plasma pro-IGF­





$;62 years (n=ll) 
>62 years (n=ll) 
Primary localisation 
Small bowel (n=9) 
Other sites (n=13) 
Disease stage 
Primary disease only (n=7) 
Metastatic disease (n=15) 
Tumour size 
$;12 cm (n=8) 
>12 cm (n=14) 
Serum LOH 
$;235 (U/L) (n=9) 
>235 (U/L) (n=13) 
Serum albumin 
<34 (g/L) (n=6) 
2::34 (g/L) (n=16) 
Initial overall response 
Response (n=16) 
No response (n=6) 
PET-response 
Response (n=17) 
No response (n=5) 
CT-response 
Partial response (n=6) 
Stable/progressive disease (n=16) 
Clinical symptoms 
Improvement (n=14) 
No improvement (n=3) 
1Mann-Whitney U test. 
Pro-IGF-IIE[68-88], median (range) 
-0.08 (-2.81-1.83) 
1.29 (-0.39-7.08) 
0.22 (-0.43 -1.28) 
0.72 (-2.17 - 7.08) 
0.92 (-0.75-1.64) 
0.22 (-2.17 -7.08) 
-0.32 (-2.17 -1.25) 
1.02 (-0.75-7.08) 
-0.09 (-2.17 - 1.25) 
1.02 (-0.75 -7.08) 
-0.25 (-2.17 - 1.25) 
1.12 (-0.75 -7.08) 
0.37 (-2.17 -1.64) 
0.67 (-0.39 -7.08) 
0.23 (-2.17 -1.64) 
0.90 (0.21 -7.08) 
0.42 (-2.17-1.64) 
0.52 (0.21 -7.08) 
0.47 (-0.75-1.25) 
0.47 (-2.17 -7.08) 
0.01 (-2.17 - 1.64) 













IGF, insulin-like growth factor; LOH, lactate dehydrogenase; PET, positron emission tomography; CT, computed 
tomography. 
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mutual relationships among the pretreatment levels of IGFs and IGFBPs. IGF-I SDS 
correlated with total IGF-11 SDS and IGFBP-3 SDS (r=0.521, p=0.013 and r=0.475, p=0.025, 
respectively). Total IGF-11 SDS correlated negatively with IGFBP-2 SDS (r=-0.562, p=0.007). 
Plasma levels of IGFs and IGFBPs in patients during treatment with imatinib 
In the total group of patients, the plasma SDS values of the various IGFs and IGFBPs did 
not change significantly after one week of imatinib treatment. After median 5 months, 
only IGFBP-3 showed a significant decline compared to pretreatment scores (median 
pretreatment SDS: -0.64 (range: -1.84 - 2.38) vs. median follow-up SDS: -1.18 (range 
-3.27 - 0.78); p=0.005; n=20). Cross-sectional analysis revealed that, during the first 
year of treatment, the plasma IGFBP-2 levels in patients with progressive disease were 
significantly higher compared to those in patients without progressive disease (table 4). 
Within the first treatment year, two additional patients (besides the one who already 
showed a high pretreatment value) had plasma pro-IGF-IIE[68-88] levels that exceeded 
2.0 SDS, and subsequently also developed NICTH (table 5). 
Table 4. Plasma levels of IGFs and IGFBPs, expressed as standard deviation scores, during 
treatment with imatinib for patients with either progressive (n=4) or non-progressive disease 
(n=18) 
Progressive Non-progressive P-value1 
disease disease 
Interval since start of imatinib, 5.7 (1.9 - 9.5) 4.6 (1 .6 - 12.0) 0.77 
median months (range) 
IGF-1, median (range) -0.27 (-1.9 - 0.4) -0.46 (-4.8 - 2.11) 0.59 
Total IGF-11, median (range) -0.60 (-1 .33 - 1.68) -0.76 (-2.21 - 1.42) 0.40 
Pro-IGF-IIE[68-88], median (range) 1 .13 (-1.62 - 8.64) -0.29 (-2.68 - 2.49) 0.11 
IGFBP-2, median (range) 3.50 (2.47 - 4.46) 1.38 (-1 .02 - 3.97) 0.002 
IGFBP-3, median (range) -1 .68 (-3.27 - -1 .22) -0.98 (-2.13 - 0.78) 0.40 
IGFBP-6, median (range) -0.79 (-1.77 - 1.37) 0.01 (-1.41 - 3.31) 0.49 
1Mann-Whitney U test. 
IGF, insulin-like growth factor; IGFBP, insulin-like growth factor-binding protein. 
IGF-11 and IGFBP-2 in GIST specimens and tumour cyst fluid 
Sixteen of the 17 (94%) tumours studied showed significant IGF-11 mRNA expression. 
Fourteen of the mRNA positive samples stained also positive for IIE[68-88] containing 
peptides. The GIST specimens of the patients with hypoglycaemia, who exhibited 
elevated pro-IGF-IIE[68-88] plasma levels, showed a pronounced expression of both IGF-
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II mRNA and protein (figure 1). In contrast, positive staining for IGFBP-2 protein was 
observed for only one GIST. Curiously, the patient from whom this tumour specimen was 
obtained showed only moderately elevated plasma IGFBP-2 levels (2.09 SDS). 
Figure 1. Expression of the IIE[68-88] containing pro-IGF-II protein and IGF-II mRNA in GISTs 
causing hypoglycaemia. (A-C) Immunohistochemistry for the IIE[68-88] protein in paraffin­
embedded GIST sections obtained from patients (numbers 1, 2 and 3, respectively) who 
appeared to develop NICTH. All samples showed diffuse cytoplasmic staining. (D-F) In situ 
hybridisation for hIGF-II mRNA expression in the same tissue sections. (Dark)blue staining 
indicates the presence of hIGF-II mRNA (magnification, x200). See page 190 for colour figure. 
Analysis of cyst fluid revealed that the concentrations of pro-IGF-IIE[68-88] in cyst 
fluid and the corresponding plasma sample were nearly similar, i.e. 6.9 nmol/L and 7.3 
nmol/L (= 0.3 SDS), respectively, in one case. For the second patient, who exhibited an 
elevated level of pro-IGF-IIE[68-88] in plasma (14.5 nmol/L, corresponding to 3.5 SDS), 
the molar ratio of pro-IGF-IIE[68-88] between cyst fluid and plasma was markedly 
higher, i.e. 1.6. For the two patients investigated, molar ratios of IGFBP-2 between cyst 
fluid and plasma were 1.1 and 0.8. 
Patients with NICTH 
The first patient was a SO-year old man and has been described previously [6]. In short, 
this patient had a large recurrent retroperitoneal GIST with a KIT exon 9 mutation. After 
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an initial response to imatinib, he suffered from progressive disease and developed 
a hypoglycaemic coma. The second patient was an 83-year old woman with type 2 
diabetes mellitus treated with insulin and a recurrent unresectable GIST with a KIT 
exon 9 mutation. During imatinib treatment, her daily insulin doses had to be reduced 
continuously to maintain acceptable glucose levels. After 3 years of imatinib treatment, 
she had disease progression, switched to sunitinib and developed nocturnal episodes 
of hypoglycaemia, without insulin treatment. She died comatose at home while having 
progressive disease. The third patient was an 82-year old woman with liver metastases 
from a gastric tumour with a PDGFRA exon 18 (Asp842Val) mutation. She did not 
respond to imatinib and developed fasting hypoglycaemias 8 weeks after the start of 
the treatment. At the time hypoglycaemia became manifest, markedly elevated plasma 
levels of both pro-lGF-IIE[68-88] and IGFBP-2 and low concentrations of IGFBP-3 and 
IGF-1 were observed in all patients (table 5). Patient 2 showed a plasma IGFBP-6 level 
that exceeded 2.0 SDS, a phenomenon that has been encountered previously for some 
patients suffering from NICTH [22]. Notably, patient 3 showed a strikingly elevated 
concentration of pro-IGF-IIE[68-88] already before and 1 week after the start of imatinib 
(table 5). Furthermore, patient 1 and 2 had slightly increased pro-IGF-IIE[68-88] within 
the first year of treatment while they still responded clinically to imatinib therapy. None 
of the patients had signs of liver- or (ad)renal failure or cachexia at the time of NICTH. 
All three patients died of progressive disease within 2 months after the first documented 
episode of hypoglycaemia. 
Table 5. Plasma levels of IGFs and IGFBPs, expressed as standard deviation scores, for patients 
with NICTH at baseline, during imatinib treatment and when suffering from hypoglycaemia 
Patient 
1 2 3 
Time point 01 2 mo2 hypo3 0 B rno hypo 0 1 wk hypo 
IGF-I 0.34 -0.46 -4.56 -2.26 -4.80 -5.54 -0.41 -0.52 0.40 
Total IGF-II 1 .08 -0.22 -0.92 -1.40 -2.21 -6.15 1 .39 -0.20 1 .68 
Pro-IGF-IIE[68-88] 1 .17 2.49 5.23 1.40 2.21 4.55 7.08 6.53 8.64 
IGFBP-2 1.43 0.66 3.27 2.85 3.97 4.32 2.09 1 .83 2.47 
IGFBP-3 -0.32 0.15 -4.44 -0.68 -2.07 -4.49 -1 .69 -2.80 -3.27 
IGFBP-6 0.50 -0.53 0.19 1.07 2.42 0.09 -0.53 1 .37 
1Baseline values; 2Plasma levels after 2 months of imatinib treatment for patient 1, after 8 months for patient 2, and 
after 1 week for patient 3; 3Plasma levels when suffering from hypoglycaemia. 
IGF, insulin-like growth factor; IGFBP, insulin-like growth factor-binding protein; Hypo, hypoglycaemia; NICTH, 




This study was performed to investigate the relationship between plasma levels of IGF-I, 
-II, pro-IGF-IIE[68-88J, IGFBP-2, -3, and -6 and disease status of patients with a GIST 
before and during treatment with imatinib. In our cohort of patients we noticed that 
plasma levels of pro-IGF-IIE[68-88J, IGFBP-2 and -3 tend to differ considerably from 
normative range values. 
It appeared that at any moment before or during treatment, 11 of the 24 (46%) patients 
studied exhibited pro-IGF-IIE[68-88J levels that were higher than 1.0 SDS. Three of these 
patients showed values of pro-IGF-IIE[68-88J that even exceeded 2.0 SDS. Later on, they 
developed hypoglycaemia. These findings and the various previous case reports on this 
subject [5,7-10], indicate that elevated plasma concentrations of pro-IGF-IIE[68-88J are not 
uncommon in patients with a GIST and would predict a high risk for the development of 
hypoglycaemia. Histological examination and analysis of cyst fluid of the various GISTs 
revealed that it is highly likely that most of the pro-IGF-IIE[68-88J detected in plasma 
is secreted by tumour tissue. Indeed, a relatively high tumour mass and/or increased 
serum LDH appeared to be associated with significantly higher plasma levels of pro-IGF­
IIE[68-88J .  In addition, our data suggest that metastatic GISTs tend to produce more pro­
IGF-IIE[68-88J . Presumably, when a certain threshold level of pro-IGF-IIE[68-88J in the 
circulation has been exceeded, GH secretion by the anterior pituitary gland will become 
reduced due to an increased feedback inhibition [3]. Moreover, the formation of 150-kDa 
IGF-IGFBP-3-acid-labile subunit complexes in the circulation is increasingly hampered. 
This cascade of events results in an increased insulin-like activity in the body that may 
ultimately overrule the various counter regulatory mechanisms for hypoglycaemia. 
The three patients with hypoglycaemia reported in this study did not suffer 
from conditions such as (ad)renal failure, hepatic dysfunction or cachexia that could 
alternatively explain the occurrence of hypoglycaemia [23]. However, there are some 
reports that suggest that imatinib, and also the second-line tyrosine kinase inhibitor 
sunitinib, could influence glucose metabolism in patients with type 2 diabetes mellitus 
and possibly also in non-diabetic patients with a disturbed glucose homeostasis, like 
NICTH [8,24,25]. We also observed an improvement of fasting blood glucose levels in a 
patient with type 2 diabetes mellitus during treatment with imatinib, and later on with 
sunitinib, which allowed a consequent reduction of her insulin dosage before she finally 
suffered from NICTH. The latter could have been facilitated by the use of a KIT kinase 
inhibitor as suggested by Hamberg et al [8]. 
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Within our total patient population, we noticed that plasma IGFBP-3 levels, being 
already slightly reduced before treatment, declined further during prolonged imatinib 
therapy. Theoretically, this could increase the tissue availability of IGFs, including 
pro-IGF-IIE[68-88], facilitating the occurrence of hypoglycaemia and reducing insulin 
resistance in type 2 diabetes mellitus [26]. Recently, it was reported that IGFBP-3 mRNA 
was induced in GISTs that responded to imatinib according to FDG-PET several days after 
initiation of treatment. In contrast, IGFBP-3 mRNA was suppressed in non-responding 
GISTs [27]. In our evaluation, however, we noticed no significant changes in IGFBP-3 
plasma levels after one week of imatinib treatment, irrespective of the PET-response 
(data not shown) suggesting that an eventual induction of IGFBP-3 mRNA and protein 
in responsive GISTs does not influence the plasma levels of this IGFBP. 
Mutation analysis carried out on tumour tissues obtained from the three patients 
with NICTH revealed that two patients had a tumour with a KIT exon 9 mutation and 
one had a PDGFRA exon 18 mutation. These mutations have a much lower incidence (i.e. 
approximately 10 and 6 percent, respectively) than those that affect KIT exon 11, being 
by far the most frequent mutation found in GISTs (-60%) [l]. So far, only one NICTH 
GIST case with a KIT exon 9 mutation has been reported [9]. Interestingly, Braconi et 
al recently reported that a decreased disease-free survival in patients with a GIST was 
independently associated with IGF-11 expression by the tumour. In addition, they found 
that IGF-11 was more frequently expressed in tumours with KIT exon 9 mutations than 
in those with other mutations suggesting that mutational status could influence IGF-11 
expression and possibly the occurrence of NICTH [28]. 
In the majority of the patients, plasma IGFBP-2 levels were markedly elevated. 
Several studies have shown that circulating IGFBP-2 levels may be elevated in various 
malignancies [29-33] and may be associated with increasing tumour size, disease 
stage and adverse prognosis [29,30,32]. There were no such associations in our study, 
although patients with progressive diseases had significantly higher plasma levels of 
IGFBP-2 than patients who responded to imatinib. It has been suggested that elevated 
circulating IGFBP-2 levels found in patients with aforementioned malignancies are 
caused by the secretion of this protein by the tumour. However, our analysis of tissue 
and cyst fluid suggests that the elevated plasma levels of IGFBP-2, as found for most 
of the GIST patients, are due to other, systemic, as yet unknown processes. Increased 
levels of IGFBP-2 have also been observed in other disease conditions such as AIDS, 
diabetes mellitus and malnourishment [30,34]. As we did not evaluate specifically the 
nutritional status of our patients, we were not able to establish whether malnutrition 
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could have contributed to the increased IGFBP-2 levels in most of our patients. In spite 
of this, we did find a significant negative correlation between plasma IGFBP-2 SDS and 
serum albumin levels which is a rather non-specific marker for nutritional status [35]. On 
the other hand, IGF-I levels are also influenced by nutritional status [26]. In our patients, 
however, IGF-I levels generally did not differ from normative range values. All together, 
an eventual role for IGFBP-2 as a laboratory marker for disease progression in GIST 
patients remains to be established. 
In conclusion, we identified pro-IGF-IIE[68-88] as a marker that can potentially be 
useful in the surveillance of patients with a GIST. Symptoms of hypoglycaemia may be 
non-specific. Hence, we expect that in daily clinical practice cases of NICTH are being 
missed. Two of our patients even became comatose, indicating the serious implications 
of NICTH. We would therefore suggest that patients with a GIST, especially those with 
progressive disease, are monitored for plasma levels of pro-IGF-IIE[68-88] to identify 
patients who are at high risk for the development of hypoglycaemia. 
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Supplementary Material 
Material and methods 
KIT and PDGFRA mutation analysis. DNA was extracted from formalin-fixed and paraffin­
embedded (FFPE) tumour samples. DNA extraction from FFPE tissues was performed 
by affinity-purification of the DNA (QIAamp DNA micro handbook, QIAGEN GmbH, 
Germany) after treatment with proteinase K. DNA sample concentration and quality 
were assessed spectrophotometrically (260/280 nm using the NanoDrop) and by PCR­
amplification using the BIOMED-2 Control gene primer set [l]. All extracted DNAs 
allowed amplification of at least the 200 bp amplicon of the Control gene PCR. KIT exon 
9, 11, 13 and 17 and PDGFRA exon 12, 14 and 18 were amplified by PCR with the primers 
indicated in the supplementary table. All primers contain an M13 forward or reverse 
consensus sequence. The PCRs were performed using AmpliTaq Gold DNA polymerase 
(Applied Biosystems), PCR buffer II and 2.5 mM MgC12• The cycling conditions were 
standardised: after denaturation at 94°C for 5 min, DNA was amplified for a total of 40 
cycles (annealing temperature at 60°C). After the last cycle, a final extension step of 5 min 
at 72°C was performed. Sequencing reactions were performed from two independent 
PCR-reactions, using the forward and the reverse primers, and assessed on an ABI 3730 
platform (Applied Biosystems). Sequencing results from the cases were compared to 
sequences from normal individuals (KIT: NM_000222.2 and PDGFRA: NM_006206.3). 
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Supplementary table. Primers used for KIT and PDGFRA mutation analysis 
KIT exon 9-1 
Forward 
Reverse 
KIT exon 9-2 
Forward 
Reverse 
KIT exon 11 
Forward 
Reverse 
KIT exon 13 
Forward 
Reverse 
KIT exon 17 
Forward 
Reverse 
PDGFRA exon 12 
Forward 
Reverse 
PDGFRA exon 14 
Forward 
Reverse 




Primer sequence 5' -3' 
TGT AAA ACG ACG GCC AGT GTA TGC CAC ATC CCA AGT G 
CAG GAA ACA GCT ATG ACC TGC CCA CAT CGT TGT AAG C 
TGT AAA ACG ACG GCC AGT GCT TCT GTA CTG CCA GTG G 
CAG GAA ACA GCT ATG ACC GTA GAC AGA GCC TAA ACA TC 
TGT AAA ACG ACG GCC AGT GTG CTC TAA TGA CTG AGA C 
CAG GAA ACA GCT ATG ACC GTG TAC CCA AAA AGG TGA C 
TGT AAA ACG ACG GCC AGT CAT CAG TIT GCC AGT TGT GC 
CAG GAA ACA GCT ATG ACC CCT GAC AGA CAA TAA AAG G 
TGT AAA ACG ACG GCC AGT GGT TIT CTI TIC TCC TCC 
CAG GAA ACA GCT ATG ACC CCT TIG CAG GAC TGT CAA GC 
TGT AAA ACG ACG GCC AGT GAC TIT GGT AAT TCA CCA G 
CAG GAA ACA GCT ATG ACC CAA GGG AAA AGG GAG TCT TG 
TGT AAA ACG ACG GCC AGT GGT AGC TCA GCT GGA CTG 
CAG GAA ACA GCT ATG ACC CAC AAC CAC ATG TGT CCA G 
TGT AAAACG ACG GCC AGT GCT ACA GAT GGC TTG ATC C 
CAG GAA ACA GCT ATG ACC AAG TGA AGG AGG ATG AGC C 
1 .  Van Dongen JJ, Langerak AW, Bruggemann M et  al. Design and standardization of  PCR 
primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene 
recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action 
BMH4-CT98-3936. Leukemia 2003; 17: 2257-2317 
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Background & Aims: Insulin-like growth factor (IGF)-11 acts as an autocrine factor in 
several tumor types by binding to IGF receptor type 1 (IGF-lR) and/or the insulin receptor 
(IR) isoform A. Previously, we reported that unprocessed pro-IGF-11, called 'big'-IGF-11, 
is expressed in gastrointestinal stromal tumors (GISTs). The aim of the present study was 
to investigate the putative role of 'big'-IGF-11 in GIST. 
Methods: Secretion of ('big' -)IGF-11 by GIST cell lines, GIST882 and GIST48, was analyzed 
by ELISA and western blotting. Expression of IGF-lR and IR isoforms in cell lines and 
frozen tumor samples were assessed with RT-PCR and western blotting. Effects of down­
regulation of IGF-11 or IR with short interference RNA were evaluated with cytotoxicity 
assays and western blotting. IGF-11 expression was analyzed in 60 primary GISTs by 
RNA in situ hybridization and immunohistochemistry. 
Results: Both cell lines secreted high levels of IGF-11, predominantly as 'big'-IGF-11. 
Expression of IR isoform A but not of IGF-lR was demonstrated in the KIT mutant cell 
lines and in the KIT and platelet-derived growth factor receptor a mutant GIST specimens. 
Down-regulation of either 'big' -IGF-11 or IR affected AKT and MAP kinase signaling and 
reduced survival. Disruption of 'big'-IGF-11 signaling in combination with imatinib had 
an additive cytotoxic effect. IGF-11 mRNA was present in 91 % of primary GISTs. ('big'-) 
IGF-11 protein expression was observed in the majority of GISTs, especially in high-risk 
tumors. 
Conclusions: Our data put forward the 'big'-IGF-11-IR isoform A axis as an autocrine 
survival pathway and potential therapeutic target in GIST. 
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Introduction 
Gastrointestinal stromal tumors (GISTs) are the most common soft tissue sarcomas of 
the gastrointestinal tract and are characterized by the over-expression of the receptor 
tyrosine kinase KIT. Various KIT genomic mutations occur in at least 80% of GISTs. 
In addition, about 5% of GISTs have mutations in the platelet-derived growth factor 
receptor a (PDGFRA) gene. These mutations lead to ligand-independent activation of 
either KIT or PDGFRA, which is considered as an initiating step in the development 
of GIST [1]. Although most patients with advanced GIST are successfully treated with 
imatinib, a small-molecule tyrosine kinase inhibitor active against KIT and PDGFRA, 
some patients are initially resistant to this compound and almost all patients finally show 
disease progression after an initial response [2]. Therefore, new treatment targets need 
to be identified. 
IGF-11 is a regulatory polypeptide, which is critical for normal growth and 
differentiation. In many types of cancer, IGF-11 is over-expressed and involved in tumor 
progression and metastasis [3]. It is synthesized as a 180 amino acid preprohormone 
with a 24 amino acid signal peptide at the N-terminal end and a C-terminal extension of 
89 amino acids called the E-domain. During intracellular processing the signal peptide 
and the E-domain are cleaved in several steps from the precursor protein resulting in 
mature IGF-11 consisting of 67 amino acids (Mw -7.5 kDa). However, many tumors have 
been found to secrete larger forms of IGF-11 (Mw 10-18 kDa) that still contain at least the 
first 21 amino acids of the E-domain, which may be differentially glycosylated [4]. These 
larger forms of IGF-11 are called pro-IGF-IIE[68-88] or 'big'-IGF-II. Mature IGF-11 and 
'big'-IGF-11 have been shown to act as autocrine growth factors in several tumor types. 
It can exert its mitogenic and anti-apoptotic effects by binding to the IGF receptor type 1 
(IGF-lR) and the insulin receptor (IR) isoform A [5]. 
Recently, we have reported on the occurrence of hypoglycemia in patients with a 
GIST being associated with increased circulating levels of tumor-derived 'big' -IGF-11 [6]. 
This observation prompted us to study the role of 'big'-IGF-11 as an autocrine factor in 
in vitro GIST model systems. We also evaluated the incidence of IGF-11 expression in 
GIST specimens. Our findings indicate that 'big'-IGF-11 secretion by GIST provides a pro­
survival signal that is relevant for the maintenance of this malignancy. 
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Materials and Methods 
Cell Culture 
�------------ ---
The GIST cell lines GIST882 en GIST48 were kindly provided by Jonathan Fletcher 
(Brigham and Women's Hospital, Boston, MA). GIST882 was developed from a primary, 
untreated, GIST with a KIT exon 13 mutation and was maintained in RPMI 1640 medium 
(Invitrogen, Praisley, UK) supplemented with 15% heat inactivated fetal calf serum 
(Bodinco, Alkmaar, The Netherlands) and 1 mmol/L L-glutamine (Invitrogen) [7]. 
GIST48 was established from a progressive tumor during imatinib therapy and harbors a 
primary KIT exon 11 mutation and a secondary exon 17 mutation. The GIST48 cells were 
maintained in F-10 medium (Invitrogen) supplemented with 10% fetal calf serum and 
0.5% mito+ serum extender (VW R  International, Roden, The Netherlands) and 1 % bovine 
pituitary extract (VWR International) [8]. The rhabdomyosarcoma cell line RD was 
cultured in Dulbecco's modified eagle medium high glucose (Invitrogen) supplemented 
with 10% fetal calf serum. 
Table 1. Primers used for RT-PCR 
Gene Forward primer Reverse primer Annealing Number Product 
(5'-3') (5'-3') temperature of cycles size (bp) 
(OC) RT-PCR 
IGF-11 CCT CCT GGA TCA TAT TGG 60 30 117 
GAC GTA CTG AAG AAC TIG 
TGC TA CCC A 
IGF-I AGC AGT CTI AGA TGC GAG 55 36 83 
CCA ACC CAA GAG GAC ATG 
TIA TTT A GT 
Insulin GCA GCC TTT CGT TCC CCG 60 36 71 
GTG AAC CAA CAC ACT AGG 
CAC TA 
IGF-lR GCC CGA AGG GGT ACC GGT 55 30 555 
TCT GTG AGG GCC AGG TIA 
AAG AA TGA 
Insulin receptor1 CTG AAG GAG CGC TGG TCG 55 30 205/169 
CTG GAG GAG TC AGG AAG TGT TG 
GAPDH CAC CCA CTC CCA CCA CCC TGT 60 30 110 
CTC CAC CTI TG TGC TGT AG 
1This primer pair detects both insulin receptor isoforms resulting in PCR products of 169 bp representing isoform 
A and of 205 bp representing isoform B. 
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Reverse transcriptase polymerase chain reaction (RT-PCR) 
Cell lines and frozen tumor samples were resuspended in 1 ml of Trizol (Invitrogen) 
and RNA was isolated and converted to complementary DNA (cDNA) [9]. For PCR, 
1 µL cDNA was amplified using primers (see table 1 for primer sequences) in a total 
volume of 25 µL using 1.25 U Taq polymerase (Invitrogen). Universal human reference 
RNA (Stratagene, La Jolla, CA, USA) was used as a positive control for IGF-1 and insulin 
expression. 
Determination of IGF-11 secretion 
GIST882, GIST48 and RD cells were cultured in 6-well plates until a 75% confluence was 
reached. After washing the cells twice, they were cultured in 1 ml of cell line specific 
maintenance medium for an additional 48 h. The final numbers of cells were counted. 
The conditioned cell culture medium was collected, centrifuged for 10 min at 110 g, 
and the supernatant stored at -20°C until further analysis. IGF-11 concentrations in the 
supernatant were determined by a non-extraction IGF-11 enzyme-linked immunosorbent 
assay (ELISA) kit (Diagnostic Systems Laboratories, Sinsheim, Germany) according to 
the manufactures instructions and related to the number of cells in the culture. This 
ELISA does not cross-react with bovine IGF-11 (according to the manufacturer and our 
own testing) and measures both human mature and 'big' -IGF-11. 
To determine the forms of IGF-11 secreted by GIST882 and GIST48 by western 
blotting, cells were cultured under serum-free conditions in RPMI 1640 or FlO with 
bovine pituitary extract, respectively, supplemented with 10 µg/mL transferrin 
(Invitrogen), 5 ng/mL sodium selenite (Sigma-Aldrich, Zwijndrecht, The Netherlands), 2 
mmol/L L-glutamine (Invitrogen), 0.1 % bovine serum albumin (Invitrogen). Conditioned 
media was lyophilized and reconstituted in demi-water. The total IGF-11 concentration 
was determined by ELISA. For western blotting, an equal volume of 4% (w/v) sodium 
dodecyl sulfate (SDS) sample buffer (0.5 mol/L Tris-HCI pH 6.8, containing 20% glycerol, 
0.002% bromophenol blue, and 10% 2-�-mercaptoethanol) was added and the samples 
were boiled for 10 min. Unconditioned serum-free media and rhIGF-11 (R&D systems, 
Abingdon, UK) were processed in parallel as a negative and positive control, respectively. 
Western blot analysis 
Frozen primary GIST samples were pulverized and dissolved in ice cold PBS. After 
centrifugation at 18,000 g for 1 min to remove debris, the supernatant was collected. The 
protein concentration was determined according to the Bradford method and 4% SDS 
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sample buffer was added. Cell lines cultured in 6-well plates were serum starved for 4 
h and then incubated for 5 min with rhIGF-II (20 nmol/L) or insulin (20 nmol/L; Novo 
Nordisk, Alphen aan den Rijn, The Netherlands). Alternatively, cells were treated with 
siRNA as described below. After treatments, cells were lysed in ice cold 2% (w/v) sample 
buffer and boiled immediately for 10 min. The protein concentration was determined 
with a detergent-compatible protein assay (Bio-Rad). Western blotting was performed as 
described previously [10]. Goat anti-IGF-II (polyclonal, 1:500; R&D Systems), rabbit anti­
IIE[68-88] antiserum (1:1000; WKZ6279) [11], rabbit anti-phospho-IGF-1R(Tyr1135/1136)/ 
IR(Tyr1150/1151), rabbit anti-IGF-lR, rabbit anti-phospho-AKT(Ser473), rabbit anti­
AKT and rabbit anti-extracellular signal-regulated kinase-1 and -2 (ERKl/2; 1:1000; 
Cell Signaling Technology, Bioke, Leiden, The Netherlands), mouse anti-phospho­
ERK1/2(Thr202/Tyr204) (clone ElO, 1:2000; Cell Signaling), rabbit anti-IR (polyclonal, 
1:200; Santa Cruz, Heerhugowaard, The Netherlands), and mouse anti-actin (clone C4, 
1:20,000; ICN Biomedicals, Zoetermeer, The Netherlands) served as primary antibodies. 
Flow cytometry 
IGF-lR and IR membrane expression was determined in GIST cells by flow cytometry [10], 
using phycoerythrin (PE)-conjugated mouse anti-IGF-lR monoclonal antibody (clone 
1H7, 1:10; BD Pharmingen, Alphen aan de Rijn, The Netherlands) and PE-conjugated 
mouse anti-IR monoclonal antibody (clone 3B6, 1:10; BD Pharmingen). PE-conjugated 
mouse IgG1 1( (BD Pharmingen) served as an isotype control. 
Short interference RNA (siRNA) transfections 
Synthetic siRNA duplexes were purchased from Eurogentec (Maastricht, The 
Netherlands). The sense sequence for IGF-II siRNA was 5'-GCA UCU UCA AAC AUG 
UAC AAA dTdT-3'and the antisense was 5'-UUU GUA CAU GUU UGAAGA UGC dTdT 
-3'. The sense sequence for the IR was 5' -GGC UCC UUC GGC AUG GUG UAU dTdT -3' 
and the antisense was 5'-AUA CAC CAU GCC GAA GGA GCC dTdT-3'. Plated cells were 
transfected using siRNAs (final concentration 50 nM) with oligofectamine (Invitrogen) 
and OptiMEM (Invitrogen) according to the manufacturer's instructions. After 4 h 
incubation, the medium was changed to complete culture medium. As a negative control, 
scrambled, non-silencing siRNA (Eurogentec) was used. 
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Cell viability and apoptosis assays 
Cells were plated at 3x104 cells per well in 96-well plates and cultured in normal media 
for 2 days before siRNA transfection or treatment with the IR tyrosine kinase inhibitor 
HNMPA-(AMh (Biomol Research Laboratories, Plymouth Meeting, PA, USA) [12,13]. 
Seventy-two h after transfection or treatment, cell viability was assessed with thiazolyl 
blue tetrazolium bromide (MTT) [10]. Alternatively, 24 h after siRNA transfection, 
GIST882 cells were washed with and incubated in RPMI 1640 supplemented with 
transferrin, sodium selenite, L-glutamine and bovine serum albumin, as described 
above. After 48 h incubation under serum-free conditions, cell viability was evaluated 
with MTT. To evaluate the combined effects of KIT inhibition and either IGF-II or IR 
silencing, cells were incubated with 0.05 or 0.1 µmol/L imatinib for 48 h, starting 24 h 
after siRNA transfections. All MTT assays were performed three times in quadruplicate. 
To evaluate apoptosis, l.5x104 cells per well in 96-well plates were treated with siRNA. 
Apoptosis was determined 48 and 72 h after siRNA transfection with the acridine orange 
assay [14]. All apoptosis assays were performed in duplicate and repeated three times. 
Tissue collection and tissue microarray construction 
Sixty primary paraffin-embedded tumor tissues of GISTs and seven frozen GIST samples 
were retrieved from the files of the Department of Pathology of the University Medical 
Center Groningen. All tumors were surgically resected between 1985 and 2006 and 
diagnosed as described previously [14]. Tumors were categorized into risk groups, 
based on tumor size, mitotic index and primary localization of the tumor, according to 
the recently modified consensus classification for prediction of metastatic potential [15]. 
Mutation analysis of KIT exons 9, 11, 13 and 17, and PDGFRA exons 12, 14 and 18 was 
performed as described previously [6]. Patient and tumor characteristics are summarized 
in table 2. Based on the corresponding H&E-stained slides, several representative regions 
were selected of each individual paraffin-embedded tumor specimen. Subsequently, 
from each of these regions three distinct 0.6 mm tissue cores were taken and transferred 
to a standard-size recipient paraffin block to create a tissue microarray [14]. All tumor 
samples used in this study were handled according to the guidelines of the Dutch 
Federation of Biomedical Scientific Societies (FMWV) as described in "Code Proper 
Secondary Use of Human Tissue". 
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Table 2. Patient (n=59) and tumor (n=60) characteristics1 
n (%) 
Sex 
Male 28 (47) 
Female 31 (53) 
Age (years), median (range) 66 (24-87) 
Risk classification 
Very low risk 4 (8) 
Low risk 15 (25) 
Intermediate risk 10 (17) 
High risk 31 (52) 
Primary site 
Stomach 32 (53) 
Small intestine 23 (38) 
Colon 4 (7) 
Unknown 1 (2) 
Histology 
Spindle cell 48 (80) 
Epithelioid 7 (12) 
Mixed 5 (8) 
Tumor size 
::;;lQ cm 41 (68) 
>10 cm 19 (32) 
Mitotic figures 
::,;5 per 50 HPF 45 (75) 
>5 per 50 HPF 15 (25) 
Mutations 
KIT exon 9 6 (10) 
KIT exon 11 31 (52) 
\ 
PDGFRA exon 12 2 (3) 
PDGFRA exon 18 7 (12) 
No mutations found 8 (13) 
Not evaluable 6 (10) 
1One patient had two primary GISTs, which were a high-risk epithelioid gastric tumor with a PDGFRA exon 18 
mutation and a low-risk spindle-cell small intestine tumor with a KIT exon 1 1  mutation, respectively. 
Abbreviations: HPF, high power fields; PDGFRA, platelet-derived growth factor receptor a. 
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RNA in situ hybridization and immunohistochemistry 
The methods used for in situ hybridization with digoxigenin-labeled hIGF-II 
complementary RNA probes have been described previously [16]. �-actin digoxigenin­
labeled complementary RNA probes were used to evaluate the preservation of RNA in 
the tissue specimens studied. Negative controls for in situ hybridization were prepared 
using sense probes. Immunohistochemistry was performed as described previously [14]. 
Antigen retrieval was performed either by boiling slides in a microwave in 0.01 mol/L 
citrate buffer (pH 6.0) for 15 min or by autoclaving in blocking solution (2% blocking 
reagent (Roche Diagnostics, Mannheim, Germany) and 0.2% SDS in maleic acid buffer 
(pH 6.0)) at 115°C for three times 5 min for the detection of IIE[68-88] or total IGF-II, 
respectively. Primary antibodies were rabbit anti-IIE[68-88] antiserum (1:200; WKZ6279) 
[11] and goat anti-IGF-II (1:50; R&D Systems). As a negative control, a serial section was 
processed by replacement of primary antibody with either preimmune rabbit antiserum 
or normal goat IgG. For both immunohistochemistry and in situ hybridization, 
normal tissue samples derived from first trimester human placenta served as positive 
controls [17]. Results for immunohistochemistry and in situ hybridization were scored 
independently in a semi-quantitative fashion for intensity of staining by two observers 
(B.R. and A.J.H.S). Tissue cores from one tumor were judged to be positive when there 
was a clear cellular cytoplamic staining (i.e. comparable or more intense staining than 
placenta) in at least two of the three cores. Tumors with less than two assessable cores 
were excluded from the analysis. 
Statistical analysis 
The student t-test was used to analyze the differences between groups. Associations 
between IGF-II expression and tumor characteristics were evaluated by the Chi-square 
or Fisher's exact test, where appropriate. A two-tailed P-value of <0.05 was considered 
to be significant. 
Results 
'Big'-IGF-11 secretion by GIST cell lines 
IGF-II expression was evaluated in imatinib-sensitive GIST882 cells and in imatinib­
resistant GIST48 cells. As shown in figure lA, both GIST cell lines expressed IGF-II 
mRNA equally to the RD rhabdomyosarcoma cell line that served as a positive control 
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[18]. Furthermore, the expression of IGF-II mRNA in the GIST cell lines was comparable 
to those found in the various GIST samples and also to the expression in a primary GIST 
cell culture. No IGF-I or insulin mRNA expression could be detected in GIST882 and 
GIST48 indicating that IGF-II is the only IGF ligand that is significantly expressed by 
these cell lines (figure lB). After culturing the cells for 48 h, both GIST cell lines secreted 
significant amounts of IGF-II into the culture medium, which largely exceeded the IGF-II 
production by the RD control cell line (figure lC). IGF-II was predominantly secreted 
as high molecular weight forms containing the IIE[68-88] domain peptide of pro-IGF-II, 
which can be differentially glycosylated [19]. GIST882 secreted mainly -11 kDa 'big' -
IGF-II and two other less abundant high molecular weight forms of -12 and -18 kDa. 
In addition, a faint -8 kDa band was observed, corresponding to fully processed IGF-II. 
GIST48 only produced 'big'-IGF-II and at least three different forms between -12-18 kDa 
were detected (figure lD). 
IGF-lR and IR expression in GIST specimen and cell lines 
The expression of the cognate receptors of 'big'-IGF-II was evaluated in frozen tumor 
samples and GIST cell cultures (figure 2A and B). In six of the seven GIST tumor samples, 
all harboring mutated KIT or PDGFRA, neither IGF-lR mRNA nor protein could be 
detected. Only the tumor with wild-type KIT and PDGFRA showed significant expression 
of IGF-lR mRNA and protein. Among the three GIST cell cultures, only GIST48 expressed 
IGF-lR mRNA, albeit at a relatively low level compared to the positive tumor. No IGF-lR 
protein could be detected in GIST48 or the other GIST cell cultures. In contrast, all GIST 
tissue samples and cell cultures expressed mRNA of both isoforms A and B of the IR 
(figure 2A), and expressed IR protein (the antibody used did not discriminate between 
both isoforms; figure 2B). IR was expressed at the cell surface of the GIST882 and GIST48 
cell lines. No IGF-lR membrane expression could be detected in these GIST cell lines 
in contrast to the highly positive control MCF-7 (figure 2C). Stimulation with IGF-II or 
insulin induced phosphorylation of IR in GIST cells (figure 2D). 
Effects of 'big'-IGF-11 signaling inhibition 
The role of 'big'-IGF-II secretion by GIST cells was further investigated using siRNA 
strategies to evaluate the effects of IGF-II and IR silencing. The expression of both IGF-II 
and IR could be effectively down-regulated with siRNA in GIST882 and GIST48 (figure 
3A). Furthermore, a marked reduction in the secretion of total IGF-II could be observed 
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Figure 1. IGF-II expression and secretion by GIST cell lines. (A) IGF-II mRNA expression in GIST samples and cell cul hires with RT-PCR. RD was 
used as a positive control and HeLa was used as a negative control [40]. GIST PC is a primary cell culture (passage 3) with a KIT exon 9 mutation 
established from a tumor that was progressive during imatinib therapy. KIT (K) and PDGFRA (P) mutations are indicated for each GIST. GAPDH 
was used as a loading control. (B) Insulin and IGF-I mRNA expression in GIST cell lines. Human reference RNA served as a positive control. 
(C) GIST882, GIST48 and RD cells were cultured for 48 h and total IGF-II secretion (both mature and 'big'-IGF-II) was measured by ELISA. RD 
served as a positive control. *p<0.01 compared with RD. (D) Lyophilized serum-free conditioned media (CM) and unconditioned media (UM) 
obtained from GIST882 and GIST48 cells were subjected to western blotting. Membranes were probed with an antibody against mahire IGF-II 
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9 5  k D a  
F i g u r e  2 .  I G F - l R  a n d  I R  e x p r e s s i o n  i n  G I S T .  ( A )  I G F - I R  a n d  I R m R N A e x p r e s s i o n  i n  G I S T  s a m p l e s  a n d  c e l l  l i n e s  w i t h  R T - P C R .  T h e  p r i m e r  p a i r  f o r  
t h e  I R  d e t e c t s  b o t h  i s o f o r m s  r e f l e c t i n g  i s o f o r m  A  ( I R - A )  a s  a  1 6 9  b p  b a n d  a n d  i s o f o r m  B  ( I R - B )  a s  a  2 0 5  b p  b a n d .  R D  w a s  u s e d  a s  a  p o s i t i v e  c o n t r o l .  
K I T  ( K )  a n d  P D G F RA  ( P )  m u t a t i o n s  a r e  i n d i c a t e d  f o r  e a c h  G I S T .  G A P D H  w a s  u s e d  a s  a  l o a d i n g  c o n t r o l .  ( B )  W e s t e r n  b l o t  a n a l y s i s  o f  I G F - l R  a n d  
I R  e x p r e s s i o n  i n  G I S T  s a m p l e s  a n d  c e l l  l i n e s ,  a n d  R D  c e l l s  ( p o s i t i v e  c o n t r o l ) .  A c t i n  s e r v e d  a s  a  l o a d i n g  c o n t r o l .  ( C )  A n a l y s i s  o f  I G F - l R  a n d  I R  
m e m b r a n e  e x p r e s s i o n  b y  f l o w  c y t o m e t r y .  T h e  g r a y  l i n e  r e p r e s e n t s  t h e  I g G  c o n t r o l ,  t h e  b l a c k  l i n e  t h e  a n t i - I R  a n t i b o d y  a n d  t h e  b l a c k  d o t t e d  l i n e  
t h e  a n t i - I G F - l R  a n t i b o d y .  M C F - 7  b r e a s t  c a r c i n o m a  c e l l s  w e r e  u s e d  a s  a  p o s i t i v e  c o n t r o l .  ( D )  S e r u m  s t a r v e d  c e l l s  w e r e  s t i m u l a t e d  w i t h  2 0  n m o l / L  
r e c o m b i n a n t  h u m a n  I G F - I I  o r  i n s u l i n  f o r  5  m i n .  I R  p h o s p h o r y l a t i o n  w a s  e v a l u a t e d  w i t h  w e s t e r n  b l o t t i n g .  
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'Big'-IGF-ll in GIST 
regulation of either IGF-II or IR caused a marked reduction in ERKl/2 phosphorylation. 
Transfection of GIST882 and GIST48 cells with IR siRNA in both cases reduced AKT 
phosphorylation. Only in GIST882 cells, the same phenomenon was seen after transfection 
with IGF-II siRNA (figure 3A). IR or IGF-11 siRNA transfection did not influence KIT 
expression nor KIT phosphorylation in both cell lines ( data not shown). 
Treatment with IGF-II siRNA caused a reduction in cell viability with -30-35 percent 
that was nearly similar for GIST882 and GIST48. For both cell lines, down-regulation of 
IR expression also decreased the viability of the cells but the effect was most pronounced 
in GIST48 (figure 4A) . The GIST882 cell line has the capacity to survive and even grow in 
serum-free media (data not shown). This may be due to an autocrine action of 'big'-IGF­
II on IR. In order to investigate this possibility, the same experiments with siRNA were 
performed with GIST882 but now under serum-free conditions. A slightly larger effect 
of IGF-II siRNA on the cell viability of GIST882 cells was observed under serum-free 
conditions compared to the viability of these cells when cultured in serum containing 
media (figure 4A and B). For both cell lines, transfection with IGF-II siRNA resulted in a 
significant proportion of apoptotic cells after 48 h, which had further increased after 72 
h. Silencing of the expression of IR for 48 h resulted in a marked induction of apoptosis 
in GIST48 cells only (figure 4C). The simultaneous treatment with the KIT tyrosine kinase 
inhibitor imatinib and transfection of the cells with either IGF-II or IR siRNA had an 
additive effect on cell viability of the imatinib-sensitive GIST882 cells (figure 4D). 
In addition to the siRNA approach, the effects of HNMPA-(AMh, a well-known 
IR tyrosine kinase inhibitor, was evaluated. HNMPA-(AMh decreased cell viability in 
GIST882 and GIST48, the latter being more sensitive to this compound, which is in line 
with the IR silencing experiments (figure 5). 
('Big'-)IGF-11 expression in GIST specimen 
For a large cohort of paraffin-embedded GIST specimens the expression of IGF-11 in 
relation to tumor characteristics was investigated. Fifty-two of 57 evaluable primary 
tumors (91 %) were positive for IGF-II mRNA as revealed by in situ hybridization (figure 
6). All four very-low-risk tumors were negative for IGF-II mRNA, whereas the tumors 
from the other risk groups were positive for IGF-II mRNA, except for one high-risk tumor. 
To investigate ('big' -)IGF-II expression at the protein level, immunohistochemistry with 
two different antibodies, an antibody raised against the IIE[68-88] domain peptide of 
pro-IGF-II and an antibody against fully processed IGF-II (i .e. detecting both mature 
and high molecular weight forms of IGF-II), was performed (figure 6). Thirty-six of 56 
-109 -
Chapter 5 
evaluable primary tumors (64%) stained positive for IIE[68-88] and 17 of 53 evaluable 
primary tumors (32%) showed positive staining for total IGF-II (table 3). All tumors 
positive for total IGF-II were also positive for IIE[68-88], except for one. With both 
antibodies, a more frequent expression of ('big' -)IGF-II was observed in high-risk tumors 
(i.e. tumors with the highest malignant potential) in contrast to tumors with a lower risk 
classification (table 3). 
A 
· • 1 8  kDa . ... ;:· � -. · . .- · • 1 2  kDa 
IR 
r=====c;;, 
,....,1 95 kDa 
pAKTl-.-- - -1 ---- 1 60 kDa 
AKTl- - - -1 ----1 60 kDa 
pERK1 t21- - I 1-w..-. =1 44/42 kDa 
ERK1 12j l l -w w 1 44/42 kDa 















Figure 3. Effects of down-regulation of IGF-II or IR on downstream signaling. (A) GIST cells 
were either treated with scrambled control siRNA or siRNA directed against IGF-II or IR. 
IR and IGF-II down-regulation and changes in phosphorylation of AKT and ERKl/2 were 
investigated with immoblotting 48 h after siRNA treatment. Actin served as a loading control. 
(B) Twenty-four h after siRNA transfection, cells were washed and incubated for 48 h in 
maintenance culture media. Total IGF-II concentrations were determined with ELISA and 
adjusted to the number of cells. The relative (i.e. normalized to transfections with scrambled 
siRNA) IGF-II secretion after siRNA transfection, was calculated for each cell line. Data 
represent the mean values (± SD) of 3 independent experiments. *p <0.01 compared with 
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Figure 4. Effects of IGF-II and IR down-regulation on cellular survival. (A) The impact of IR and IGF-II down-regulation on cell viability was 
determined in GIST cells 72 h after siRNA transfection with MTT. The data were normalized to scrambled siRNA treated control cells. (B) 
GIST882 cells were switched to serum-free media 24 h after siRNA transfection and cell viability was determined with MTT after an additional 
48 h. (C) The apoptotic response after siRNA treatment was determined in GIST cells with acridine orange apoptosis assays 48 and 72 h 
after transfection. (D) IR or IGF-II siRNA transfection of GIST882 was combined with imatinib treatment. The effects on cell viability were 
determined with MTT. The data were normalized to scrambled siRNA/DMSO-treated control cells. All data represent the mean values (± SD) of 
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Figure 5. Effects of insulin receptor inhibition by the tyrosine kinase inhibitor HNMPA-(AMh 
on GIST cell viability. Viability was determined 72 h after treatment with HNMPA-(AMh with 
MTT. The data were normalized to untreated ( DMSO-only treated) controls. Data are shown 
as mean values (± SD) of 3 independent experiments. 
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Figure 6. Representative examples of RNA in sihi hybridization and immunohistochemical 
stainings. (A) In sihi hybridization for IGF-II mRNA expression in a GIST tissue microarray 
core. (Dark)blue staining indicates the presence of IGF-II mRNA. (B) Sense probes were used 
as a negative control for in siru hybridization showing no staining in first trimester human 
placenta. (C) An example of GIST that showed immunostaining of IIE[68-88] being part of 
the E-domain of IGF-II. (D) No staining was observed using preimmune serum as a negative 
control for IIE[68-88] immunohistochemistry. (E) An example of a GIST showing diffuse 
cytoplasmic staining of total IGF-II, with no staining when normal goat IgG was applied as a 
negative control (F); (A-F, magnification x200). See page 190 for colour figure. 
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Table 3. IGF-II expression and tumor characteristics 
Pro-IGF-IIE[68-88] positive Total IGF-11 positive 
n (%) pl n (%) p 
All primary tumors 36/562 (64) 17/53 (32) 
Risk category3 
(very) low/intermediate risk 12/26 (46) 0.012 3/23 (13) 0.016 
High risk 24/30 (80) 14/30 (47) 
Primary site 
Stomach 16/31 (52) 0.022 2/28 (7) <0.001 
Small intestine/colon 20/24 (83) 15/24 (63) 
Histology 
Spindle cell 26/44 (59) 0.18 11/41 (27) 0.17 
Epithelioid/mixed 10/12 (83) 6/12 (50) 
Tumor size 
:510 cm 22/38 (58) 0.23 9/34 (26) 0.36 
>10 cm 14/18 (78) 8/19 (42) 
Mitotic figures 
:55/50 HPF 25/42 (60) 0.33 9/39 (23) 0.042 
>5/50 HPF 11/14 (79) 8/14 (57) 
Mutation 
KIT Exon 11  16/294 (55) 0.14 5/26 (19) 0.066 
No KIT exon 11  17/22 (77) 10/22 (45) 
1P-values are derived from the Chi-square or Fisher's exact test, where appropriate. 
2Number of evaluable cases (tumors with less than 2 evaluable cores were excluded from the analysis). 
3Toe risk group classification is based on size, mitotic index and primary localization of the tumor [15]. 
4Tumors that were not evaluable for mutation analysis were not included in this analysis. 
Abbreviation: HPF, high power fields 
Discussion 
KIT and PDGFRA gain-of-function mutations are found in the far majority of GISTs. 
These mutations are considered as initiating steps in the development of a GIST. 
Additional oncogenic events could then contribute to the malignant outgrow of GIST [l]. 
The identification of critical pathways that cooperate with oncogenic KIT and PDGFRA 
signaling in the development of a malignant GIST could be useful for the development 
of new therapeutics for the treatment of this cancer. The existence of additional KIT 
signaling-dependent and KIT signaling-independent pathways has been implied in GIST 
tumors as well as in GIST cell lines [20,21] .  We have previously reported that 'big'-IGF-11 
- 113 -
Chapter 5 
is expressed in GISTs [6]. Since the IGF signaling system is involved in the pathogenesis 
of several sarcoma (sub)types [5], the purpose of this study was to investigate the putative 
biological role of 'big'-IGF-11 in GIST. 
We demonstrated that IGF-11 is actively secreted by GIST cells in vitro, predominantly 
as 'big'-IGF-II. These results would supplement our recent findings that increased plasma 
levels of 'big'-IGF-11 frequently occur in GIST patients. This is probably due to excessive 
production of 'big'-IGF-11 by tumor tissue which may finally result in the induction of 
fasting hypoglycemia [6]. Many tumors, including sarcoma cells of different origin, have 
been shown to secrete increased amounts of incompletely processed forms of pro-IGF-
11 that still contain the first 21 amino acids of the E-domain . The latter peptide may be 
differentially 0-glycosylated leading to the size heterogeneity of 'big' -IGF-11 as we also 
observed for the cultured GIST cells in the present study [4,22] . The change in post­
translational processing of pro-IGF-11 in tumor cells could simply be the result of an 
inadequate capacity of intracellular enzymes to process the relatively high amounts of 
pro-IGF-11 produced. Similar to mature IGF-11, 'big'-IGF-11 is able to activate IGF-lR and 
IR isoform A. Sparse data suggest that 'big' -IGF-11 is at least as mitogenic as mature IGF-11, 
which possibly depends on the amount of glycosylation of 'big'-IGF-11 [5] . Nonetheless, 
in GIST, 'big'-IGF-11 appeared a potent protein capable of providing an autocrine signal. 
In several sarcoma types such as rhabdomyosarcoma, synovial sarcoma and 
osteosarcoma, IGF-11 acts as an autocrine growth and survival factor [18,23,24]. IGF-11 
is involved in the pathogenesis of these tumors, amongst other oncogenic events, by 
signaling through IGF-lR. Recently, it has been demonstrated that a subset of GISTs lacking 
KIT and PDGFRA mutations, so called wild-type GISTs, express much higher levels of 
IGF-lR than the mutated GISTs, which was associated with IGFlR gene amplification 
[25]. Also in rarely occurring pediatric GIST, typically associated with wild-type tumors, 
markedly increased IGF-lR mRNA levels have been observed that even exceeded those 
in wild-type adult tumours [26]. IGF-lR expression has been detected in GISTs with 
KIT and PDGFRA mutations although to a lower level than in wild-type tumors, an 
observation that was primarily based on immunohistochemical stainings [25,27]. Indeed, 
in the wild-type GIST specimen investigated by us, we also encountered significant IGF­
lR expression both at the mRNA and protein level. However, in our limited cohort of 
KIT or PDGFRA mutated GISTs, IGF-IR expression appeared to be undetectably low. 
Our data are nevertheless consistent with those very recently reported by Pantaleo et al 
[28]. At present, this apparent discrepancy with data from two previous studies on this 
subject remains unclear. Recently, it has been recognized that the IR isoform A also serves 
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as a high affinity receptor for IGF-II which mediates IGF-II-dependent signaling [29]. 
The IR (isoform A) actually was detectable in tumor specimens of our cohort of mutated 
GISTs suggesting that this receptor is the most likely candidate for autocrine 'big'-IGF-II 
signaling. 
In order to inhibit autocrine 'big'-IGF-II signaling in GIST cell lines, we used siRNA 
against either IGF-II or IR. For both cell lines, the reduction in cell viability following 
down-regulation of IGF-II or IR expression with siRNA was more or less in the same 
order of magnitude as the extent of induction of apoptosis, suggesting that autocrine 
'big'-IGF-II is mainly involved in eliciting an anti-apoptotic survival signal rather than 
a proliferation stimulus. Notably, GIST882 expressed the IR predominantly as isoform 
A whereas in GIST48 both isoforms were expressed. Interestingly, GIST48 cells were 
highly sensitive towards IR silencing. This phenomenon could be due to differences in 
the cellular context of insulin receptor signaling between GIST48 and GIST882 cells or 
(partial) dependence on an exogenous IGF ligand, for example insulin, that is present 
in the enriched media these cells are cultured in. In both cell lines, down-regulation of 
IGF-II expression resulted in a markedly decreased phosphorylation of ERK, whereas 
phosphorylation of AKT was affected to a variable and much lesser extent. Recent studies 
have shown that the phosphatidylinositol-3-kinase (PI3K)/AKT pathway is an important 
survival pathway in several GIST cell lines, including GIST882 and GIST48. Specific 
inhibition of the mitogen-activated protein (MAP) kinase/ERK pathway, however, also 
reduced survivat albeit to a lesser extent, suggesting that both the PI3K/AKT and the 
MAPK/ERK pathway are involved in the survival of GIST cells [30]. Several studies 
showed that the MAPK/ERK pathway in GIST cells is only partially or not at all depending 
on activated KIT in contrast to the PI3K/AKT pathway [31,32]. Presumably, stimulation 
of other tyrosine kinase receptors contribute to the activation of intracellular signaling 
pathways in GIST as welt including the 'big' -IGF-II/IR autocrine loop. Nonetheless, 
despite the fact that AKT phosphorylation was only marginally inhibited by IR siRNA 
treatment in GIST48 cells, apoptosis was readily induced in these cells, when compared 
to the more sensitive GIST882 cells. This is in agreement with a previous study showing 
that specific inhibition of PI3K only in GIST48 induced high levels of apoptosis, even 
though AKT phosphorylation was not completely inhibited [30]. 
Our results imply an association between IGF-II protein expression and the potential 
aggressive behavior of GISTs. Similar observations have been reported by Braconi et 
al and Steigen et al who found that IGF-II expression was associated with decreased 
disease-free survival and decreased overall survivat respectively [27,33]. Furthermore, 
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microarray analysis performed in 181 different sarcomas, revealed that IGF2 was one 
of the top discriminating genes associated with GIST [34]. Recent studies showed that 
minute (1 to 10 mm) GIST-like lesions are a common finding in the stomach of the adult 
population. In the majority of these lesions, KIT or PDGFRA mutations were found [35-
37]. These findings suggest that GISTs could arise from premalignant lesions initially 
caused by KIT or PDGFRA mutations but which require additional oncogenic events. 
In our study, only a very small number of GISTs were classified as very-low-risk with 
an extremely low malignant capacity [15] .  Three of these tumors were even smaller 
than 10 mm in size and in each of these tumors, KIT or PDGFRA mutation have been 
detected (data not shown). We noticed that all four very-low-risk tumors did not show 
any detectable IGF-II mRNA expression in contrast to tumors of the other risk groups 
except for one high risk tumor. This suggests, together with our in vitro findings, that 
gain of IGF-II (over-)expression could be an additional oncogenic event contributing to 
the malignant potential of GIST. 
From a therapeutic point of view for those (wild-type) GISTs expressing IGF-lR, 
inhibition of this receptor would be an attractive option as several humanized monoclonal 
antibodies are currently (successfully) being tested in clinical studies [38]. Blocking of IR 
would be an interesting option in mutant KIT or PDGFRA GISTs, although the induction 
of hyperglycemia in patients with this strategy could be of concern. Alternatively, 'big' -
IGF-II could be a direct target for therapy in both imatinib-sensitive and imatinib-resistant 
wild-type and mutant GISTs. IGF-II neutralizing antibodies have been developed but 
are not used in the clinics yet [39], but based on our results 'big'-IGF-II neutralizing 
antibodies may even have more tumor selective properties. 
In conclusion, we showed that IGF-II is commonly expressed in GIST. Our data 
suggest that secreted 'big'-IGF-II is involved in the pathogenesis of GIST by providing a 
pro-survival signal in an autocrine manner. Targeting its receptors or directly neutralizing 
the action of 'big'-IGF-II might be attractive new therapeutic options in the fascinating 
area of GIST treatment, still being the role model for targeted therapy in the 21st century. 
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Abstract 
Although the tyrosine kinase inhibitor imatinib has been shown to be an active agent in 
patients with gastrointestinal stromal tumours (GIST}, complete remissions are almost 
never seen and most patients finally experience disease progression during their course 
of treatment. An alternative therapeutic option is to target death receptors such as Fas. 
We showed that a panel of imatinib-sensitive (GIST882) and imatinib-resistant (GIST48, 
GIST430 and GIST430K-) cell lines expressed Fas. MegaFasL, a recently developed 
hexameric form of soluble Fas ligand (FasL}, appeared to be an active apoptosis­
inducing agent in these cell lines. Moreover, MegaFasL potentiated the apoptotic effects 
of imatinib. Immunohistochemical evaluations, in 45 primary GISTs, underscored the 
relevance of the Fas pathway: Fas was expressed in all GISTs and was expressed strongly 
in 93%, whereas FasL was expressed at moderate and strong levels in 35% and 53% of 
GISTs, respectively. Fas and FasL expression were positively correlated in these primary 
GISTs, but there was no association between Fas or FasL expression and primary site, 
histological subtype, tumour size, mitotic index, risk classification, and KIT mutation 
status. The abundant immunohistochemical Fas and FasL expression were corroborated 
by western blot analysis. In conclusion, our data implicate Fas as a potential therapeutic 
target in GIST. 
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Introduction 
The observation that nearly all spindle cell and epithelial tumours of the stomach and 
bowel highly express the receptor tyrosine kinase KIT has led to the characterisation 
of gastrointestinal stromal tumours (GIST) as a distinct clinicopathological entity 
different from other gastrointestinal mesenchymal tumours. Various KIT genomic 
mutations occur in about 80% of GISTs. In addition, about 5% of GISTs have mutations 
in the platelet-derived growth factor receptor ex. (PDGFRA) [1]. These mutations lead to 
ligand-independent activation of KIT or PDGFRA, which plays an essential role in the 
development and progression of GIST [2,3]. Since GISTs are insensitive to conventional 
chemotherapy, the introduction of imatinib, a small-molecule receptor tyrosine kinase 
inhibitor active against KIT and PDGFRA, has been a major therapeutic breakthrough. 
Imatinib therapy has dramatically improved the survival of patients with unresectable 
or metastatic GIST [4]. Despite these successes, about 10% of the patients show initial 
resistance to imatinib. Moreover, complete remissions are almost never seen and most 
patients experience disease progression after a median period of approximately 2-3 years 
[4]. To date, sunitinib, an inhibitor of multiple receptor tyrosine kinases including KIT, 
PDGFRA, vascular endothelial growth factor receptor (VEGFR) and fms-related tyrosine 
kinase 3 (FLT3), is used as a second line treatment providing clinical benefit in patients 
with imatinib-resistant GIST for a limited time period [5]. However, there is urgent 
need for development of new therapeutics acting via pathways complementary to those 
targeted by KIT kinase inhibitors such as imatinib and sunitinib. 
Fas (CD95) and Fas ligand (FasL; CD95L) belong to the TNF family of death receptors 
and ligands [6,7]. At the molecular level, binding of FasL to Fas induces receptor 
trimerisation, followed by the binding of Fas-associated death domain (FADD) with 
caspase 8 and/or 10 to the intracellular death domain of Fas. Caspase activation within 
this complex initiates cleavage and activation of an intracellular cascade of effector 
caspases (e.g. caspase 3, 6 and 7), eventuating in cleavage of specific death substrates 
and apoptosis [8]. Thus, in tumours expressing Fas, targeting of Fas-mediated apoptosis 
could be a promising therapy. Although many in vitro and in vivo cancer models 
have shown sensitivity towards Fas agonistic antibodies, clinical application of these 
antibodies is hampered because of severe liver toxicity [9]. Furthermore, resistance to 
Fas-mediated apoptosis because of inhibitory mechanisms along the apoptotic signalling 
pathway has been observed in other cancer models [10]. Soluble forms of FasL (sFasL) 
are potentially less toxic [11], and a hexameric form of sFasL, produced by fusing the 
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dimer-forming serum protein stalk of human ACRP30 to the trimeric portion of human 
FasL, has recently been developed. This compound, called MegaFasL, is more cytotoxic 
to tumour cells compared to trimeric sFasL [12-14]. MegaFasL is currently tested in a 
phase-I clinical trial (ClinicalTrials.gov identifier: NCT00437736). 
This study was initiated given the lack of data on expression of Fas and FasL in GIST. 
Therefore, the sensitivity of GIST cell lines towards Fas activation and the potentiating 
effect of imatinib on this activation were investigated. In addition, the expression of Fas 
and FasL in primary GIST samples was studied. Together, these data implicate Fas as a 
potential therapeutic target in GIST. 
Materials and Methods 
Cell Culture 
The GIST cell line GIST882 was developed from a primary, untreated, GIST, with a 
homozygous KIT exon 13 mutation [15]. Cells were maintained in RPMI 1640 (Invitrogen, 
Praisley, UK) supplemented with 15% heat inactivated fetal calf serum (FCS; Bodinco, 
Alkmaar, The Netherlands) and 1 mM L-glutamine (Invitrogen). The GIST cell lines 
GIST48 and GIST430 were established from tumours that were progressive during 
imatinib therapy after an initial clinical response [16]. GIST48 harbours a homozygous 
primary KIT exon 11 mutation and a heterozygous secondary exon 17 mutation. 
GIST430 has a heterozygous primary KIT exon 11 and a secondary heterozygous exon 
13 mutation. The KIT-negative GIST430K- cell line was derived from GIST430 cells. The 
GIST48 and GIST430 cells were maintained in F-10 (Invitrogen) supplemented with 10% 
and 15% FCS, respectively, and 0.5% mito+ serum extender (VWR International, Roden, 
The Netherlands) and 1 % bovine pituitary extract (VWR International). The cervical 
carcinoma cell line HeLa was maintained in 1:1 DMEM/HAM supplemented with 10% 
FCS. 
Flow cytometry 
Fas membrane expression was determined in GIST cells by flow cytometry as described 
previously [17]. Phycoerythrin (PE)-conjugated mouse anti-Fas monoclonal antibody 
(clone DX-2, 1:10; BD Pharmingen, Alphen aan de Rijn, The Netherlands) was used. PE­
conjugated mouse IgG1 (BD Pharmingen) served as an isotype control. 
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Acridine orange apoptosis assay 
Cells were treated with MegaFasL (kindly provided by Apoxis, Lausanne, Switzerland) 
for 6 hr. To investigate the effect of MegaFasL on imatinib-induced apoptosis, cells were 
pretreated with imatinib (kindly provided by Novartis, Basel, Switzerland) for 24 hr 
followed by 24 hr incubation with MegaFasL without removing imatinib. Alternatively, 
cells were first treated with MegaFasL for 24 hr with subsequent treatment with imatinib 
for 24 hr. Control cells were incubated with DMSO, which was used as a solvent for 
imatinib, where appropriate, or a single-drug. After these treatments, acridine orange (10 
mg/ml) was added to each well to distinguish apoptotic cells from vital cells. Apoptosis 
was defined as the appearance of apoptotic bodies and/or chromatin condensation, using 
a fluorescence microscope. Results were expressed as the percentage of apoptotic cells 
in a culture by counting at least 300 cells per well. All apoptosis assays were performed 
three times in duplicate. 
Western blot analysis 
After treatment with MegaFasL, as described above, GIST882 and GIST48 cells were 
lysed and the protein concentration was determined according to the Bradford method. 
Western blotting was performed as described previously [17]. Primary antibodies were 
goat anti-Fas (polyclonal, 1:400; Santa Cruz, Heerhugowaard, The Netherlands), mouse 
anti-FasL and mouse anti-caspase 3 (clone 33 and clone 19 respectively, 1:1000; BD 
Transduction Laboratories, Alphen aan den Rijn, The Netherlands), rabbit anti-cleaved 
caspase 3 and rabbit anti-caspase 6 (1:1000; Cell Signalling Technology, Bioke, Leiden, 
The Netherlands), mouse anti-caspase 8 (clone 1Cl2, 1:500; Cell Signalling) and mouse 
anti-actin (clone C4, 1:20,000; ICN Biomedicals, Zoetermeer, The Netherlands). 
Tissue collection 
The study group consisted of 45 primary GISTs derived from 44 patients. Paraffin­
embedded tumour tissues of primary GISTs were retrieved from the files of the 
Department of Pathology of the University Medical Center Groningen. Tumours were 
surgically resected between 1985 and 2005. All tumours were reviewed by a pathologist 
with special expertise in soft tissue tumours (A.J.H.S.). The diagnosis of GIST was based 
on the typical histological features of a cellular spindle cell or epithelioid mesenchymal 
tumour of the gastrointestinal tract. In addition, all tumours were positive for CDl 17 
(KIT) by immunohistochemistry. Tumours were categorised into risk groups, based on 
tumour size and mitotic index, according to the consensus classification for prediction of 
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metastatic potential [18]. Tumour size was obtained from the pathology reports. Mitotic 
index was counted in 50 consecutive high power fields (x 40 objective; field diameter 0.55 
mm). Clinicopathological data collected included sex and age of the patient at diagnosis, 
primary tumour site and histological subtype. For the detection of KIT mutations, 
genomic DNA was extracted from paraffin-embedded tumour samples and KIT exon 9 
or 11 were amplified by PCR. Both forward and reverse PCR products were sequenced 
and results were compared with normal sequences. One patient had two primary 
GISTs, which were a high risk epithelioid gastric tumour lacking a KIT exon 9 and 11 
mutation and a low risk spindle-cell small intestine tumour with a KIT exon 11 mutation, 
respectively. Patient and tumour characteristics are summarised in table 1. 
For the detection of Fas and FasL by western blotting, six frozen primary GIST 
samples were pulverized and dissolved in ice cold PBS. After centrifugation at 18,000 g 
for 1 min to remove debris, the supernatant was collected. Western blot analysis was 
performed as described above. 
All tumour samples used in this study were handled according to the guidelines of 
the Dutch Federation of Biomedical Scientific Societies (FMWV) as described in "Code 
Proper Secondary Use of Human Tissue" 
Tissue micro-array construction 
Representative regions of the paraffin-embedded primary tumours were selected using 
H&E-stained slides and arrayed into a tissue micro-array (TMA), as described previously 
[19] .  Briefly, three 0.6 mm tissue cores were taken from (distinct) representative areas 
of each tumour specimen using a manual tissue arrayer (Beecher Instruments, Sun 
Prairie, WI, USA) and then transferred to a standard-size recipient paraffin block. The 
array contained 161 tissue cores including 45 tumour samples in triplicate and 13 normal 
tissues in duplicate, the latter serving as an internal control for immunohistochemistry. 
Immunohistochemistry 
Sections of 4 µm were taken from each array block and deparaffinised in xylene. 
Immunohistochemistry was performed as previously described [20]. Antigen retrieval 
was carried out by autoclaving sections in blocking solution (2% blocking reagent 
(Roche Diagnostics, Mannheim, Germany) and 0.2% SDS in maleic acid buffer (pH 6.0)) 
at 115°C for three times 5 min. Primary antibodies were mouse anti-Fas (clone CH-11, 
1:100; Upstate Biotechnology, Lake Placid, NY) and mouse anti-FasL (clone 33, 1:160; BD 
Transduction Laboratories). As a negative control, a serial section was processed without 
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the addition of primary antibody. Normal tissue samples within the TMA block derived 
from liver and kidney served as positive controls for Fas and FasL staining [21,22]. 
Table 1. Patient (n=44) and tumour (n=45) characteristics 
n (%) 
Sex 
Male 19 (43) 
Female 25 (57) 
Age (years), median (range) 65.5 (36-87) 
Risk classification 
Very low risk 4 (9) 
Low risk 13 (29) 
Intermediate risk 13 (29) 
High risk 15 (33) 
Primary site 
Stomach 29 (64) 
Small intestine 12 (27) 
Colon 3 (7) 
Unknown 1 (2) 
Histology 
Spindle cell 37 (82) 
Epithelioid 7 (16) 
Mixed 1 (2) 
Tumour size 
� cm 19 (42) 
5-10 cm 17 (38) 
>10 cm 9 (20) 
Mitotic figures 
� per 50 HPF 38 (84) 
>5 per 50 HPF 7 (16) 
KIT mutation 
Exon 11 mutation 28 (62) 
Exon 9 mutation 1 (2) 
No exon 11 or 9 mutation 15 (33) 
Unknown 1 (2) 




Immunohistochemistry results were scored independently by two observers (B.R. and 
A.J.H.S.) without knowledge of the clinicopathological data . As in each individual core all 
tumour cells showed the same staining, cores were scored in a semi-quantitative fashion 
for staining intensity: no staining (0), weakly positive staining (1), positive staining (2), 
strong positive staining (3). Discrepant scoring results were discussed under a multi­
headed microscope to achieve consensus. If cores from one tumour differed in staining 
intensity, the median score of the three related cores determined the score of this tumour. 
Furthermore, the staining pattern was determined from each core. 
Statistical analysis 
Data analysis was performed using SPSS 12.0 software package for windows (SPSS 
Inc., Chicago, IL) . Differences in distributions of Fas or FasL staining intensity and the 
different tumour characteristics were evaluated by the Chi-square test. To determine the 
correlation between Fas and FasL staining, the spearman's rank test was used. A two­
tailed P-value <0 .05 was considered to be significant. 
Results 
MegaFasL-induced apoptosis in GIST cells 
To evaluate whether Fas could be used as a target in GIST, we first investigated Fas 
membrane expression in a panel of imatinib-sensitive (GIST882) and imatinib-resistant 
(GIST48, GIST430 and GIST430K-) cell lines. The cervical carcinoma cell line HeLa is 
responsive to MegaFasL and was used as positive control [12]. Flow cytometry analysis 
revealed that all the GIST cell lines had a high level of Fas membrane expression (figure 
lA). We therefore tested the effectiveness of MegaFasL, a hexameric form of sFasL. After 
as little as 6 hr of MegaFasL treatment, dose dependent apoptosis was observed in all the 
GIST cell lines. MegaFasL induced substantially higher levels of apoptosis in GIST882, 
GIST430 and GIST430K- than in HeLa, while nearly equal amounts were observed in 
GIST48 compared to HeLa (figure 1B and C). Treatment of GIST882 and GIST48 with 
MegaFasL resulted in caspase 8 activation and the disappearance of the inactive proform 
of caspase 3 and 6. The active pl9/pl7 fragments of caspase 3 were detected in both cell 
lines although to a lesser extend in GIST48 which is in agreement with the observed 
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Figure 1. Apoptosis induction by MegaFasL in GIST cell lines. (A) Analysis of Fas membrane 
expression by flow cytometry. The thin grey line represents the IgG control and thick black line 
reflects the anti-Fas antibody. HeLa was used as a positive control. (B) Representative images 
of acridine orange staining of GIST882 and GIST48 with or without treatment with 50 ng/ml 
MegaFasL for 6 hr. Nuclear fragmentation is seen in cells treated with MegaFasL. (C) GIST cell 
lines, and He La, were incubated with different concentrations of MegaFasL for 6 hr. Apoptosis 
was quantified with acridine orange staining. Data represent the mean ± SD of 3 independent 
experiments. (D) Expression of caspase 8, caspase 6, caspase 3, and cleaved caspase 3 after 
treatment of GIST882 and GIST48 cells with 50 ng/ml MegaFasL for 6 hr, analysed by western 
blot. Immunoblotting of actin was used as a loading control. See page 191 for colour figure. 
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MegaFasL (53% apoptosis in GIST882 and 25% in GIST48; figure lC and D). The effect of 
MegaFasL was dependent on caspase activation as zVAD-fmk, a pan-caspase inhibitor, 
completely blocked apoptosis induction by this compound (data not shown). 
The effect of MegaFasL on irnatinib-induced apoptosis 
Following the identification of MegaFasL as a potent apoptosis-inducing agent in GIST 
cells, we investigated its effect in combination with imatinib. GIST882 pretreatment 
with MegaFasL followed by the addition of imatinib, appeared to be the most effective 
schedule. In this way, low concentrations of MegaFasL for 24 hr followed by the addition 
of imatinib for another 24 hr substantially increased the amount of apoptosis compared 
to levels seen with either MegaFasL or imatinib treatments alone (figure 2A). When 
imatinib was administered before MegaFasL, no synergistic but rather an additive effect 
was observed (data not shown). 
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Figure 2. The effect of MegaFasL on imatinib-induced apoptosis. (A) GIST882 cells were 
pretreated with MegaFasL, as indicated, for 24 hr followed by incubation with either DMSO­
only or 1 µM imatinib for an additional 24 hr. Apoptosis was determined by acridine orange 
staining. (B) GIST48 cells were treated with MegaFasL and/or imatinib, as described in (A). 
Data represent the mean ± SD of 3 independent experiments. 
Recently, Bauer et al showed that GIST48 cells are relatively resistant towards imatinib 
[16]. We therefore also evaluated the combination of MegaFasL and imatinib in GIST48 
by using the same treatment schedule as GIST882. As in GIST882, synergistic apoptosis 
induction was seen for the combination of MegaFasL and imatinib, although higher 
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concentrations of MegaFasL were necessary to induce a substantial amount of apoptosis 
(figure 2B). 
Fas and FasL expression in GIST by immunohistochemistry 
As MegaFasL appeared to be an active agent in GIST cells, we studied the expression 
of Fas and FasL in 45 GIST samples by immunohistochemistry using a TMA. Table 2 
shows the overall staining characteristics of Fas and FasL in the 45 GISTs tested. Fas was 
detectable in all the tumour samples studied and was strongly expressed in 62%. FasL 
expression was discerned in 89% of the tumours with 27% staining strongly positive. 
A significant correlation between Fas and FasL expression was found (spearman's 
correlation coefficient = 0 .4, p=0.006). Further statistical analysis revealed that Fas and 
FasL staining intensity was not associated with (1) risk classification, (2) primary site, 
(3) histological subtype, (4) tumour size, (5) mitotic index, and (6) KIT mutation status. 
Both Fas and FasL immunohistochemical staining was predominantly cytoplasmic. 
The staining pattern for Fas was diffuse, in contrast to FasL which was mainly granular 
(figure 3). 
Table 2. Expression of Fas and FasL in GIST 
Staining intensity Fas, n (%) 
0 0 (0) 
1 3 (7) 
2 14 (31) 
3 28 (62) 
Total 45 (100) 






Fas and FasL expression in GIST by western blot analysis 
In addition to immunohistochemistry, Fas and FasL protein expression in six GIST 
samples and the GIST882 cell line was evaluated by western blot analysis. HeLa was 
used as a positive control [23]. As shown in figure 4, protein products corresponding to 
the predicted molecular mass of -36 kDa for FasL were detected in HeLa, GIST882, and in 
all six GISTs. The -48 kDa Fas protein product was also detectable in GIST882 and in all 
GIST samples. Furthermore, most GIST samples - as well as the HeLa cell line - showed 
a lower band of -43 kDa. In addition, most of the GISTs featured an additional band that 
migrated more slowly than the two bands shown in HeLa (Figure 4). This additional -52 
kDa band could represent a highly sialylated but functional form of Fas [24,25]. 
- 131 -
Chapter 6 
Figure 3. Immunohistochemical staining for Fas and FasL in paraffin-embedded GIST samples. 
Representative examples of immunostaining for Fas (A and B) showing predominantly 
diffuse cytoplasmic staining and FasL (C and D) showing granular cytoplasmic staining 
(magnification, 400x). See page 191 for colour figure. 
52/48/43 kDa +- Fas 
36 kDa • .... 
l• __ WE ___ @i4Lk __ Iwit_-____ ...,_ FasL 
Figure 4. Expression of Fas and FasL in six resected GISTs and the GIST882 cell line as 
determined by western blot analysis. HeLa served as  a positive control. GIST 2, 3 and 4 
harbour a KIT exon 1 1  mutation, GIST 1, 5 and 6 have no KIT exon 9 or 1 1  mutations. 
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Discussion 
The results of this study indicate that Fas may be a promising therapeutic target in GIST. 
The GIST cell lines in our panel were found to be highly sensitive to MegaFasL, which 
proved to be an active apoptosis-inducing agent. Moreover, MegaFasL sensitised GIST 
cells to imatinib-induced apoptosis . In addition to these in vitro data, we found that each 
of 45 primary GISTs expressed Fas, and most expressed FasL. 
This is the first study investigating the role of death receptors in the treatment of 
GIST. Both imatinib-sensitive (GIST882) and imatinib-resistant GIST cell lines (GIST48, 
GIST430 and GIST430K-) were responsive to MegaFasL. Furthermore, MegaFasL 
sensitivity appeared to be independent of KIT expression because the GIST430 cell line 
that expresses KIT was as sensitive to MegaFasL as its KIT-negative daughter cell line. 
We found that low concentrations of MegaFasL sensitised GIST cells to imatinib-induced 
apoptosis. Notably, it appeared that the sequence of drug delivery was important. 
Pretreatment of cells with imatinib followed by incubation with MegaFasL had no 
more than an additive effect . Reversing this schedule, however, resulted in synergistic 
apoptosis induction. The underlying mechanism for this observation remains unclear. 
Nimmanapalli et al showed that the sensitising effect of imatinib to TRAIL in Bcr-Abl­
positive leukaemia cells was reduced when TRAIL was administered after exposure to 
imatinib [26] . Although imatinib causes cell cycle arrest, it is unlikely that this mechanism 
is involved in the reduced potentiation of MegaFasL-induced apoptosis by imatinib 
pretreatment as Fas-mediated apoptosis is not cell cycle dependent [27,28] . Possibly, KIT 
inhibition by imatinib alters the membrane distribution of Fas, making it less accessible 
for MegaFasL. Alternatively, the activated caspase cascade by MegaFasL may induce 
cleavage of proteins involved in cellular resistance to imatinib . 
In our patient cohort, which was representative for an unselected GIST population 
with regard to sex, age, tumour localisation, histology, risk classification, and KIT exon 
1 1  mutations [1,29], Fas and FasL were abundantly expressed. Western blot analysis 
confirmed these findings. Acquisition of FasL expression by tumour cells is one of the 
mechanisms involved in tumour immune escape. Various tumour types have been 
reported to express FasL, which can be negatively correlated with prognosis as described 
for colon and breast carcinomas [30,31] . In our study, 89% of the GISTs expressed FasL, 
but no correlation was found with tumour size and mitotic index or risk groups based on 
these prognostic factors which predict metastatic behaviour. The FasL staining pattern in 
the cytoplasm was granular, an expression pattern that has also been observed in ovarian 
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carcinoma and melanoma, where FasL is stored in cytoplasmic microvesicles and, upon 
release, induces apoptosis in Fas-bearing immune cells [20,32,33]. FasL could therefore 
be involved in the protection of GIST cells against the immune system. In addition, we 
found a significant correlation between Fas and FasL expression in GIST, which has 
been observed in many other tumour types as well [20]. This co-expression has been 
implicated in tumour progression, since FasL can act in an autocrine or juxtacrine Fas­
dependent manner to promote tumour growth [10,34]. Further studies are needed to 
determine whether such mechanisms also apply in GIST. 
GIST patients generally respond to therapy with imatinib, which inhibits the KIT 
and PDGFRA oncoproteins that appear to be initiating oncogenic events in most GISTs. 
However, in the long run, most patients develop resistance to imatinib therapy, as 
manifested by tumour progression. It appears that, although imatinib treatment induces 
apoptosis and causes cell cycle arrest of GIST cells, a fraction of the cells usually survive, 
and these surviving cells may subsequently form the nidus of an imatinib-resistant GIST, 
often containing secondary KIT mutations [35,36]. Therefore, novel systemic therapeutic 
approaches are needed to maximise GIST cell death. Targeting death receptors, such as 
Fas, is a promising anticancer strategy by which apoptotic cell death can be induced. 
Unfortunately, the introduction of therapies targeting Fas with agonistic antibodies 
has been hampered by liver toxicity [9]. However, the recently developed MegaFasL 
is potentially less toxic and has been shown to be active in several in vitro and in vivo 
models [12-14]. MegaFasL is formed by cross-linking two sFasL trimers resulting in a 
hexameric protein that much more efficiently induces clustering of Fas on the cell surface 
leading to a higher degree of multimerisation of activated receptors as compared with 
sFasL. As a consequence, a high local concentration of the intracellular death domains 
might be formed, leading to more efficient activation of caspase 8 after binding to the 
adaptor molecule FADD [12]. 
We found that very low doses of MegaFasL potentiate the effect of imatinib. Therefore, 
even when the therapeutic window is low, systemic use of MegaFasL could still have 
a beneficial effect in combination with imatinib. As many GISTs tend to metastasise 
in the abdominal cavity, potential liver toxicity by MegaFasL might be circumvented 
by intraperitoneal applications to prevent MegaFasL from reaching high levels in 
the circulation [14,37]. In this way, MegaFasL might be applied in combination with 
systemic imatinib. The abundant Fas expression in GISTs suggests that also MegaFasL 
alone might be an option for patients with primary or acquired resistance to imatinib. 
However, besides Fas membrane expression, one should take in account the expression 
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of intracellular components affecting sensitivity to Fas-mediated apoptosis in these 
GISTs. 
In conclusion, we have identified Fas as a uniformly expressed receptor in GIST, 
which may be used as a therapeutic target. This is supported by our in vitro studies, 
in which MegaFasL is a potent apoptosis-inducing agent that is even more efficient in 
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Chapter 7 
Abstract 
Background: Recently, case reports of patients treated with imatinib (imatinib 
mesylate; Gleevec®; Glivec®) indicated that this tyrosine kinase inhibitor may induce 
cardiomyopathy. Consequently, careful cardiac monitoring was advocated for clinical 
studies. The purpose of this study was to prospectively evaluate whether imatinib 
(Gleevec®) induces early, subclinical, cardiac toxicity. 
Patients and methods: History and physical examination were carried out with special 
attention for symptoms of heart failure. Additionally, assessments of serial plasma 
N-terminal pro B-type natriuretic peptide (NT-proBNP) and serum cardiac troponin 
T (cTnT) measurement before and one and three months after the start of imatinib 
treatment (400-800 mg daily) were done in patients with advanced and/or metastatic 
gastrointestinal stromal tumours (GIST). 
Results: A total of 55 GIST patients were enrolled. Only one patient, with a normal 
pretreatment NT-proBNP, showed an increase in NT-proBNP to above age-specific 
normal values during imatinib treatment and developed symptomatic heart failure due 
to pre-existent cardiac valvular disease. cTnT levels remained stable. 
Conclusions: In our study population, imatinib treatment for GIST was not associated 
with an increase in plasma NT-proBNP levels, indicating that the risk of subclinical 
cardiac toxicity is limited with the use of this agent. These results do not support the 
current strategy to standard cardiac monitoring in all patients. This may be restricted to 
GIST patients with a history of cardiac disease. 
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Introduction 
Imatinib (imatinib mesylate; Gleevec®; Glivec®, Novartis, Basel, Switzerland), a small 
molecule tyrosine kinase inhibitor, is applied successfully as standard therapy for 
the treatment of chronic myelogenous leukaemia (CML) and gastrointestinal stromal 
tumours (GIST) [l]. A recent publication of Kerkela et al [2], however, without giving a 
patient denominator, suggested a risk of cardiotoxicity induced by imatinib, which was 
unexpected, given the previous toxicity data of large patient studies. Subsequent specific 
reports indicated a low incidence (if any) of New York Heart Association (NYHA) class 
III-VI heart failure due to imatinib, varying from 0.2% to 1.8% [3-5]. Although the clinical 
problem of imatinib-related cardiotoxicity may be limited, lower NYHA class, as well 
as subclinical cardiotoxicity, may be more frequently observed in patients treated with 
imatinib if paid attention to [6]. 
Natriuretic peptides are neurohormones which are increased in plasma in case of 
cardiac dysfunction. N-terminal pro B-type natriuretic peptide (NT-proBNP) is the 
prohormone of BNP and is secreted by cardiomyocytes in response to ventricular 
dilation or local wall stress, and can be used as a sensitive biochemical marker to detect 
left ventricular systolic dysfunction [7]. 
To evaluate whether imatinib induces (subclinical) cardiac toxicity, we prospectively 
evaluated cardiac function, including history, a physical examination, and determination 
of plasma NT-proBNP and serum cardiac troponin T (cTnT) concentrations in GIST 
patients treated with this agent. 
Patients and methods 
Patients and treatments 
As part of surveillance programmes, plasma and serum from patients treated with 
imatinib for locally advanced and/or metastatic GIST were collected after informed 
consent before treatment and at 1 and 3 months thereafter. Imatinib (Novartis) was 
administered orally at 400-800 mg daily, continuously. Treatment was continued until 




A cardiac evaluation, including a history and physical examination with special attention 
to signs and symptoms related to heart failure, was carried out before the start of imatinib 
treatment and 1 and 3 months after the start of treatment. If present, heart failure severity 
was classified according to the NYHA scale [8]. 
Natriuretic peptides and cTnT concentrations 
For the determination of plasma NT-proBNP and serum cTnT levels, peripheral blood 
samples were collected as serum or lithium-heparin plasma specimens using standard 
sampling tubes. Serum or plasma was separated and stored at -80°C until determination. 
NT-proBNP and cTnT levels were measured with an electrochemiluminescence 
immunoassay (Elecsys proBNP assay and Elecsys Troponin T assay, respectively; Roche 
Diagnostics, Mannheim, Germany). NT-pro BNP has an upper limit of normal of 125 ng/L 
[9]. Age-dependent cut-off values are as follows: ::;50 years: 450 ng/L; 50-75 years: 900 ng/L, 
>75 years: 1800 ng/L [10]. cTnT values of >50 ng/L indicate myocardial injury. 
Statistics 
Values are given in mean (±standard deviation) for normally distributed variables and 
median (range) for variables with a skewed distribution. Paired analysis was carried 
out with a Wilcoxon paired samples test. All P-values are two-sided and P-values <0.05 
indicate statistical significance. 
Results 
Patients 
Serum en plasma were obtained from 55 patients (34 male) with a mean age of 62 (±12) 
years. The mean follow-up duration was 9 (±3.7) months. Two patients had received 
prior chemotherapy; one had received 4 cycles of bleomycin, etoposide and cisplatin 
for a testicular germ-cell tumour, 18 years before imatinib, and the other 6 months of 
adjuvant capecitabine for colon carcinoma, 6 months before imatinib. 
Cardiac evaluation and cardiac marker measurements 
Figure 1 represents individual plasma NT-proBNP values during imatinib treatment. 
Before the start of imatinib, two patients had chronic heart failure. One patient had 
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NYHA class III symptoms on the basis of atrial fibrillation and mitral regurgitation, 
which remained stable during treatment. She had an elevated pretreatment NT-proBNP 
level, which increased from 2384 to 4014 ng/L after 3 months. The second patient had 
NYHA class IV symptoms at the start of imatinib therapy due to idiopathic dilated 
cardiomyopathy. The use of diuretics markedly improved his symptoms and lead to a 





pretreatment 1 month 3 months 
Time since start of imatinib 
Figure 1. Individual N-terminal pro B-type natriuretic peptide (NT-proBNP) values before, 
1 month after the start and 3 months after the start of imatinib treatment. Two patients with 
a plasma NT-proBNP level above the upper limit of normal are not shown due to the scale. 
One patient had a pre-treatment value of 19229 ng/L, that decreased to 2358 ng/L at 1 month 
after the start of imatinib and to 294 ng/L after three months. In the other patient, NT-proBNP 
before imatinib was 2384 ng/L, 2303 ng/L after one month imatinib, and 4014 ng/L after 3 
months of treatment (see explanation in the text). Two patients showed an increase in NT­
proBNP during treatment; however, in only one of these two, NT-proBNP increased to above 
the age-adjusted cut-off value. 
Only one of the patients with normal pretreatment NT-proBNP levels developed 
a plasma NT-proBNP level above the age-specific cut-off level (from pretreatment 437 
to 1009 ng/L). This 58-year-old woman, with pre-existing asymptomatic mitral valve 
regurgitation, developed NYHA class II heart failure after 5 months. As she had had 
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heart failure in the past, the relapse of symptoms was considered to be due to the mitral 
valve regurgitation. No other patient presented symptoms of cardiac failure during the 
study period. 
Serum cTnT levels remained below the lower limit of normal for all patients during 
the follow-up period. 
Discussion 
Imatinib is currently widely and successfully applied in the treatment of patients with 
CML or GIST. The recent report by Kerkela et al [2], indicating that the use of imatinib 
could induce cardiac dysfunction, alarmed many oncologists treating these patients. In 
the current study, we found that plasma NT-proBNP levels remained stable during the 
first three months of treatment. Only 1 of 55 patients developed symptomatic, drug­
unrelated heart failure during imatinib treatment, coinciding with a marked increase in 
plasma NT-proBNP value. An increase in serum cTnT was not observed at the various 
time points, as compared to pretreatment values. 
The alarming data of Kerkela et al [2], who did not mention the total number of patients 
at risk, have not been confirmed in subsequent reports with large patient numbers. For 
example, in the EORTC-ISG-AGITG phase III trial, the frequency of cardiomyopathy in 
942 GIST patients treated imatinib at a dose of either 400 or 800 mg daily was 0.2% [5], 
indicating that treatment with imatinib is not related to an increased risk of heart failure. 
Our data are in line with those, and may indicate that short-term imatinib treatment is 
not related to an increased rate of (subclinical) cardiotoxicity. In combination with the 
other studies reported that indicated that the few imatinib-related cardiac events can also 
occur after only a few days of treatment, indicating that if any, the drug rather than the 
cumulative dose may be responsible, our data confirm that standard cardiac monitoring 
does not appear required. 
During the last years, the value of NT-proBNP has been studied in the oncological 
setting. For instance, plasma NT-proBNP measurement in anthracycline-treated breast 
cancer patients, proved to be a useful early marker for a decrease in left ventricular 
ejection fraction [11] .  Interestingly, measurement of plasma BNP has recently been shown 
to be a practical and useable marker for the detection of imatinib-related cardiotoxicity 
[12] .  
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Next to NT-proBNP, we also measured serum cTnT. In oncology, serum cTnT may be 
a useful marker for detecting subclinical cardiotoxicity induced by doxorubicin in adults 
[13,14], although most data are currently derived from studies carried out in children. 
In our study, we measured for the first time cTnT prospectively in patients treated with 
imatinib and could not demonstrate any change in time. 
A limitation of our study may be the fact that no objective measures of left ventricular 
function were included in the cardiac assessment. Another limitation of the current study 
may be our relatively small study population, considering the low reported incidence 
of cardiomyopathy during treatment of GIST patients with imatinib. Additionally, the 
follow-up duration was short. 
In conclusion, plasma NT-proBNP and serum cTnT levels did not change during 
imatinib treatment, further indicating that treatment with imatinib is not related to an 
increased incidence of subclinical cardiotoxicity. Standard cardiac monitoring does not 
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Background: The tyrosine kinase inhibitor imatinib is the first-line treatment for patients 
with an advanced gastrointestinal stromal tumour (GIST) or chronic myeloid leukaemia 
(CML). Several studies in small series of patients with CML treated with imatinib 
reported changes in bone and mineral metabolism and occurrence of hypogonadism in 
male patients. The objective was to assess hormonal and electrolyte changes in patients 
with GIST during treatment with imatinib and to analyse their relation with clinical 
outcome. 
Patients and methods: Patients with GIST treated with imatinib at the University 
Medical Center Groningen between February 2001 and February 2009 were eligible for 
this study. Levels of calcium, phosphate, magnesium, PTH, TSH, FT4, FT3, LH, FSH, 
testosterone, estradiol and prolactin were determined in serum samples obtained before 
start of imatinib and up to 6 months after start of imatinib. Progression-free survival was 
determined for all patients. 
Results: 36 patients were eligible. Compared to baseline, permanent significant decreases 
in serum calcium and phosphate were observed within one week and one month of 
treatment, respectively. A long-term increase in PTH was seen after one week of imatinib. 
No consistent changes in thyroid hormones were detected. The sex hormones did not 
change over time, except a small but significant increase of FSH in male patients. Patients, 
who developed hypophosphataemia after 3 months of treatment, had a decreased 
progression-free survival. 
Conclusions: Imatinib causes hyperparathyroidism in patients with advanced GIST but 
does not affect thyroid and gonadal function. The development of hypophosphataemia 
is associated with a worse clinical outcome. 
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Introduction 
The tyrosine kinase inhibitor imatinib is an inhibitor of KIT, platelet derived growth 
factor receptor (PDGFR), c-Abl and Bcr-Abl. Nowadays, imatinib is the first-line 
treatment for patients with Bcr-Abl positive chronic myeloid leukaemia (CML) and 
advanced gastrointestinal stromal tumours (GISTs) [1,2]. GISTs are neoplasms of 
mesenchymal origin arising from the gastrointestinal tract. The majority of GISTs 
(-80%) are characterized by an activating mutation in the KIT proto-oncogene. In a small 
proportion of GISTs, an activating mutation in PDGFR a (PDGFRA) gene is present. 
These mutations play a central role in the development and progression of GIST [3]. 
Several case reports and studies with small series of patients described hormonal 
changes during imatinib treatment. Secondary hyperparathyroidism was found in 
patients with GISTs as well as in patients with CML [4-6]. Studies have addressed 
imatinib-associated alterations in bone metabolism as an important factor that influenced 
serum calcium, phosphate and parathyroid hormone (PTH) levels [4,6-8]. In patients with 
CML treated with imatinib, development of hypophosphataemia was associated with 
response to treatment suggesting that "off-target" effects of imatinib could be predictive 
for tumour response [5]. 
Other effects of imatinib have been reported to be likely attributable to inhibition of 
its molecular targets in normal tissues including hypogonadism in male patients [9] and 
hypothyroidism in patients on thyroid hormone suppletion after thyroidectomy [10]. 
Given the limited data regarding the occurrence of the above mentioned changes in 
patients with GIST, we studied hormonal and electrolyte alterations in a single centre 
cohort of GIST patients during the first 6 months of treatment with imatinib. In addition, 
we analysed whether these changes were associated with clinical outcome. 
Patients and methods 
Patients 
Newly diagnosed patients with advanced unresectable or metastatic GIST, histologically 
proven by CD117 positivity, who started systemic treatment with imatinib at the 
Department of Medical Oncology of the University Medical Center Groningen between 
February 2001 and February 2009, were eligible for this study. Imatinib was administered 
orally at 400-800 mg daily, continuously. The study protocol was approved by the Medical 
- 149 -
Chapter 8 
Ethics Committee of the University Medical Center Groningen and all patients gave their 
informed consent . 
Tumour response evaluation 
Every patient underwent a routine contrast enhanced CT scan prior to the start of therapy, 
8 weeks after start of therapy, and every 3 months thereafter until progression of disease. 
Disease progression was defined as (1) the occurrence of a new lesion, (2) increasing size 
of the pre-existing lesions (as defined by RECIST version 1.0 [11]), or (3) development 
of an intratumoral nodule and/or an increase in 'solid' tissue, in the background of a 
hypodense lesion [12]. Progression-free survival was defined as the time from imatinib 
initiation until disease progression. 
Biochemical analyses 
Blood samples were collected prior to the start of imatinib therapy, and 1 week and 
1, 3 and 6 months after initiation of treatment. After the samples were drawn, tubes 
were placed on ice immediately and serum was separated within 30 min of collection 
by centrifugation at 4°C. All serum samples were stored at -20°C until analysis. Serum 
calcium, phosphate, magnesium, and albumin were measured on a Roche Modular 
automated analyser. Albumin-adjusted serum calcium was calculated using the 
formula Ca = serumCa [mmol/L] + 0.02 (43 - serumAlb [g/L]). Serum concentrations 
of prolactin were determined using an electrochemiluminescence immunoassay (Cobas, 
Roche diagnostics, Mannheim, Germany). Serum thyroid stimulating hormone (TSH), 
free thyroxine (FT4), free triiodothyronine (FT3), follicle stimulating hormone (FSH), 
luteinizing hormone (LH) and estradiol were measured using a fluoroimmunoassay 
(AutoDELFIA, PerkinElmer, Zaventem, Belgium). Sex-hormone binding globulin (SHBG) 
was measured using an in-house binding assay and total testosterone was determined 
with a radioimmunoassay [13] . Serum intact PTH levels were analysed with a two-site 
chemiluminescent enzyme-labeled immunometric assay (Immulite 2500, Siemens, The 
Hague, The Netherlands). 
KIT and PDGFRA mutation analysis 
Mutation analysis of KIT exons 9, 11, 13 and 17 and PDGFRA exons 12, 14 and 18 was 
performed as described previously [14]. 
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Statistics 
Changes in serum levels were evaluated with the paired samples t-test or the Wilcoxon 
signed ranks test, as appropriate. The log rank test was applied to analyse the impact of 
changes of biochemical markers during imatinib treatment on progression-free survival. 
For this, patients were divided into groups according to quartile changes from baseline 
for each marker at each time point, or, alternatively, into groups based on the normal 
reference values. Correlations were described by the Pearson's correlation coefficient 
(r). A double-sided P-value <0.05 was considered statistically significant using SPSS for 
windows version 16.0. 
Results 
Thirty-six patients treated with imatinib entered this study. Patient characteristics are 
summarized in table 1. All patients were evaluable for tumour response assessment. 
The median follow-up was 32 (range 4 - 87) months and the median progression-free 
survival was 23 months. 
Calcium, phosphate, magnesium and PTH 
One patient was on calcium and vitamin D supplements at start of treatment and was 
excluded from analysis. Before treatment, the serum concentrations of calcium, phosphate, 
magnesium and PTH were within the normal reference range. During treatment with 
imatinib, significant sustainable changes in serum levels of calcium, phosphate and PTH 
were observed (figure 1 and table 2). A decrease in albumin-adjusted serum calcium levels 
was observed already 1 week after start of imatinib with a further decline after 1 month, 
which remained stable thereafter. The mean (±SD) calcium reduction at one month was 
0.14 (±0.11) mmol/L with 27 percent of the patients developing a mild hypocalcaemia 
(i.e. a calcium level below normal). A drop in serum phosphate levels was seen from 1 
month after start of treatment, which remained reduced at 3 and 6 months. The mean 
(±SD) decrease in serum phosphate at 1 month was 0.20 (±0.15) mmol/L while one patient 
developed hypophosphataemia after 1 month. In 25 of 32 patients (78%), who had both 
calcium and phosphate levels analysed at 3 months, both electrolytes were decreased. A 
transient small increase in serum magnesium was observed after one week of treatment. 
A rise in serum PTH levels was observed after one week of treatment inclining after 
1 month and remaining stable at this increased level at the later time points. Up to 50 
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percent of the patients developed hyperparathyroidism (i.e. serum PTH values above the 
normal upper limit of 8.7 pmol/L; table 2). 
Table 1. Patient characteristics (n=36) 
n (%) Median (range) 
Sex 
Male 23 (64) 
Female 13 (36) 
Age (years) 62 (24 -81) 
Imatinib dose 
400 mg 34 (94) 
800 mg 2 (6) 
Primary tumour localization 
Stomach 13 (36) 
Small bowel 14 (39) 
Colon 3 (8) 
Other site 6 (17) 
Disease stage 
Primary disease only 10 (28) 
Metastatic disease 26 (72) 
Mutation 
KIT exon 9 5 (14) 
KIT exon 11 16 (44) 
PDGFRA exon 18 3 (8) 
Wild-type 2 (6) 
Not evaluable 10 (28) 
Progression-free survival (months) 23 
Follow-up (months) 32 (4 -87) 
W hen analysing the mutual relationships between the changes in calcium, phosphate 
and PTH levels, there was no significant correlation between the changes of any of these 
factors at the different time points (r between -0.2 and 0.2, and p >0.10 for all correlations). 
There were no associations between changes in serum levels of calcium or PTH and 
progression-free survival. Patients who developed hypophosphataemia after 3 months 
of treatment had a worse progression-free survival than those with a phosphate level 
within normal range (p=0.013; figure 2). In contrast, no associations were found between 
the degree of decrease in phosphate levels and progression-free survival. 
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Figure 1. Electrolyte and PTH serum levels during imatinib treatment. (A) Albumin-adjusted 
serum calcium, (B) serum phospate, (C) serum magnesium, (D) serum PTH. Data are mean 
(95% confidence interval). *, p<0.05; **, p<0.01, ***, p<0.001 vs baseline. 
Thyroid hormones 
Three patients with known thyroid disorders (one with hypothyroidism and two with 
hyperthyroidism) were excluded from this analysis. The values of TSH, FT4 and FT3 at 
baseline and at one month are shown in table 3. TSH and FT3 did not change during 
treatment. An increase in FT4 with median 0.90 (range -7.40 - 1 .90; p=0.014) pmol/L and 
1 .00 (range -7.80 - 2.00; p=0.012) pmol/L was found after one week and one month of 
treatment, respectively. At 3 and 6 months, the levels of FT4 did not differ from baseline. 




Table 2A. Levels of albumin-adjusted serum calcium (mmol/L) 
Time point Cases Mean Median Cases below lower Cases above upper 
(months) (SD) (range) reference value (%) reference value1 (%) 
0 35 2.40 (0.11) 2.40 (2.15-2.68) 1 (3) 1 (3) 
0.25 34 2.30 (0.11) 2.30 (2.10-2.58) 6 (18) 0 (0) 
1 34 2.25 (0.11) 2.26 (2.03-2.46) 9 (27) 0 (0) 
3 34 2.25 (0.12) 2.26 (2.04-2.56) 12 (35) 0 (0) 
6 32 2.27 (0.10) 2.25 (2.11-2.53) 9 (28) 0 (0) 
1 Reference values: 2.20-2.60 (mmol/L) 
Table 2B. Levels of serum phosphate (mmol/L) 
Time point Cases Mean (SD) Median (range) Cases below lower reference 
(months) value1 (%) 
0 35 1 .06 (0.13) 1 .06 (0.77-1.24) 0 (0) 
0.25 30 1 .01 (0.15) 1 .00 (0.79-1 .33) 0 (0) 
1 30 0.86 (0.13) 0.86 (0.56-1.29) 1 (3) 
3 33 0.86 (0.16) 0.86 (0.50-1 .20) 5 (15) 
6 30 0.87 (0.16) 0.86 (0.55-1 .29) 3 (10) 
1 Reference values: 0.70-1.50 (mmol/L) 
Table 2C. Levels of serum PTH (pmol/L) 
Time point Cases Mean (SD) Median (range) Cases above upper reference 
(months) value1 (%) 
0 35 6.1 (2.6) 5.8 (1.5-12.0) 6 (17) 
0.25 30 7.3 (3.5) 6.0 (3.2-17.0) 8 (27) 
1 30 8.7 (3.9) 7.4 (4.0-22.0) 12 (40) 
3 33 8.6 (4.7) 7.7 (3.5-26.0) 10 (30) 
6 30 9.0 (3.9) 8.8 (3.5-18.0) 15 (50) 
1 Reference values: <8.7 (pmol/L) 
Abbreviation: PTH, parathyroid hormone 
Sex hormones 
One male patient was excluded from this analysis because he suffered from a 
prolactinoma. The values of the various sex hormones at baseline and at three months are 
shown in table 4. Six male patients (27%) showed testosterone levels below the normal 
reference value at baseline, which was accompanied with an increased LH in two of these 
patients. No changes in testosterone, estradiol, SHBG and prolactin were observed in 
the total group of patients or in the male or female subgroups. In the group of 22 male 
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patients, an increase in FSH but not of LH was detected. Median FSH levels at baseline 
were 7.33 U/L (range 2.84-23.90) and increased after 1 week and after 1, 3 and 6 months 
with median 0.83 (range -1 .25 - 10.01), 0.88 (range -2.00 - 8 .30), 1 .02 (range -5.30 - 8.60) 
and 1 .18 (-1 .90 - 9.60) U/L, respectively ( P < 0.05 for all time points vs. baseline). Notably, 
50 percent of the male patients had FSH levels above the upper reference limit of 7.2 U/L 
at baseline already and this percentage did not change during treatment. There was no 
association between alterations in the levels of FSH and progression-free survival. 
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Figure 2. Progression-free survival for patients with GIST developing hypophosphataemia 
versus patients remaining serum phosphate levels within normal range after 3 months of 
treatment with imatinib. 
Table 3. Thyroid hormones in GIST patients (n=33)1 at baseline and after one month of imatinib 
treatment 
Median value (range) Median value (range) 
at baseline al l month 
TSH (rnU/L) 1 .30 (0.34 - 19.00) 1 .30 (0.56 - 14.00) 
FT4 (prnol/L) 14.2 (8.3 - 25.0) 14.8 (10.8 - 23.1) 
FT3 (prnol/L) 5.7 (3.3 - 7.6) 5.6 (3.3 - 7.7) 
1Three patients with thyroid disorders were excluded from analysis. 
2Paired samples test 
P-value2 Reference 
values 
0.85 0.5 - 4.0 
0.012 11 .0 - 19.5 
0.27 4.4 - 6.7 
Abbreviations: TSH, thyroid stimulating hormone; FT4, free thyroxine; FT3, free triiodothyronine. 
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Table 4. Sex hormones in male (n=22)1 and female (n=13) patients at baseline and after three 
months of imatinib treatment 
Median value (range) Median value (range) P-value2 Reference 
at baseline at 3 months values 
Testosterone (runol/L) 
Male 14 (3 -26) 16 (1 - 23) 0.87 12-40 
Female 1.7 (0.1 - 4.5) 1.6 (0.0 -3.3) 0.07 0 - 3.5 
Estradiol (runol/L) 
Male 0.10 (0.03 - 0.13) 0.08 (0.05 - 0.13) 0.66 0.06-0.13 
Female 0.05 (0.02 -0.25) 0.05 (0.02 - 0.34) 0.34 0.03-0.09 
SHBG (nmol/L) 
Male 36 (13 -61) 35 (17 -89) 0.75 12 - 30 
Female 39 (27-99) 49 (27-95) 0.93 10-100 
Prolactin (mU/L) 
Male 165.3 (92.6 -371.8) 189.8 (100.5 -429.4) 0.13 <300 
Female 201.0 (63.7 -729.1) 205.8 (77.0 -518.5) 0.75 <500 
FSH (U/L) 
Male 7.33 (2.84 - 23.9 ) 8.12 (3.53 - 32.20) 0.036 1.8 -7.2 
LH (U/L) 
Male 5.61 (2.72 - 27.0) 5.31 (2.57 -23.50) 0.17 2.1-11.2 
1One male patient with prolactinoma was excluded from analysis. 
2Paired samples test 
Abbreviations: SHBG, sex-hormone binding globulin; FSH, follicle stimulating hormone; LH, luteinizing hormone. 
Discussion 
Most GIST patients are effectively treated with imatinib. Many patients achieve long­
lived responses resulting in a significant number of patients (-30 percent) using imatinib 
for even more than 5 year [2,15]. In general, imatinib is well tolerated and dose limiting 
toxicity is seen in a limited number of patients using the standard daily dose of 400 mg 
[16]. As imatinib is used as a long-term, chronic therapy, the recognition of side-effects is 
of importance for preventing discontinuation of therapy and maintaining quality of life. 
Most of the oncogenes that are targeted by imatinib, such as KIT, PDGFR and c-ABL, are 
not only expressed in malignancies but also in normal tissues, e.g. in the testis [17,18]. 
As a result, irnatinib could influence normal tissue homeostasis as a reflection of its 
pharmacodynamic activity. Recent reports, predominantly studying patients with CML, 
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suggested that imatinib can affect bone metabolism and male gonadal function [ 4-9] .  In 
the present study, we investigated the biochemical effects of imatinib in GIST patients in 
relation to bone metabolism and gonadal and thyroid function. In addition, we evaluated 
whether these effects could predict clinical outcome. 
Changes in bone and mineral metabolism in patients with CML during treatment 
with imatinib have been reported. These changes were associated with a decrease in 
serum phosphate and calcium and the development of hyperparathyroidism, which 
coincide with alterations in markers of bone turnover [4-6,8,19] .  It appears that imatinib 
stimulates bone formation causing an increase in trabecular bone volume and bone 
mineral density [6,8,19] .  It has been suggested that imatinib stimulates osteoblast 
differentiation and function via inhibition of PDGFR and, on the other hand, suppression 
of osteoclast function as a consequence of inhibition of c-Fms signal transduction [7,8,20] .  
This increase in bone formation results in the sequestration of calcium and phosphate 
to bone. As a consequence, decreased serum calcium stimulates PTH secretion which 
decreases renal phosphate resorption, leading to hypophosphataemia [4,8] . The results 
of our study in a cohort of GIST patients are consistent with those found in CML patients. 
For so far, only a limited number of patients with GIST, while on imatinib therapy, 
have been studied regarding changes in calcium phosphate metabolism [4,21] .  Our 
study is by far the largest study performed on this topic in GIST. We noticed in our 
GIST population that changes in serum calcium and PTH were already detectable after 
one week of imatinib treatment suggesting an immediate action on bone metabolism. 
Although serum phosphate and calcium decreased in the fast majority of patients, the 
levels of most patients remained within the normal range. Furthermore, most patients 
developed a mild hyperparathyroidism, which is in agreement with previous reports 
[5,6] .  Apparently, the magnitude of these biochemical effects are rather small and critical 
electrolyte deficiencies, which are clinical significant are not to be expected in GIST 
patients treated with imatinib. 
Although we observed a transient increase in FT4 shortly after start of therapy, 
there were no persistent changes in thyroid hormones during imatinib treatment. This 
is consistent with the findings reported by Dora et al [22]. There were also no changes 
observed in the sex hormones except for a mild increase in FSH levels. This is in contrast 
with a study in CML patients suggesting that imatinib influences serum testosterone 
and free testosterone, at least in a subset of male patients developing gynaecomastia 
[9] .  These differences might be attributable to the fact that almost all our male patients 
were treated with 400 mg imatinib daily in contrast to the 600-800 mg daily dose that 
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was associated with the development of hypogonadism and gynaecomastia described 
by Garnbacorti-Passerini et al. Furthermore, these patients with CML were pre-treated 
with interferon alpha, a drug that has been reported to have testosterone lowering effects 
[23,24]. 
Given the lack of predictive biomarkers for the response of patients with GIST to 
imatinib, we evaluated whether changes in hormones and electrolytes could predict 
clinical outcome. Predictive biomarkers can provide information on different aspects of 
the efficacy of a therapeutic intervention. Upfront predictive markers can be used for 
patient selection, while early predictive markers give information shortly after start of 
treatment [25]. Mutations in KIT and PDGFRA in GIST are upfront predictive markers for 
the response to imatinib and for progression-free survival [26,27]. Mutational status will 
probably guide the choice and the dose of tyrosine kinase inhibitor treatment in patients 
with GIST in the near future. Early predictive markers for efficacy of imatinib treatment 
in patients with GIST are not available yet, although monitoring changes in glucose 
uptake in GIST lesions with 2-[fluorine-lB]fluoro-2-deoxy-D-glucose-positron emission 
tomography scanning is an interesting approach [28,29]. Hormonal and electrolyte 
changes during imatinib treatment may potentially be novel biomarkers. We noticed that 
patients developing hypophosphataemia after 3 months of treatment had a decreased 
progression-free survival. This is in contrast with the results published by Osorio et al 
who found the largest reduction in phosphate in CML patients exhibiting a major genetic 
response to imatinib [5] .  Theoretically, imatinib might influence the microenvironment 
of CML stem cells within the bone marrow by altering bone metabolism. In this way, 
changes in bone metabolism might contribute to the treatment effect of imatinib in CML 
as reflected by serum phosphate levels [30]. Nonetheless, changes in serum phosphate 
levels shortly after initiation of imatinib treatment as an early predictive marker for 
imatinib treatment need to be studied further in patients with GIST and CML. 
In conclusion, imatinib affects calcium and phosphate homeostasis and causes 
mild hyperparathyroidism in patients with GIST. Furthermore, our data suggest that 
imatinib does not influence thyroid or male gonadal function. The development of 
hypophosphataemia appears to predict a worse clinical outcome. 
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Summary 
Gastrointestinal stromal tumours (GISTs) are mesenchymal neoplasms that arise in 
the wall of the gastrointestinal tract. GISTs represent a continuum from incidentally 
discovered small nodules with a benign or extremely low malignant potential to large 
highly malignant sarcomas. Characteristically, virtually all GISTs (>95 percent) over­
express the receptor tyrosine kinase and proto-oncogene KIT, which is used as an 
immunophenotypical marker for the diagnosis of GIST. Moreover, oncogenic mutations 
that affect KIT or, much less often, the closely related platelet-derived growth factor 
receptor a. (PDGFRA), have been detected in 85-90 percent of GISTs. These mutations 
result in ligand-independent, constitutive activation of these receptors leading to 
activation of cellular signal transduction cascades involved in cellular proliferation and 
survival. KIT and PDGFRA mutations are mutually exclusive and play a fundamental 
role in the development of GIST. The tyrosine kinase inhibitor imatinib blocks the activity 
of KIT and PDGFRA. It has become the standard first-line treatment of patients with 
unresectable or metastasized GIST. Imatinib therapy results in high objective response 
and disease stabilisation rates but none of the patients are cured with this compound. The 
same holds true for second-line treatment with sunitinib, a tyrosine kinase inhibitor of 
KIT, PDGFR but also vascular endothelial growth factor (VEGFR) and FMS-like tyrosine 
kinase 3 (FLT3), of which clinical benefit, i.e. response and disease stabilisation, has been 
described but which is effective just as imatinib for a limited period of time. Therefore, 
new therapeutic strategies need to be developed. 
The first aim of this thesis was to explore new molecular targets for the treatment of 
GIST. Secondly, potential side-effects of imatinib and markers for response to this drug 
were evaluated. 
The first part of this thesis focuses on the role of the insulin-like growth factor (IGF) 
signalling system in GIST. Chapter 2 reviews the current knowledge about the IGF 
system. Special attention was drawn to the function of IGF signalling in the pathogenesis 
of several types of sarcomas. In GIST, it has been demonstrated that tumours without KIT 
or PDGFRA mutations, so called wild-type GIST, express high levels of IGF receptor type 
1 (IGF-lR), suggesting that this IGF receptor could be involved in the pathogenesis of this 
subgroup of GISTs. Currently, therapies inhibiting IGF signalling are being developed 
and tested. Humanized monoclonal antibodies directed against IGF-lR have entered 
phase 2 and 3 clinical testing and objective tumour responses were reported in several 
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patients with Ewing's sarcoma encouraging further clinical testing in Ewing's sarcoma 
and other sarcoma entities, including possibly wild-type GISTs. 
Non-islet cell tumour-induced hypoglycaemia (NICTH) is a paraneoplastic 
syndrome occasionally observed in patients with sarcomas. NICTH is characterized by 
the occurrence of recurrent fasting hypoglycaemia. Tumours involved in NICTH secrete 
high amounts of incompletely processed precursors of IGF-11, called 'big' -IGF-11, leading 
to markedly increased levels of 'big' -IGF-11 in the circulation. Subsequently, this induces 
alterations in the circulating levels of insulin, IGF-I and the insulin-like growth factor 
binding proteins (IGFBPs), causing an insulin-like hypoglycaemic activity of 'big'-IGF-11. 
Chapter 3a discusses the tumour types and symptoms associated with NICTH as well 
as the pathogenesis, diagnosis and treatment of this rare paraneoplastic phenomenon. 
In addition, two illustrative cases of patients suffering from NICTH caused by a solitary 
fibrous tumour and a haemangiopericytoma, respectively, are reported. In chapter 3b, 
an illustrative case of a patient with a GIST suffering from NICTH is described. The 
conclusion of this case-report is that NICTH should be considered in patients with GIST, 
especially in those with loss of consciousness. 
In chapter 4, the prognostic relevance of plasma levels of 'big'-IGF-11 and other 
IGF-related proteins in patients with a GIST before and during imatinib treatment was 
investigated. It appeared that before or during treatment, 3 of 24 included patients (13%) 
showed increased plasma levels of 'big'-IGF-II. Later on, all three patients developed 
hypoglycaemia. In the total group of patients, the highest 'big'-IGF-11 levels were found 
in patients with either metastatic disease, elevated serum lactate dehydrogenase activity, 
or a relatively high tumour mass. Most patients had increased plasma IGFBP-2 levels 
and these levels were significantly higher in patients with progressive disease during 
treatment. Analysis of tumour tissues and cyst fluid for 'big'-IGF-11 and IGFBP-2 
revealed that it is likely that most of the 'big'-IGF-11 detected in plasma is secreted by 
tumour tissue in contrast to IGFBP-2. All together, these results indicate that elevated 
plasma concentrations of 'big'-IGF-11 are not uncommon in patients with a GIST and are 
prognostic for the development of hypoglycaemia. 'Big' -IGF-11 could therefore be useful 
as marker in the surveillance of GIST. An eventual role for IGFBP-2 as a biomarker in 
GIST remains to be established. 
The observations in the previous chapter regarding the production of 'big'-IGF-11 
by GIST prompted us to investigate the biological role of this secretion in in vitro GIST 
models described in chapter 5. IGF-11 (both in its mature and immature forms) acts as 
an autocrine factor in several tumour types by binding to IGF-lR and/or insulin receptor 
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isoform A. Analysis of IGF-II secretion by two GIST cell lines revealed that both cell 
lines secreted high amounts of IGF-II, predominantly as 'big'-IGF-II. At the mRNA 
and protein level, expression of the insulin receptor isoform A but not of IGF-lR was 
demonstrated in the KIT mutant GIST cell lines and in KIT and PDGFRA mutant GIST 
specimen. Down-regulation of 'big' -IGF-II production or insulin receptor expression 
with short interference RNA reduced the survival of both cell lines by affecting AKT 
and mitogen-activated protein kinase signalling. Disruption of 'big'-IGF-II signalling in 
combination with imatinib had an additive cytotoxic effect in GIST cells. Finally, IGF-II 
expression was investigated in an extended cohort of 60 paraffin-embedded tumours 
of various malignant potential most having activating mutations in KIT or PDGFRA. 
IGF-II mRNA was present in 52 of 57 (91 %) primary GISTs and absent in all four very­
low-risk tumours. IGF-II protein was expressed in the majority of these GISTs, far most 
in high-risk tumours, and its expression was irrespective of KIT or PDGFRA mutation 
status. These findings indicate that 'big'-IGF-II secretion by GIST provides an autocrine 
pro-survival signal by interacting with insulin receptor isoform A that is relevant for the 
pathogenesis of GIST. 
In chapter 6, the possibility of targeting the death receptor Fas with MegaFasL, a 
recently developed hexameric form of soluble Fas ligand (FasL), was explored. MegaFasL 
appeared to be an active apoptosis-inducing agent in a panel of imatinib-sensitive and 
imatinib-resistant cell lines which all expressed Fas. Moreover, MegaFasL potentiated the 
apoptotic effects of imatinib. Histological evaluations, in 45 primary GISTs, underscored 
the relevance of the Fas pathway: Fas was expressed in virtually all GISTs, independent 
from the presence of certain KIT mutations, whereas FasL was expressed in the majority. 
These results show that Fas is a potential therapeutic target in GIST. 
The last part of this thesis addresses potential side-effects of imatinib. In chapter 7, 
the suggested risk of imatinib-induced cardiotoxicity was evaluated. Therefore, plasma 
N-terminal pro B-type natriuretic peptide (NT-proBNP) and serum cardiac troponin 
T (cTnT) levels were used as markers for cardiotoxicity. Both markers were determined 
before treatment with standard dose of imatinib and up to three months after start of 
treatment in 55 patients with locally advanced and/or metastatic GIST. NT-proBNP 
and cTnT levels remained stable in all patients except one. This patient developed 
symptomatic heart failure during the study period that was likely caused by pre-existing 
cardiac valvular disease. We concluded that, in our study population, the risk on early 
subclinical cardiac toxicity with the use of imatinib was not present. 
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Several studies in small series of patients with chronic myeloid leukaemia reported 
imatinib-associated changes in bone and mineral metabolism, and occurrence of 
hypogonadism in male patients. Hence, the influence of imatinib on various serum 
electrolytes and hormones was studied in GIST patients in chapter 8. In 36 patients 
with advanced GIST, serial analysis from baseline up to 6 months after start of therapy 
revealed that serum calcium and phosphate significantly decreased within one week 
and one month of treatment, respectively. Imatinib caused hyperparathyroidism and an 
increase in serum parathyroid hormone was detected already after one week of treatment. 
On the other hand, imatinib did not affect thyroid and gonadal function. Patients, who 
developed hypophosphataemia after 3 months of treatment, had a decreased progression­
free survival. Whether changes in phosphate levels might be used as a predictive marker 
for response should be explored prospectively in larger patient groups. 
General discussion 
GIST is considered as the role model for successful application of targeted therapy 
in solid tumours. Apparently, most GISTs are tumours driven by oncogenic KIT and 
PDGFRA gain-of-function mutations, which are clearly targets for therapy. The KIT and 
PDGFRA tyrosine kinase inhibitor imatinib has revolutionized the treatment of GIST 
making this drug one of the most successful new agents introduced for the treatment of 
a solid tumour in the last decade. However, clinical resistance to this drug either initially 
or during a prolonged period of treatment has been proven to be a significant problem. 
Therapeutic targets in GIST 
In current clinical practice, optimal inhibition of constitutively activated KIT and PDGFRA 
signalling is the mainstay of systemic treatment of GIST. This is also the main focus of 
most of the present (pre)clinical research performed in GIST. The recognition that the 
type of KIT or PDGFRA mutation has an important predictive value for the response of 
GIST to a particular kinase inhibitor has tailored the way for further individualization of 
treatment [1]. For example, tumours with KIT exon 11 mutations respond much better to 
imatinib than tumours with KIT exon 9 mutations (or wild-type tumours) [2,3]. Sunitinib 
was approved for the treatment of imatinib-resistant GIST. Interestingly, it was shown 
that this drug is much more effective than imatinib in GISTs with KIT exon 9 mutations 
[4]. Currently, other KIT and PDGFRA targeting compounds, such as sorafenib and 
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nilotinib, with an inhibitory preference for certain KIT or PDGFRA mutations that are 
partly different from those targeted by imatinib, are also clinically tested [5,6]. It might, 
therefore, be possible that future therapies for GIST patients will largely be directed by 
the GIST genotype using tyrosine kinase inhibitors that have the most potent inhibitory 
activity towards a particular KIT or PDGFRA mutation. This is also of importance when 
resistance to imatinib or sunitinib has developed, which most often occurs through the 
development of secondary mutations in KIT or PDGFRA [7]. Several of the new tyrosine 
kinase inhibitors are able to inhibit these secondary receptor alterations, which makes 
these kinase inhibitors potentially suitable to target progressive imatinib and sunitinib­
resistant GISTs that have acquired particular secondary mutations [8]. Of major concern 
with respect to resistance in GIST, however, is the occurrence of several different 
secondary mutations in distinct tumour lesions of individual patients whose tumours 
progressed during imatinib treatment [9,10]. This heterogeneity of secondary receptor 
mutations could hamper the application of successful universal targeted therapy 
with tyrosine kinase inhibitors when resistance against standard treatment has been 
developed. Alternative strategies could then be the use of surgery of focal progressive 
lesions, which policy should be further explored, or agents that influence the expression 
of KIT and PDGFRA such as heat shock protein 90 inhibitors or inhibitors of downstream 
signalling cascades such as phosphatidylinositol-3-kinase or mammalian target of 
rapamycin inhibitors [11-15]. 
The main focus of this thesis was to identify therapeutic targets other then those 
involved in activated KIT and PDGFRA. Although these two receptors and their cellular 
signal cascades are highly important in the pathogenesis of GIST, also other oncogenic 
signalling cascades are likely to be of importance. For the development of GIST, genetic 
aberrations and activation of oncogenic pathways are a requisite for further progression 
of prematurely transformed GIST-progenitor cells towards a malignant tumour [16]. To 
date, little is known about these secondary events in the development of malignant GIST. 
Several successive chromosomal alteration have been described such as the loss of 14q 
and 22q [17]. However, knowledge about the involvement of alternative oncogenes and 
tumour suppressors in GIST oncogenesis is limited. Identification of such secondary hits 
could lead to the identification of drugable targets. 
The studies presented in this thesis put forward that gain of IGF-11 expression is 
an oncogenic event involved in the pathogenesis of GIST. Therefore, targeting 'big' -
IGF signalling could be useful as a new treatment option. The recognition that the IGF 
signalling system is involved in many cancer types has encouraged the development of 
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new therapeutics that can block the different members of this system [18]. One strategy 
interesting for GIST would be 'big' -IGF-II neutralizing antibodies. Such antibodies 
have been developed and show preclinical potential [19]. For those wild-type GISTs 
expressing IGF-lR, receptor-specific blocking antibodies or small-molecule tyrosine 
kinase inhibitors, which are currently in early clinical trials, could be a potential 
therapy [20]. However, as shown in this thesis, most GISTs, carrying KIT and PDGFRA 
mutations, do not express IGF-lR but show the expression of an alternative 'big' -IGF­
II receptor, that is the insulin receptor isoform A. In line with other malignant tissues, 
GISTs have a preference for the expression of the isoform A splice variant of the insulin 
receptor rather than the isoform B, which is much less responsive to IGF-II than isoform 
A. Isoform B is commonly expressed by normal insulin-sensitive tissues in adults and 
has dominant effects on cell metabolism. In contrast, the isoform A has important 
effects on cellular survival and proliferation [21]. Knowledge about the mechanisms 
involved in the preferred expression of isoform A in cancer cells is limited. This is also 
the case for the spatial effects of the 12 amino acid difference between both isoforms 
of the insulin receptor that leads to differences in ligand affinities and intracellular 
signalling [21]. Targeting both isoforms of the insulin receptor as an anticancer strategy 
could result in serious metabolic toxicity. It would therefore be a challenge to develop 
compounds that selectively target isoform A. Until now, only small molecule tyrosine 
kinase inhibitors have been developed that inhibit both isoforms of the insulin receptor 
together with IGF-lR [22]. In preclinical xenograft models, such agents caused (transient) 
hyperglycaemia. Further (pre)clinical testing will reveal whether these compounds will 
be beneficial for the treatment of GIST. 
Activation of the extrinsic apoptosis pathway through activation of members of the 
tumour-necrosis factor receptor family of death receptors has been shown to induce 
apoptosis in a wide variety of cancer cells [23]. Strategies activating the death receptor 
Fas, as described in this thesis, were an alternative therapeutic approach we explored 
in GIST cells. Inhibition of KIT only results in modest levels of apoptosis and causes 
predominantly cell cycle arrest in the majority of cells in a GIST [24]. In this way, 
a significant number of cells are able to survive and give rise to the development of 
resistance towards imatinib or other tyrosine kinase inhibitors. Systemic therapeutic 
approaches that maximize GIST cell death, such as MegaFasL, could therefore be a 
promising treatment. Although agonistic antibodies against Fas appeared to be highly 
toxic in mice, hexameric Fas ligand (MegaFasL; also called APO0lO) showed only modest 
transient toxicity in animal studies [25,26]. Currently, MegaFasL has entered phase 1 
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clinical testing. The results from these clinical studies will have to reveal whether this 
compound comes further into sight for studying its efficacy in GIST patients. 
Aspects involving personalised treatment 
Besides the development of new treatment strategies, also other aspects are involved in 
optimizing the treatment of the individual patient. These include the identification of 
prognostic and predictive factors, as well as the elucidation of markers of response to a 
given treatment, or toxicity-related issues. 
The type and dosing of systemic treatment in GIST is ideally guided by predictive 
factors. The presence of molecular targets including KIT and PDGFRA will likely guide 
future therapies including those targeting alternative signalling pathways. Till now, 
the KIT and PDGFRA genotype of a GIST is the most important factor predicting the 
response to imatinib and sunitinib [8]. Identification of other biomarkers could result 
in further fine-tuning of KIT /PDGFRA targeting agents. In daily practice, CT scanning 
is used to evaluate h1mour response to imatinib or other tyrosine kinases and has been 
shown to be of value to discriminate between progressive and nonprogressive disease 
[27]. 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography scanning 
has been shown to be an additional valuable tool for response evaluation in GIST, but 
well powered prospective studies regarding its exact place in daily clinical practice of 
GIST patients are lacking [28]. The identification of tumour-derived proteins, measured 
in serum or plasma of patients and serving as a reliable tumour marker, could simplify 
and be cost effective for the follow-up of GIST patients. No such markers are nowadays 
available. Candidates for further research on this topic could be the soluble KIT [29,30] 
and DOG-1 (discovered on GIST-1) [31] proteins that are extensively expressed in GIST, 
but also 'big' -IGF-II. 
The occurrence of toxicity by tyrosine kinase inhibitors is also important for the 
tailoring of treatment of GIST. Although imatinib, and similarly sunitinib, as targeted 
cancer therapy is aimed at inhibition of constitutively activated KIT and PDGFRA 
in GIST, these receptor tyrosine kinases are also expressed in normal tissues playing 
a role in organ physiology. Therefore, these therapies could influence normal tissue 
homeostasis resulting in toxicity. In the last few years, several unexpected toxicities 
have been reported that were associated with imatinib, including heart failure, testicular 
insufficiency and hypophosphataemia [32-34] . Although the studies presented in this 
thesis showed that these toxicities are of limited significance during imatinib treatment, 
the recognition of side effects and the identification of those patients at risk of toxic 
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effects have important implications for the prolonged application of this drug. The 
development of a risk calculator for predicting imatinib-induced toxicity is an example 
of a useful initiative to guide the dosage of this compound [35]. The same principles hold 
for sunitinib that, in general, has a toxicity profile associated with more adverse events 
than imatinib, including hypertension, hypothyroidism and cardiotoxicity. This is likely 
the result of the broad range of tyrosine kinases, such as VEGFR and FLT3 in addition 
to KIT and PDGFR, that are inhibited by this compound [36]. Close monitoring of side 
effects of imatinib, sunitinib and new agents in the treatment of GIST will optimize the 
treatment success of these agents. 
Conclusions 
In conclusion, this thesis provides new insights in the pathogenesis of GIST. As for many 
other sarcomas, the IGF signalling system is involved in the development of GIST. We 
identified 'big'-IGF-II as an autocrine factor that is relevant for the maintenance of this 
malignancy by signalling through the insulin receptor isoform A. Furthermore, 'big­
IGF-II could be useful for the surveillance of GIST, at least for those patients at risk for 
developing NICTH. In addition, we implied the death receptor Fas as a promising new 
treatment target. Finally, issues regarding imatinib-associated toxicity and their value as 
predictive markers were addressed. Hopefully, these studies form the basis for further 
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Chapter 10 --- ---
Samenvatting 
Gastro-intestinale stromaceltumoren (GIST) vormen een zeldzame groep van mesen­
chymale tumoren uitgaande van het maag-darmkanaal. GISTen kunnen voorkomen als 
kleine, incidenteel ontdekte tumortjes met een nagenoeg benigne karakter tot grote, sterk 
maligne tumoren. Ze worden gekenmerkt door de expressie van de receptortyrosine­
kinase KIT, die als belangrijke pathologische marker fungeert bij de diagnostiek naar 
GIST. In circa 85% van de gevallen worden oncogene mutaties aangetroffen in het KIT 
gen. Daarnaast wordt in een klein deel van de tumoren mutaties in het platelet-derived 
growth factor receptor ex (PDGFRA) gen gevonden. Deze mutaties zorgen ervoor dat het 
KIT of PDGFRA eiwit zichzelf activeert onafhankelijk van ligandbinding met als gevolg 
dat er continu intracellulaire signaalcascades worden geactiveerd die betrokken zijn 
bij de proliferatie en overleving van tumorcellen. KIT en PDGFRA mutaties spelen een 
fundamentele rol bij de ontwikkeling van GIST. De tyrosinekinaseremmer imatinib remt 
de activiteit van beide receptoren en wordt gebruikt als standaard eerstelijnsbehandeling 
bij patienten met irresectabele of gemetastaseerde GIST. Bij het merendeel van de 
patienten die met imatinib behandeld worden, wordt objectieve tumorrespons dan 
wel ziektestabilisatie waargenomen. Deze behandeling leidt echter niet tot genezing 
van GIST. Hetzelfde geldt voor sunitinib, een tyrosinekinaseremmer die eveneens de 
activatie van KIT en PDGFRA blokkeert, maar tevens andere receptoren zoals vascular 
endothelial growth factor receptor (VEGFR) en FMS-like tyrosinekinase 3 (FLT3). Ook 
van dit middel zijn klinische effecten in de vorm van tumorrespons en ziektestabilisatie 
beschreven, maar net als bij imatinib is deze werking niet blijvend. Om deze reden bestaat 
er de noodzaak tot de ontwikkeling van nieuwe therapeutische strategieen. 
Het eerste doel van het onderzoek beschreven in <lit proefschrift was om nieuwe 
moleculaire aangrijpingspunten voor de behandeling van GIST te identificeren. In 
de tweede plaats werden mogelijke bijwerkingen van imatinib en markers die de 
tumorrespons op dit middel zouden kunnen voorspellen nader onderzocht. 
Het eerste deel van dit proefschrif t richt zich op de rol van het insulineachtige 
groeifactor (IGF) systeem bij GIST. Hoofdstuk 2 zet de huidige kennis over het IGF 
systeem uiteen. Hierbij wordt de nadruk gelegd op de rol van IGF signalering in de 
pathogenese van diverse typen sarcomen. Bij GIST is aangetoond dat tumoren zonder KIT 
of PDGFRA mutaties, de zogenaamde 'wild-type' GISTen, de IGF receptor type 1 (IGF­
IR) in hoge mate tot expressie brengen. Dit suggereert dat deze IGF receptor betrokken is 
bij de pathogenese van deze subgroep van tumoren. Recent zijn verscheidene middelen 
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onderzocht en getest, die gericht zijn op de remming van IGF signalering. Humane 
monoclonale antilichamen gericht tegen IGF-lR bevinden zich momenteel voor diverse 
tumortypen in klinisch fase 2 en 3 onderzoek. Bij verscheidene patienten met een Ewing 
sarcoom zijn in deze studies objectieve tumorresponsen gezien, hetgeen een belangrijke 
stimulus vormt voor verder klinisch onderzoek naar het effect van deze antilichamen bij 
de behandeling van het Ewing sarcoom en andere typen sarcomen, zoals bijvoorbeeld 
'wild-type' GISTen. 
Non-islet cell tumour-induced hypoglycaemia (NICTH) is een paraneoplastisch 
syndroom <lat incidenteel wordt gediagnosticeerd bij patienten met een sarcoorn. 
NICTH wordt gekenrnerkt door het bij herhaling optreden van hypoglykemieen bij 
vasten. Tumoren waarbij NICTH optreedt, scheiden grote hoeveelheden onrijp IGF-II 
uit, genaamd 'big'-IGF-II. Dit leidt tot een aanzienlijk verhoogde spiegel 'big'-IGF-II 
in de circulatie. Hierdoor veranderen de concentraties van circulerend insuline, IGF-I 
en IGF-bindende protei:nen (IGFBPs), waardoor een hypoglykemische werking van 
'big'-IGF-II kan optreden, vergelijkbaar met het effect van insuline. In hoofdstuk 3a 
worden de verschillende tumortypen en syrnptomen die geassocieerd zijn met NICTH, 
beschreven, alsmede de pathogenese, diagnose en behandeling van <lit zeldzarne 
paraneoplastische fenorneen. Tevens worden twee illustratieve casus gepresenteerd van 
patienten met NICTH, veroorzaakt door respectievelijk een solitaire fibreuze tumor en 
een hernangiopericytoom. In hoofdstuk 3b wordt de casus van een patient met een GIST 
en NICTH beschreven. De conclusie van deze casu·istiek is dat NICTH overwogen client 
te worden bij patienten met GIST, zeker bij het optreden van bewustzijnsdalingen. 
In hoofdstuk 4 wordt de studie naar de prognostische relevantie van de bepaling 
van 'big'-IGF-II en andere IGF-gerelateerde eiwitten in het plasma van patienten met 
een GIST voor en tijdens behandeling met imatinib weergegeven. Bij drie van de 24 
gei:ncludeerde patienten (13%) bleek de plasmaspiegel van 'big'-IGF-II v66r of tijdens 
behandeling verhoogd. Later ontwikkelden deze drie patienten hypoglykemieen. In de 
totale groep patienten werden de hoogste 'big'-IGF-II spiegels gemeten bij patienten met 
gernetastaseerde ziekte, een verhoogd LDH of een relatief grote tumormassa. Verder 
hadden de meeste patienten verhoogde IGFBP-2 plasmaspiegels en waren die significant 
hoger bij patienten met progressieve ziekte tijdens behandeling met imatinib. Analyse 
van 'big'-IGF-II en IGFBP-2 in GIST tumorweefsel en cystevloeistof liet zien <lat het 
merendeel van de in plasma gerneten 'big' -IGF-II waarschijnlijk wordt uitgescheiden 
door de tumor, in tegenstelling tot IGFBP-2. Deze resultaten geven aan <lat verhoogde 
plasmaspiegels van 'big' -IGF-II niet zelden voorkomen bij patienten met een GIST en 
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een prognostische factor zijn voor het ontwikkelen van hypoglykemieen. De rol voor 
IGFBP-2 als eventuele biomarker in GIST moet nog nader onderzocht worden. 
Na de observatie dat GIST 'big' -IGF-II kan produceren, hebben we verder onderzocht 
wat de biologische rol is van 'big'-IGF-II bij in vitro GIST modellen. Dit onderzoek wordt 
in hoofdstuk 5 beschreven. Bij meerdere tumortypen is aangetoond dat IGF-II (zowel 
in rijpe als onrijpe vorm) als autocriene factor fungeert door te binden aan IGF-lR en/of 
insuline receptor isovorm A. De door ons uitgevoerde bepaling van IGF-II secretie door 
twee GIST cellijnen met KIT mutaties liet zien dat beide cellijnen grote hoeveelheden 
IGF-II uitscheidden, voornamelijk in de vorm van 'big'-IGF-II. Bij deze GIST cellijnen 
en bij een cohort tumoren met eveneens KIT of PDGFRA mutaties werd zowel op 
mRNA als op eiwitniveau expressie van de insuline receptor isovorm A aangetoond, in 
tegenstelling tot IGF-lR. Het uitschakelen van de expressie van 'big' -IGF-II of de insuline 
receptor met korte interferentie RNA (siRNA) verkorte de overleving van beide cellijnen 
middels be"invloeding van AKT en MAP kinase signalering. Het onderbreken van 'big' -
IGF-II signalering in combinatie met imatinib had een additief cytotoxisch effect op GIST 
cellen. Tot slot werd de ('big'-)IGF-II expressie onderzocht in een uitgebreid cohort van 
60 primaire tumoren, ingebed in paraffine, waarvan de maligniteitsgraad varieerde en 
waarvan het overgrote merendeel KIT of PDGFRA mutaties bevatte. IGF-II mRNA was 
bij 52 van de 57 (91 %) evalueerbare GISTen aanwezig en afwezig bij alle vier zeer-laag­
risico tumoren. IGF-II eiwit werd door de meerderheid van deze GISTen tot expressie 
gebracht, met name bij hoog-risico tumoren, en deze expressie was onafhankelijk van de 
aanwezigheid van KIT of PDGFRA mutaties. Onze bevindingen in cellijnen en tumoren 
wijzen erop dat de secretie van 'big'-IGF-II een autocrien signaal kan geven via interactie 
met de insuline receptor isovorm A dat de overleving van GIST cellen stimuleert. 'Big'­
IGF-II secretie lijkt daarom relevant te zijn in de pathogenese van GIST. 
In hoofdstuk 6 wordt onderzocht of de death receptor Fas een mogelijk therapeutisch 
aangrijpingspunt is bij GIST. Hierbij werd de effectiviteit van MegaFasL onderzocht. Dit is 
een hexamere vorm van Fas ligand (FasL), dat de eigenschap heeft de " death" receptor Fas 
te activeren. MegaFasL bleek zowel in imatinib gevoelige als in imatinib resistente GIST 
cellijnen in hoge mate geprogrammeerde celdood (apoptose) te induceren. Daarnaast 
versterkte MegaFasL het apoptotische effect van imatinib in GIST cellen. Histologisch 
onderzoek van preparaten afkomstig van 45 primaire GISTen bevestigde de relevantie 
van de Fas route zoals die was gevonden in de GIST cellijnen, namelijk dat in nagenoeg 
alle tumoren Fas expressie werd gevonden en in het merendeel FasL. De expressie van 
Fas en FasL in deze GISTen was onafhankelijk van de aanwezigheid van bepaalde KIT 
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mutaties. Deze resultaten suggereren dat Fas een potentieel aangrijpingspunt is voor 
therapie bij GIST. 
Het laatste deel van dit proefschrift richt zich op mogelijke bijwerkingen van imatinib. 
In hoofdstuk 7 wordt de gesuggereerde toxiciteit van imatinib op de hartspier nader 
bestudeerd. Om dit verder te onderzoeken zijn de plasma spiegels van N-terminal pro 
B-type natriuretic peptide (NT-proBNP) en serum cardiaal troponine T (cTnT) gebruikt 
als markers voor cardiotoxiciteit. Beide markers werden bepaald in 55 patienten met 
een lokaal uitgebreide clan wel gemetastaseerde GIST voorafgaand aan de behandeling 
met imatinib en vervolgens gedurende de eerste drie maanden van behandeling met dit 
middel, dat gegeven werd in een standaard dosering. Afgezien van een patient, bleven 
de NT-proBNP en cTnT concentraties stabiel in de patienten tijdens de studieperiode. 
De patient waarbij een stijging in de markers werd waargenomen, ontwikkelde 
symptomatisch hartfalen tijdens de studieperiode, dat meest waarschijnlijk veroorzaakt 
werd door pre-existent hartkleplijden. Kortom, in deze studiepopulatie werd geen 
vroegtijdige cardiale toxiciteit door imatinib waargenomen. 
Verschillende studies die betrekking hadden op met name kleine groepen patienten 
met chronische myeloi'de leukemie, waarbij imatinib ook de eerstekeusbehandeling is, 
hebben gesuggereerd dat dit middel veranderingen veroorzaakt in bot- en mineraal­
metabolisme, en tevens hypogonadisme teweegbrengt in mannelijke patienten. Om deze 
reden werd in hoofdstuk 8 de invloed van imatinib op verschillende serum elektrolyten 
en hormonen onderzocht in 36 patienten met GIST, die in aanmerking kwamen voor 
behandeling met dit medicament. Seriele serumbepalingen bij deze patientengroep 
gedurende 6 maanden behandelen lieten zien dat de serum calcium en fosfaat spiegels 
respectievelijk na een week en na een maand significant daalden. Daarnaast veroorzaakte 
imatinib (milde) hyperparathyreoi'die, wat na reeds een week behandelen kon worden 
waargenomen. Er werden geen veranderingen in schildklier- en gonadale functies 
gevonden. Patienten die na 3 maanden behandeling met imatinib een hypofosfatemie 
ontwikkelden, hadden een slechtere progressievrije overleving dan zij die dat niet 
ontwikkelden. Nader (prospectief) onderzoek zal moeten uitwijzen of een verlaging 





GIST wordt beschouwd als het rolmodel voor de succesvolle applicatie van doelgerichte 
therapie (targeted therapy) bij solide tumoren. De meeste GISTen worden gedreven 
door oncogene mutaties in de KIT en PDGFRA genen. De geactiveerde eiwitten 
die hieruit voortkomen, vormen duidelijke aangrijpingspunten voor therapie. De 
tyrosinekinaseremmer imatinib heeft een revolutie teweeg gebracht bij de behandeling 
van GIST en is daarmee een van de meest succesvolle nieuwe medicijnen die in het 
afgelopen decennium zijn ge"introduceerd voor de behandeling van een solide tumor. 
Helaas blijkt er bij een (beperkte) groep patienten initiele resistentie tegen dit middel te 
bestaan, terwijl het overgrote deel van de GIST patienten vroeg of laat geconfronteerd 
wordt met ongevoeligheid voor imatinib. 
Therapeutische aangrijpingspunten in GIST 
Het optimaal remmen van continu geactiveerde KIT en PDGFRA signaleringsroutes is 
in de huidige klinische praktijk het belangrijkste doel bij de systemische behandeling 
van GIST. Dit is ook het voornaamste doel van het meeste (pre)klinische onderzoek dat 
momenteel verricht wordt bij GIST. De recente waarneming dat het type KIT of PDGFRA 
genmutatie een belangrijke voorspellende waarde heeft voor de respons van een GIST 
op een bepaalde tyrosinekinaseremmer, maakt het mogelijk om de behandeling verder 
te individualiseren [l]. Zo laten tumoren met KIT exon 11 mutaties een veel betere 
respons op imatinib zien clan tumoren met KIT exon 9 mutaties of tumoren met 'wild­
type' KIT [2,3]. Sunitinib is geregistreerd voor de behandeling van imatinib resistente 
GIST. Dit middel is bij GIST met KIT exon 9 mutaties effectiever gebleken clan imatinib 
[ 4]. Momenteel worden er verschillende klinische studies verricht met andere KIT en 
PDGFRA remmende middelen, zoals sorafenib en nilotinib. Deze medicamenten hebben 
een voorkeur voor het inhiberen van bepaalde KIT of PDGFRA mutanten die deels 
verschillen van de door imatinib geremde mutanten [5,6]. Het zou daarom goed mogelijk 
kunnen zijn dat toekomstige therapieen bij GIST patienten in belangrijke mate gestuurd 
gaan worden door het genotype van de tumor, waarbij er gekozen wordt voor de 
tyrosinekinaseremmer met de meest potente activiteit richting een bepaalde mutatie. Dit 
lijkt ook van belang te zijn bij het ontstaan van resistentie tegen imatinib of sunitinib, wat 
meestal het gevolg is van het ontwikkelen van secundaire mutaties in KIT of PDGFRA 
[7]. Enkele van de nieuwe tyrosinekinaseremmers zijn, ondanks de aanwezigheid 
van bepaalde secundaire mutaties, in staat om de functionaliteit van KIT en PDGFRA 
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te remmen. Hierdoor zijn ze mogelijk geschikt voor het behandelen van tumoren die 
door secundaire mutaties resistent zijn geworden voor imatinib en sunitinib [8].  Bron 
van zorg is echter de mogelijkheid <lat gedurende langdurige behandeling met imatinib 
verschillende secundaire mutaties in diverse tumorlesies in een individuele patient 
kunnen optreden [9,10].  Deze heterogeniteit wat betreft secundaire mutaties kunnen het 
succes van doelgerichte therapie belemmeren zodra er resistentie is ontwikkeld tegen 
de standaard tyrosinekinaseremmers. Alternatieve behandelingsstrategieen kunnen 
dan zijn het toepassen van chirurgie op focaal progressieve lesies, of het gebruik van 
middelen die de expressie van KIT en PDGFRA eiwit op de celmembraan be"invloeden, 
zoals heat shock protein 90 remmers, of remmers van intracellulaire eiwitten in de 
signaaltransductiecascade van KIT en PDGFRA, zoals phosphatidylinositol-3-kinase of 
mammalian target of rapamycin remmers [11-15] . 
De kern van het onderzoek <lat in dit proefschrift is beschreven, is de zoektocht naar 
nieuwe aangrijpingspunten voor therapie, anders dan geactiveerd KIT en PDGFRA. 
Want hoewel deze twee receptoren en hun signaleringseiwitten zeer belangrijk zijn voor 
de pathogenese van GIST, is het zeer aannemelijk <lat ook andere oncogene signaalroutes 
van belang zijn. Het ontstaan van multipele genetische afwijkingen en activatie van 
oncogene signaalroutes ligt waarschijnlijk aan de basis van de ontwikkeling van 
prematuur getransformeerde GIST voorlopercellen tot een maligne tumor [16]. Tot op 
heden is er echter weinig bekend over deze secundaire gebeurtenissen bij de ontwikkeling 
van een GIST. Zo zijn er verscheidene opeenvolgende chromosomale veranderingen 
beschreven zoals het verlies van 14q en 22q [17] .  Over de betrokkenheid van alternatieve 
oncogenen en tumorsuppressors bij de oncogenese van GIST is echter weinig bekend. De 
identificatie van dergelijke eiwitten zou kunnen leiden tot de ontwikkeling van nieuwe 
medicijnen gericht tegen deze eiwitten of tegen de route waar die eiwitten onderdeel van 
zijn. 
Verschillende studies in di t proefschrift la ten zien da t het ver krijgen van I GF-II expressie 
een rol speelt bij de ontwikkeling van GIST. Het aangrijpen op 'big' -IGF-11 signalering 
zou daarom gebruikt kunnen worden als nieuwe behandelingsmogelijkheid. Het feit <lat 
het IGF systeem is betrokken bij vele kankersoorten, heeft geleid tot de ontwikkeling 
van nieuwe middelen die de verschillende leden van <lit systeem kunnen blokkeren 
[18].  Van deze middelen zijn de recent ontwikkelde neutraliserende antilichamen tegen 
'big' -IGF-11 erg interessant als potentiele behandeling van GIST [19] . Voor 'wild-type' 
GISTen die IGF-lR tot expressie brengen, zouden receptorspecifieke antagonistische 
(blokkerende) antilichamen of klein-moleculaire tyrosinekinaseremmers in aanmerking 
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komen [20]. Zoals echter naar voren komt in dit proefschrift, brengen de meeste GISTen, 
namelijk de tumoren met KIT of PDGFRA mutaties, geen IGF-lR tot expressie maar 
een alternatieve receptor, de insuline receptor isovorm A. In overeenstemming met 
andere maligniteiten hebben GISTen de voorkeur voor de expressie van de insuline 
receptor isovorm A variant boven de isovorm B variant. De insuline receptor isovorm 
B heeft veel minder affiniteit voor IGF-11 clan isovorm A. Daarnaast wordt de isovorm 
B normaalgesproken tot expressie gebracht door normale, niet-foetale weefsels waar 
het een dominante rol heeft op gebied van het stimuleren van het celmetabolisme. De 
isovorm A daarentegen speelt een belangrijke rol bij het stimuleren van de proliferatie 
en overleving van cellen [21]. De kennis over de mechanismen, die betrokken zijn bij de 
geprefereerde expressie van isovorm A in kankercellen, is beperkt. Dit geldt ook voor 
het ruimtelijke effect veroorzaakt door een verschil van 12 aminozuren tussen beide 
isovormen, dat klaarblijkelijk het verschil in affiniteit voor bepaalde liganden en zo de 
activering van intracellulaire signaaltransductieroutes be:invloedt [21]. Het remmen 
van beide isovormen van de insuline receptor als antikankerbehandeling zou kunnen 
leiden tot ernstige metabole toxiciteit. Om deze reden zou het een uitdaging zijn om 
middelen te ontwikkelen die selectief isovorm A inhiberen. Tot op heden zijn er alleen 
klein-moleculaire tyrosinekinaseremmers ontwikkeld die zowel beide isovormen van de 
insuline receptor als IGF-lR remmen [22]. In preklinische diermodellen veroorzaakten 
dergelijke middelen (transiente) hyperglykemie. Verder (pre)klinisch onderzoek zal 
moeten uitwijzen of deze middelen geschikt zijn voor de behandeling van GIST. 
Door het activeren van de extrinsieke apoptoseroute via activatie van 'death' 
receptoren, die behoren tot de tumornecrosefactorreceptorfamilie, kan apoptose worden 
ge"induceerd in een grote verscheidenheid aan kankercellen [23]. In dit proefschrift is 
beschreven hoe activatie van de death receptor Fas in vitro een beloftevolle benadering 
is. Het remmen van KIT door imatinib induceert slechts in beperkte mate apoptose en 
veroorzaakt vooral celcyclusarrest in de meerderheid van de GIST cellen [24]. Hierdoor 
is een belangrijk deel van de cellen in staat om te overleven en daarmee bij te dragen 
aan de ontwikkeling van resistentie tegen imatinib en andere tyrosinekinaseremmers . 
Therapeutische benaderingen die celdood veroorzaken, zoals het gebruik van MegaFasL, 
zouden daarom veelbelovend kunnen zijn bij de behandeling van GIST. Ondanks het 
feit dat agonistische antilichamen tegen Fas uiterst toxisch zijn voor muizen, blijkt de · 
toxiciteit van de hexamere vorm van Fas ligand (MegaFasL, ook wel APO0lO genoemd) 
in muizen erg mee te vallen [25,26]. Momenteel wordt MegaFasL onderzocht in een 
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klinische fase 1 studie. De resultaten van <lit onderzoek zullen bepalend zijn voor het 
eventueel verder bestuderen van de effecten van <lit middel bij patienten met GIST. 
Aspecten met betrekking tot gepersonaliseerde behandeling 
Naast de ontwikkeling van nieuwe medicamenteuze behandelingen zijn er ook andere 
aspecten die relevant zijn voor het optimaliseren van de behandeling van de individuele 
patient. Het gaat hierbij om het identificeren van predictieve en prognostische factoren, 
het vaststellen van responsmarkers, of toxiciteit gerelateerde kwesties. 
De keuze voor en de dosering van een bepaald type medicijn bij GIST wordt idealiter 
gestuurd door predictieve factoren. De aanwezigheid van bepaalde moleculaire 
aangrijpingspunten kan bijvoorbeeld bepalend zijn voor het starten van toekomstige 
therapieen. Tot op heden is het KIT en PDGFRA genotype de meest belangrijke 
voorspeller wat betreft de (progressievrije en totale) overleving en tumorrespons bij het 
gebruik van imatinib en sunitinib [8]. De identificatie van andere biomarkers zou voor 
een verdere verfijning van de behandeling met KIT /PDGFRA remmers kunnen zorgen . 
In de hedendaagse klinische praktijk worden CT-scans gebruikt voor de evaluatie van de 
respons van een GIST op imatinib of een andere tyrosinekinaseremmer [27]. Met behulp 
van 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG­
PET) zou additionele informatie verkregen kunnen worden wat betreft tumorrespons. 
Het ontbreekt momenteel echter aan goede prospectieve studies die kunnen aangeven 
wat exact de plaats is van FDG-PET bij de behandeling van GIST [28]. Onderzoek naar 
eiwitten afkomstig van de tumor, die gemeten kunnen worden in serum of plasma en 
die zouden kunnen dienen als betrouwbare tumormarkers, zou een bijdrage kunnen 
leveren aan het vergemakkelijken van de follow-up van patienten met GIST. Momenteel 
zijn dergelijke biomarkers niet beschikbaar. Kandidaat markers voor verder onderzoek 
op <lit gebied zijn oplosbare KIT [29,30] en DOG-1 (discovered on GIST-1) [31], maar ook 
'big'-IGF-II. 
Bij de individualisering van de behandeling van GIST speelt het optreden van 
toxiciteit als gevolg van de behandeling met een tyrosinekinaseremmer ook een 
belangrijke rol. Ondanks het feit <lat imatinib, net als sunitinib, zogenaamde doelgerichte 
antikankertherapie is, zijn deze middelen wel gericht tegen receptoren die ook in normale 
weefsels voorkomen. Daardoor kunnen deze middelen tevens de homeostase van 
normale weefsels be"invloeden, met als gevolg het optreden van toxiciteit. In de afgelopen 
jaren zijn er meerdere vaak onverwachte bijwerkingen van imatinib gemeld, waaronder 
hartfalen, testiculaire insufficientie en hypofosfatemie [32-34]. Hoewel onderzoek in djt 
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proefschrift laat zien dat deze bijwerkingen slechts van beperkte betekenis lijken te zijn, 
is de herkenning van bijwerkingen en het identificeren van patienten met een verhoogd 
risico hierop van belang bij langdurige behandeling met imatinib. De ontwikkeling van 
een risicocalculator die het optreden van imatinib gei'.nduceerde toxiciteit voorspelt, is 
hierbij een waardevol initiatief die richting kan geven bij de keuze voor een bepaalde 
dosering van <lit middel [35]. Dezelfde principes gelden voor sunitinib, een middel <lat 
over het algemeen meer toxiciteit laat zien dan imatinib, zoals hypertensie, hypothyreoi'.die 
en cardiotoxiciteit . Dit is meest waarschijnlijk het gevolg van het feit <lat sunitinib naast 
KIT en PDGFR multipele andere tyrosinekinases remt, waaronder VEGFR en FLT3 [36]. 
Kennis van en vroegtijdig inspelen op de toxiciteit van imatinib, sunitinib en andere 
nieuwe middelen bij de behandeling van GIST zal het therapeutische succes van deze 
middelen ten goede komen. 
Conclusie 
In dit proefschrift worden nieuwe inzichten in de pathogenese van GIST gepresenteerd. 
Gelijk als bij veel andere typen sarcomen is het IGF systeem ook betrokken bij de 
ontwikkeling van GIST. We hebben hierbij laten zien <lat 'big'-IGF-11 fungeert als een 
autocriene factor die via een interactie met de insuline receptor isovorm A de overleving 
van GIST cellen kan bevorderen. Daarnaast zou 'big' -IGF-11 gebruikt kunnen worden 
als marker voor het vervolgen van met name die patienten die het risico lopen op het 
ontwikkelen van NICTH. Verder blijkt uit dit proefschrift dat de death receptor Fas 
bruikbaar zou kunnen zijn als nieuw aangrijpingspunt voor therapie bij GIST. Tenslotte 
is ingegaan op factoren die samenhangen met imatinib gerelateerde toxiciteit en de 
predictieve waarde van veranderingen in elektrolyten en hormonen. Deze studies dienen 
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Chapter 4 (figure 1) see page 88. 
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Chapter 6 (figure 1) see page 129 .  
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